<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Defeat Osteosarcoma &#187; Natural Therapies</title>
	<atom:link href="http://defeatosteosarcoma.org/category/generalcancerresearch/naturaltherapies/feed/" rel="self" type="application/rss+xml" />
	<link>http://defeatosteosarcoma.org</link>
	<description>This site is dedicated to curing osteosarcoma</description>
	<lastBuildDate>Sun, 20 May 2012 05:20:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>Alkylglycerols (shark oil)</title>
		<link>http://defeatosteosarcoma.org/2011/06/alkylglycerols-shark-oil/</link>
		<comments>http://defeatosteosarcoma.org/2011/06/alkylglycerols-shark-oil/#comments</comments>
		<pubDate>Wed, 22 Jun 2011 06:15:43 +0000</pubDate>
		<dc:creator>James Street</dc:creator>
				<category><![CDATA[AKG (alkylglycerol - SHARK liver oil)]]></category>
		<category><![CDATA[Complementary and Alternative Medicine]]></category>
		<category><![CDATA[Complementary Therapy]]></category>
		<category><![CDATA[Natural Therapies]]></category>
		<category><![CDATA[Nutrition and Cancer]]></category>

		<guid isPermaLink="false">http://defeatosteosarcoma.org/?p=2939</guid>
		<description><![CDATA[Multiple Beneficial Health Effects of Natural Alkylglycerols from Shark Oil An Update on the Therapeutic Role of Alkyglycerols]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.mdpi.com/1660-3397/8/7/2175/pdf"> Multiple Beneficial Health Effects of Natural Alkylglycerols from Shark Oil</a></p>
<p><a href="http://www.mdpi.com/1660-3397/8/8/2267/pdf">An Update on the Therapeutic Role of Alkyglycerols </a></p>
]]></content:encoded>
			<wfw:commentRss>http://defeatosteosarcoma.org/2011/06/alkylglycerols-shark-oil/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Complementary and Alternate Medicine</title>
		<link>http://defeatosteosarcoma.org/2011/06/2890/</link>
		<comments>http://defeatosteosarcoma.org/2011/06/2890/#comments</comments>
		<pubDate>Mon, 20 Jun 2011 05:16:25 +0000</pubDate>
		<dc:creator>James Street</dc:creator>
				<category><![CDATA[Complementary and Alternative Medicine]]></category>
		<category><![CDATA[Drugs]]></category>
		<category><![CDATA[Natural Therapies]]></category>
		<category><![CDATA[Nutrition and Cancer]]></category>

		<guid isPermaLink="false">http://defeatosteosarcoma.org/?p=2890</guid>
		<description><![CDATA[The Journal of Allergy and Clinical Immunology Volume 123, Issue 2 , Pages 283-294.e10, February 2009 Complementary and alternative medicine: Herbs, phytochemicals and vitamins and their immunologic effects Timothy Mainardi, MD, MS , Simi Kapoor, MD , Leonard Bielory, MD Received 11 November 2008; received in revised form 18 December 2008; accepted 19 December 2008. Article Outline Abstract [...]]]></description>
			<content:encoded><![CDATA[<div id="container">
<div>
<div><a href="http://www.jacionline.org/home"><img title="Journal of Allergy and Clinical Immunology Home" src="http://www.jacionline.org/webfiles/images/journals/ymai/logo.gif" alt="Journal of Allergy and Clinical Immunology Home" width="275" height="100" /></a></div>
<p><strong>The Journal of Allergy and Clinical Immunology</strong><br />
<a href="http://www.jacionline.org/issues?issue_key=S0091-6749%2809%29X0002-3">Volume 123, Issue 2</a> , Pages 283-294.e10, February 2009</p>
</div>
<div id="content">
<div id="primary">
<h1 id="article-title">Complementary and alternative medicine: Herbs, phytochemicals and vitamins and their immunologic effects</h1>
<form action="/search/quick" method="get">
<ul>
<li><a title="Search for all articles by this author" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">Timothy Mainardi</a>, MD, MS</li>
<p>,</p>
<li><a title="Search for all articles by this author" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">Simi Kapoor</a>, MD</li>
<p>,</p>
<li><a title="Search for all articles by this author" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">Leonard Bielory</a>, MD<a href="mailto:bielory@umdnj.edu"><img src="http://www.jacionline.org/webfiles/images/icon_email.png" border="0" alt="email address" /></a></li>
</ul>
</form>
<p id="articleHistory">Received 11 November 2008; received in revised form 18 December 2008; accepted 19 December 2008.</p>
<p>Article Outline</p>
<div>
<ul id="outline-level1">
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#abstract">Abstract</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec2">Use of CAM</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec3">Risks of CAM use</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec4">NCCAM and clinical trials</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec5">Immune impact of specific herbs and vitamins</a>
<ul id="outline-level2">
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec5.1">Vitamin D</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec5.2">Vitamin E</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec5.3">Vitamin A</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec5.4">Vitamin C</a></li>
</ul>
</li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec6">Herbal medicines and potential mechanisms of action</a>
<ul id="outline-level2">
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec6.1">Magnolol</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec6.2">Quercetin</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec6.3">Antiasthma herbal medicine interventions</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec6.4">Resveratrol</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec6.5">Ma huang (Ephedrine sinica)</a></li>
</ul>
</li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec7">Clinical applications for the practicing allergist</a>
<ul id="outline-level2">
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec7.1">Asthma</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec7.2">Atopic dermatitis</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec7.3">Allergic rhinitis</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec7.4">Indian Ayurvedic medicine</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec7.5">TCM</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec7.6">Kampo medicine (Japanese)</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec7.7">Conclusions</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec7.8">What do we know?</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#sec7.9">What is still unknown?</a></li>
</ul>
</li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#appseca1">Table E1. </a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bibliography">References</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#further-reading">References</a></li>
<li><a id="outline-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#copyright">Copyright</a></li>
</ul>
<p><a name="abstract"></a>Complementary  and alternative medicines (CAMs) are used in more than 80% of the  world&#8217;s population and are becoming an increasing component of the US  health care system, with more than 70% of the population using CAM at  least once and annual spending reaching as much as $34 billion. Since  the inception of the National Center for Complementary and Alternative  Medicine, there has been an enormous increase in the number of basic  science and therapy-based clinical trials exploring CAM. The  subspecialty of allergy and immunology represents a particularly fertile  area with a large number of CAM therapies that have been shown to  affect the immune system. Recent work has uncovered potential  biochemical mechanisms involved in the immunomodulatory pathway of many  supplemental vitamins (A, D, and E) that appear to affect the  differentiation of CD4<sup>+</sup> cell T<sub>H</sub>1 and T<sub>H</sub>2  subsets. Other research has shown that herbs such as resveratrol,  quercetin, and magnolol may affect transcription factors such as nuclear  factor-κB and the signal transducer and activator of  transcription/Janus kinase pathways with resultant changes in cytokines  and inflammatory mediators. Clinically, there have been hundreds of  trials looking at the effect of CAM on asthma, allergic rhinitis, and  atopic dermatitis. This article reviews the history of CAM and its use  among patients, paying special attention to new research focusing on  herbals, phytochemicals, and vitamins and their potential interaction  with the immune system.</p>
<p><strong>Key words: </strong><a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=Complementary%20and%20alternative%20medicine&amp;restrictName.ymai=ymai">Complementary and alternative medicine</a>, <a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=immunology&amp;restrictName.ymai=ymai">immunology</a>, <a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=herbal%20medicines&amp;restrictName.ymai=ymai">herbal medicines</a>, <a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=vitamin&amp;restrictName.ymai=ymai">vitamin</a>, <a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=NIH%E2%80%94National%20Center%20for%20Complementary%20and%20Alternative%20Medicine&amp;restrictName.ymai=ymai">NIH—National Center for Complementary and Alternative Medicine</a>, <a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=asthma&amp;restrictName.ymai=ymai">asthma</a>, <a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=allergic%20rhinitis&amp;restrictName.ymai=ymai">allergic rhinitis</a>, <a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=atopic%20dermatitis&amp;restrictName.ymai=ymai">atopic dermatitis</a></p>
<p><strong>Abbreviations used: </strong><a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=CAM&amp;restrictName.ymai=ymai">CAM</a>, <a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=Complementary%20and%20alternative%20medicine&amp;restrictName.ymai=ymai">Complementary and alternative medicine</a>, <a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=FDA&amp;restrictName.ymai=ymai">FDA</a>, <a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=US%20Food%20and%20Drug%20Administration&amp;restrictName.ymai=ymai">US Food and Drug Administration</a>, <a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=NCCAM&amp;restrictName.ymai=ymai">NCCAM</a>, <a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=National%20Center%20for%20Complementary%20and%20Alternative%20Medicine&amp;restrictName.ymai=ymai">National Center for Complementary and Alternative Medicine</a>, <a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=NF-%CE%BAB&amp;restrictName.ymai=ymai">NF-κB</a>, <a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=Nuclear%20factor-%CE%BAB&amp;restrictName.ymai=ymai">Nuclear factor-κB</a>, <a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=STAT&amp;restrictName.ymai=ymai">STAT</a>, <a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=Signal%20transducer%20and%20activator%20of%20transcription&amp;restrictName.ymai=ymai">Signal transducer and activator of transcription</a>, <a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=TCM&amp;restrictName.ymai=ymai">TCM</a>, <a title="Search for this keyword within this periodical." href="http://www.jacionline.org/search/quick?search_area=journal&amp;search_text1=Traditional%20Chinese%20medicine&amp;restrictName.ymai=ymai">Traditional Chinese medicine</a></p>
<div>
<div>
<div><a name="section"></a>&nbsp;</p>
<p id="back-to-article-outline-link"><a href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#article-outline">Back to Article Outline</a></p>
<h2>Information for Category 1 CME Credit</h2>
<p>Credit  can now be obtained, free for a limited time, by reading the review  articles in this issue. Please note the following instructions.</p>
<p><strong>Method of Physician Participation in Learning Process:</strong> The core material for these activities can be read in this issue of the Journal or online at the JACIWeb site: <a id="inter-ref" href="http://www.jacionline.org/">www.jacionline.org</a>. The accompanying tests may only be submitted online at <a id="inter-ref" href="http://www.jacionline.org/">www.jacionline.org</a>. Fax or other copies will not be accepted.</p>
<p><strong>Date of Original Release:</strong> February 2009. Credit may be obtained for these courses until January 31, 2011.</p>
<p><strong>Copyright Statement:</strong> Copyright © 2009-2011. All rights reserved.</p>
<p><strong>Overall Purpose/Goal:</strong> To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease.</p>
<p><strong>Target Audience:</strong> Physicians and researchers within the field of allergic disease.</p>
<p><strong>Accreditation/Provider Statements and Credit Designation:</strong> The American Academy of Allergy, Asthma &amp; Immunology (AAAAI) is  accredited by the Accreditation Council for Continuing Medical Education  (ACCME) to provide continuing medical education for physicians. The  AAAAI designates these educational activities for a maximum of 1 <em>AMA PRA Category 1 Credit™</em>. Physicians should only claim credit commensurate with the extent of their participation in the activity.</p>
<p><strong>List of Design Committee Members:</strong> <em>Authors:</em> Timothy Mainardi, MD, MS, Simi Kapoor, MD, and Leonard Bielory, MD</p>
<p><strong>Activity Objectives</strong></p>
<p>1. To recognize the frequent practice of complementary and alternative medicines.</p>
<p>2. To understand the potential risks and benefits associated with complementary and alternative medicines.</p>
<p>3.  To provide a critical review of the literature supporting and opposing  the use of alternative medication to treat atopic disorders.</p>
<p><strong>Recognition of Commercial Support:</strong> This CME activity has not received external commercial support.</p>
<p><strong>Disclosure of Significant Relationships with Relevant Commercial</strong></p>
<p><strong>Companies/Organizations:</strong> Leonard Bielory has received research support from Lev Pharma, Otsuka,  Schering-Plough, Novartis, Astellas, and Dyax; has served a consultant,  speaker, or advisory board member for Forest, Schering-Plough,  GlaxoSmithKline, Merck, Novartis, UCB Pharma, Alcon, Meda, Inspire,  Santen, Nycomed, Bausch &amp; Lomb, Ocusense, Vistakon, Genentech,  Sanofi-Aventis, and Jerini; owns stocks in Ocusense and APPI; and has  provided legal consultation or expert witness testimony on the topics of  ocular allergy and asthma and allergy. Timothy Mainardi and Simi Kapoor  have no significant relationships to disclose.</p>
</div>
</div>
</div>
<p>Complementary  and alternative medicines (CAMs) represent a diverse group of  interventions that exist outside the realm of traditional medical  therapeutics in that their efficacy and safety have yet to be  determined. In the 1998 editorial accompanying an article on alternative  therapies to prostate cancer, Marcia Angell, then editor of the <em>New England Journal of Medicine</em>,  stated that what sets alternative medicine apart from conventional  medicine “is that it has not been scientifically tested and its  advocates largely deny the need for such testing”<a id="cross-ref-bib1" name="back-bib1" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib1"><sup>1</sup></a> and that “alternative medicine also distinguishes itself by an ideology  that largely ignores biologic mechanisms, [and] often disparages modern  science.”<a id="cross-ref-bib1" name="back-bib1" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib1"><sup>1</sup></a> (pp 839-40) This is all too often a viewpoint shared by many health  care practitioners in the United States, and is also engrained in many  medical school curriculums. However, to provide a balance, the US  Congress in 1991 enacted funding for the National Institute of Health&#8217;s  Office of Alternative Medicine, which in 1998 evolved to become the  National Center for Complementary and Alternative Medicine (NCCAM). One  year later, Dr Stephen Straus was named as its first director. He  focused on discovering the biochemical mechanisms and clinical  application of a variety of alternative therapies (<a id="cross-ref-fig1" name="back-fig1" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#fig1">Fig 1</a>).  Being a member of the National Institute of Allergy and Infectious  Diseases, Dr Straus had a particular interest in the immunologic  mechanisms surrounding complementary and alternative medicine. This  article is a review of the recent advances in CAM on the immune system  and its clinical relevance.</p>
<ul>
<li><a name="fig1"><img src="http://download.journals.elsevierhealth.com/images/journalimages/0091-6749/PIIS0091674908024391.gr1.sml.gif" alt="View full-size image." /></a>
<ul id="image-list">
<li><a name="fig1"> View Large Image </a></li>
<li><a name="fig1" href="http://download.journals.elsevierhealth.com/ppt/journals/0091-6749/PIIS0091674908024391.ppt?ll=gr1"> Download to PowerPoint </a></li>
</ul>
</li>
<li><a name="fig1"><img src="http://download.journals.elsevierhealth.com/images/journalimages/0091-6749/PIIS0091674908024391.gr1a.sml.gif" alt="View full-size image." /></a>
<ul id="image-list">
<li><a name="fig1"> View Large Image </a></li>
<li><a name="fig1" href="http://download.journals.elsevierhealth.com/ppt/journals/0091-6749/PIIS0091674908024391.ppt?ll=gr1a"> Download to PowerPoint </a></li>
</ul>
</li>
<li>
<h5>Fig 1.</h5>
<p>National Institutes of Health NCCAM timeline. A graphical timeline of the events surrounding the formation of NCCAM. <em>CDC,</em> Centers for Disease Control and Prevention; <em>HHS,</em> Health and Human Services; <em>NIH,</em> National Institutes of Health; <em>OAM,</em> Office of Alternative Medicine; <em>WHO,</em> World Health Organization.</li>
</ul>
<p>The  number of researchers publishing general CAM articles has exploded with  more than 1700 articles cited in PubMed using “complementary medicine”  as a keyword for the year 2007, compared with only 355 in 1990. There  has been a similar upswing in the number of articles and the general  interest in the effect of CAM on allergy and immunology. The number of  articles published every year just using the key words <em>immunology</em> and <em>complementary medicine</em> has tripled since 1990 (<a id="cross-ref-fig2" name="back-fig2" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#fig2">Fig 2</a>).</p>
<ul>
<li><a name="fig2"><img src="http://download.journals.elsevierhealth.com/images/journalimages/0091-6749/PIIS0091674908024391.gr2.sml.gif" alt="View full-size image." /></a>
<ul id="image-list">
<li><a name="fig2"> View Large Image </a></li>
<li><a name="fig2" href="http://download.journals.elsevierhealth.com/ppt/journals/0091-6749/PIIS0091674908024391.ppt?ll=gr2"> Download to PowerPoint </a></li>
</ul>
</li>
<li>
<h5>Fig 2.</h5>
<p>Annual  CAM publications related to allergy and immunology. The numbers of  articles published and available for search through PubMed using the  search terms <em>complementary medicine</em> and <em>immunology</em>, <em>asthma</em>, <em>allergy</em>, <em>autoimmune</em>, <em>hypersensitivity</em>, or <em>inflammation</em> are shown.</li>
</ul>
<p><a name="sec2"></a></p>
<p id="back-to-article-outline-link"><a href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#article-outline">Back to Article Outline</a></p>
<h2>Use of CAM</h2>
<p>Complementary  and alternative medicine encompasses several major categories:  alternative medical systems, biologically based therapies, manipulative  therapies, mind-body therapies, and energy therapies (<a id="cross-ref-fig3" name="back-fig3" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#fig3">Fig 3</a>).  The use of CAM in the United States has been increasing at a  substantial rate over the past 2 decades from a total of 34% (427  million) to 42% (628 million), which was in excess of the 385 million  visits to a primary care physician visits in both 1990 and 1997  combined.<a id="cross-ref-bib2" name="back-bib2" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib2"><sup>2</sup></a>, <a id="cross-ref-bib3" name="back-bib3" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib3"><sup>3</sup></a>, <a id="cross-ref-bib4" name="back-bib4" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib4"><sup>4</sup></a> Because the costs of CAM are mostly paid out-of-pocket, the annual  spending for CAM is approximately $27 to $34 billion, compared with $29  billion in out-of-pocket expenditures for all other US physician  services.<a id="cross-ref-bib4" name="back-bib4" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib4"><sup>4</sup></a>, <a id="cross-ref-bib5" name="back-bib5" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib5"><sup>5</sup></a>, <a id="cross-ref-bib6" name="back-bib6" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib6"><sup>6</sup></a> In a recent report, the use of CAM at least once in a lifetime,  including prayer, was as high as 75%. Similarly, the use of CAM in the  past 12 months was 62%, with 26% of respondents stating that they used 1  or more CAM modalities at the suggestion of a physician.<a id="cross-ref-bib3" name="back-bib3" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib3"><sup>3</sup></a> When this is compared to a recent survey of allergists (see letter to  the editor by Engler et al in this issue), there are many similarities  to the trends noted, except for the large difference among those who  have ever used herbal medicines (8% vs 25%; <a id="cross-ref-fig4" name="back-fig4" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#fig4">Fig 4</a>).</p>
<ul>
<li><a name="fig3"><img src="http://download.journals.elsevierhealth.com/images/journalimages/0091-6749/PIIS0091674908024391.gr3.sml.gif" alt="View full-size image." /></a>
<ul id="image-list">
<li><a name="fig3"> View Large Image </a></li>
<li><a name="fig3" href="http://download.journals.elsevierhealth.com/ppt/journals/0091-6749/PIIS0091674908024391.ppt?ll=gr3"> Download to PowerPoint </a></li>
</ul>
</li>
<li>
<h5>Fig 3.</h5>
<p>CAM  classifications. The alternative medical system involves whole medical  systems that are built on other theories and practices including  acupuncture, Ayurveda, homeopathic treatment, and naturopathy.  Manipulative therapies include chiropractic care and massage. Mind-body  therapies use a variety of techniques designed to enhance the mind&#8217;s  capacity to affect bodily function and symptoms and include biofeedback,  meditation, guided imagery, progressive relaxation, deep breathing,  hypnosis, yoga, Tai Chi, Qi-gong, Reiki, and prayer. The biologically  based therapies use substances found in nature, such as herbs, foods,  and vitamins and include megavitamin therapy, various diet-based  therapies, folk medicine, chelation therapy, and herbal medicines.<a id="cross-ref-bib3" name="back-bib3" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib3"><sup>3</sup></a> Energy therapies are essentially made up of biofield therapies that are  intended to affect energy fields that purportedly surround and  penetrate the human body, whereas bioelectromagnetic-based therapies  involve the unconventional use of electromagnetic fields.</li>
</ul>
<ul>
<li><a name="fig4"><img src="http://download.journals.elsevierhealth.com/images/journalimages/0091-6749/PIIS0091674908024391.gr4.sml.gif" alt="View full-size image." /></a>
<ul id="image-list">
<li><a name="fig4"> View Large Image </a></li>
<li><a name="fig4" href="http://download.journals.elsevierhealth.com/ppt/journals/0091-6749/PIIS0091674908024391.ppt?ll=gr4"> Download to PowerPoint </a></li>
</ul>
</li>
<li>
<h5>Fig 4.</h5>
<p>National versus allergist survey. A comparison of the allergy and immunology <em>(AI)</em> subspecialty survey conducted in 2007 compared with the Centers for Disease Control and Prevention survey<a id="cross-ref-bib3" name="back-bib3" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib3"><sup>3</sup></a> of the US population use of CAM demonstrates an overall similarity in  use except for the US population using more prayer, herbal, and  chiropractic interventions, whereas the allergy and immunology  subspecialty was more inclined to use special diets.</li>
</ul>
<p><a name="sec3"></a></p>
<p id="back-to-article-outline-link"><a href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#article-outline">Back to Article Outline</a></p>
<h2>Risks of CAM use</h2>
<p>When  evaluating the potential risk of a medication, one must consider  intrinsic risks, which consist of predictable and expected adverse  reactions (type A) and idiosyncratic reactions (type B). Type A  reactions account for 80% of adverse reactions, whereas type B reactions  account for 6% to 10%.<a id="cross-ref-bib7" name="back-bib7" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib7"><sup>7</sup></a> In addition, there are extrinsic risks that are attributed to erroneous  handling and manufacturing of the product, resulting in misidentified  materials, contamination, substitutions, lack of standardization of the  product, adulteration, incorrect preparation of the dose, and incorrect  labeling and advertising. Although CAM is viewed as natural, it too runs  these same risks.<a id="cross-ref-bib8" name="back-bib8" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib8"><sup>8</sup></a> Unfortunately, unlike pharmacotherapy, there is no comprehensive list  of potential or predictable reactions with CAM. Along with the listed  intrinsic and extrinsic risks, some additional risks of using CAM  involve the interruption of conventional therapies because of to the  lack of perceived necessity or direct interference of therapeutic  actions and the failure to recognize the precautions of the treatment  because of the misassumption that the products are “natural” and hence  “safe.”<a id="cross-ref-bib9" name="back-bib9" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib9"><sup>9</sup></a> This misconception is alarming if one considers that 18% of people in  the United States (equivalent to 2-4 million people in February 2004)  are simultaneously using CAM and conventional medical therapies and are  thus at potential risk for a herb-drug interaction. However, some relief  is offered if one considers that in 2001, a systematic review of  herb-drug interactions included 41 case reports and 17 formal clinical  trials relating to 5 herbs that seemed to have the most potential for  such an adverse interaction. Of the 17 clinical trials, 10 trials  involved St John&#8217;s wort (<em>Hypericum perforatum</em>), and the remainder involved garlic (<em>Allium sativum)</em>, ginseng (<em>Panax ginseng)</em>, ginkgo (<em>Ginkgo biloba</em>), and kava (<em>Piper methysticum)</em>.  Considering the millions of people using CAM, this would suggest that  the real risks from the hundreds of medicinal plants is underreported,  hypothetical, or still unknown.<a id="cross-ref-bib7" name="back-bib7" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib7"><sup>7</sup></a></p>
<p>Some examples of adverse reactions with herbs are reviewed in this article&#8217;s <a id="cross-ref-appseca1" name="back-appseca1" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#appseca1">Table E1</a> in the Online Repository at <a id="inter-ref" href="http://www.jacionline.org/">www.jacionline.org</a>.  Examples of agents commonly used by patients for allergic and immune  disorders include ma huang, a Chinese herb containing ephedra previously  used to promote weight loss, which has been associated with  cardiovascular events<a id="cross-ref-bib10" name="back-bib10" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib10"><sup>10</sup></a>, <a id="cross-ref-bib11" name="back-bib11" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib11"><sup>11</sup></a> that in 2004 resulted in the US Food and Drug Administration (FDA)  banning the sale of dietary supplements with ephedrine alkaloids.  Vitamin A, which has some immunopotentiating properties (relative risk),  was studied in the Beta-Carotene and Retinol Efficacy Trial,<a id="cross-ref-bib12" name="back-bib12" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib12"><sup>12</sup></a> which evaluated the effects of β-carotene and vitamin A on the  development of lung cancer in smokers and workers exposed to asbestos.  The results showed the intervention group had a higher mortality from  lung cancer (relative risk, 1.46) and cardiovascular disease (relative  risk, 1.26). A meta-analysis of placebo-controlled trials involving  vitamin E, vitamin A, and β-carotene demonstrated increased mortality in  the intervention groups.<a id="cross-ref-bib13" name="back-bib13" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib13"><sup>13</sup></a> In addition, a recent study of Ayurvedic preparations showed that more  than 20% had been found to be contaminated with potentially toxic levels  of heavy metals including lead, mercury, and arsenic.<a id="cross-ref-bib14" name="back-bib14" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib14"><sup>14</sup></a>, <a id="cross-ref-bib15" name="back-bib15" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib15"><sup>15</sup></a> Concerns for the subspecialty of allergy and immunology are the  development of allergic responses such as anaphylaxis, asthma,  urticaria, contact dermatitis,<a id="cross-ref-bib8" name="back-bib8" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib8"><sup>8</sup></a> and the reports of drug interactions with herbal remedies<a id="cross-ref-bib16" name="back-bib16" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib16"><sup>16</sup></a> such as St John&#8217;s wort because of its ability to interact with  cytochrome oxidases, including CYP3A, resulting in alterations in  concentrations of fexofenadine, cyclosporine, and antiretroviral agents  such as indinavir.<a id="cross-ref-bib17" name="back-bib17" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib17"><sup>17</sup></a>, <a id="cross-ref-bib18" name="back-bib18" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib18"><sup>18</sup></a> Despite the 100-fold rise in reported adverse reactions to traditional  Chinese medicine (TCM) in the last 20 years, the number of adverse  events is still negligible compared with the number of adverse events  reported from conventional medical therapies, although are certainly not  to be considered without risk.</p>
<p><a name="sec4"></a></p>
<p id="back-to-article-outline-link"><a href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#article-outline">Back to Article Outline</a></p>
<h2>NCCAM and clinical trials</h2>
<p>In  the world of scientific research, randomized controlled trials are  accepted as the gold standard when defining the methodologic quality of a  clinical trial, especially a double-blind trial. When a clinical trial  is designed, attempts are made to minimize bias (placebo effects,  observational bias, sampling bias), exclude effects of cointerventions,  and prevent the progression of the natural disease course to obtain  reliable, reproducible, and generalizable results worthy of recognition.  However, some barriers exist that make such scientific designs  difficult to achieve and in some cases impossible for researchers  investigating complementary and alternative medical therapies. Examples  include finding and randomizing representative CAM sample populations  into equal comparison groups. This is challenging as a result of the  differing world views regarding CAM, because the motivation to follow  the treatment regimen is influenced by the patient&#8217;s preference. Some  have alluded to allocating patients to their preference group and  randomizing those who have no preference; however, this suggestion has  the potential for biased reporting of a positive response. In another  example resulting from ethical implications, some institutions are  hesitant to approve clinical trials using CAM when conventional  therapies exist that are both effective and evidence-based. As a result,  many clinical trials are designed using the CAM intervention as an  adjuvant to the conventional therapy, as opposed to being the primary  treatment under investigation. Blinding in some CAM therapies is also  difficult, especially in mind-body therapies such as tai chi,  acupuncture, biofeedback, and other manipulative therapies, because the  investigator is critical to the treatment intervention. Similarly,  finding a suitable control or placebo for comparison is a hurdle that  researchers have tried to overcome using sham interventions, as in the  case of acupuncture; however, this attempt has received scrutiny by  many, because some claim that sham acupuncture offers some benefits  through the process of needling. Because the mechanism of action for  most CAM therapies is yet unknown, standardized diagnostic criteria and  endpoint measurements to determine the treatment efficacy are lacking,  making it difficult to compare multiple study results accurately. Also,  some CAM regimens, such as TCM, are individualized and cannot always be  standardized for the large groups preferred in conventional randomized  controlled trials, which decreases the external validity of the results  and increases the likelihood of type II error in these studies. In  addition, this form of therapy yields results with less internal  validity than orthodox medical trials because the formulations are often  polyherbal and the effectiveness cannot be attributed to any 1  ingredient but rather is a product of the synergistic effect of the  formulation as a whole. By the same token, the efficacious results of  some Chinese herbal remedies have been linked to contamination by  steroids, as in 1 case of atopic dermatitis treated with a topical  herbal formula.<a id="cross-ref-bib19" name="back-bib19" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib19"><sup>19</sup></a> However, despite the potential for the surreptitious inclusion of  glucocorticoids in polyherbal formulations, which can explain the  positive outcome, some herbal remedies have withstood rigorous tests  disproving the presence of glucocorticoid contamination while  demonstrating efficacy.<a id="cross-ref-bib20" name="back-bib20" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib20"><sup>20</sup></a>, <a id="cross-ref-bib21" name="back-bib21" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib21"><sup>21</sup></a> Considering all the obstacles in making a well designed clinical trial,  it seems that the best approach is to allow the question under  investigation to dictate the methodology of the study design and to take  an interdisciplinary approach when determining the therapeutic  effectiveness, considering both the qualitative and quantitative data  before defining the clinical significance of the results.<a id="cross-ref-bib22" name="back-bib22" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib22"><sup>22</sup></a> NCCAM has developed a scientifically appropriate support mechanism that  has resulted in funding for more than 228 general CAM clinical trials.  Many of the initial trials have shown enough promise to warrant further  investigations, with several investigating CAM and immunity.</p>
<p><a name="sec5"></a></p>
<p id="back-to-article-outline-link"><a href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#article-outline">Back to Article Outline</a></p>
<h2>Immune impact of specific herbs and vitamins</h2>
<p><a name="sec5.1"></a></p>
<h3>Vitamin D</h3>
<p>1α-25-Dihydroxyvitamin D<sub>3</sub> (vitamin D) is a fat-soluble vitamin necessary in the human diet whose  affects include not only calcium homeostasis and bone metabolism but  also immune function. Vitamin D has its actions promoted through binding  to the vitamin D receptor (VDR) and translocating to the nucleus. A  variety of immune cells express VDR and are under investigation into the  effect of vitamin D on autoimmune or infectious diseases.<a id="cross-ref-bib23" name="back-bib23" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib23"><sup>23</sup></a> Early studies demonstrated<a id="cross-ref-bib24" name="back-bib24" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib24"><sup>24</sup></a> that the addition of vitamin D interrupted mitogenesis of T cells  because vitamin D appears to suppress preferentially the differentiation  of CD4<sup>+</sup> cells to the T<sub>H</sub>1 subtype, with subsequent shifting of the CD4<sup>+</sup> cells to the T<sub>H</sub>2 subtype,<a id="cross-ref-bib25" name="back-bib25" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib25"><sup>25</sup></a>, <a id="cross-ref-bib26" name="back-bib26" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib26"><sup>26</sup></a> and lower levels of vitamin D showing negative effects in both multiple sclerosis and inflammatory bowel disease.<a id="cross-ref-bib27" name="back-bib27" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib27"><sup>27</sup></a>, <a id="cross-ref-bib28" name="back-bib28" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib28"><sup>28</sup></a></p>
<p><a name="sec5.2"></a></p>
<h3>Vitamin E</h3>
<p>Vitamin  E is a lipid soluble molecule that is known to have at least 8  different isoforms (α, β, γ, and δ-tocopherols and α, β, γ, and  δ-tocotrienols), all with a chromanol nucleus surrounded by different  lipophilic side chains. Vitamin E intercalates itself into lipid  membranes of cells, and it can help in halting peroxidation of lipid  molecules. The activity of vitamin E in gene expression and  transcription in mast cells has been described recently as affecting the  activation of protein kinase C, protein phosphatase 2A, and protein  kinase B in mast cells,<a id="cross-ref-bib29" name="back-bib29" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib29"><sup>29</sup></a> with inhibition of protein kinase C halting the proliferation of mast cells <em>in vitro</em>,<a id="cross-ref-bib30" name="back-bib30" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib30"><sup>30</sup></a> and other studies showing inhibition of eosinophilic infiltration of mucosal surfaces.<a id="cross-ref-bib31" name="back-bib31" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib31"><sup>31</sup></a></p>
<p><a name="sec5.3"></a></p>
<h3>Vitamin A</h3>
<p>Using the theory that high levels of vitamin A shift the immune system from a predominantly T<sub>H</sub>1 to a T<sub>H</sub>2 paradigm,<a id="cross-ref-bib32" name="back-bib32" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib32"><sup>32</sup></a> vitamin A deficiency appears potentially to ameliorate experimental  asthma, whereas supplementation with vitamin A increases bronchial  hyperreactivity, levels of IL-4 and IL-5, and pulmonary eosinophilia.  The effect of vitamin A on shifting the immune response toward a T<sub>H</sub>2  phenotype and increasing antibody production has also been demonstrated  in the successful seroconversion of children vaccinated in areas known  to be vitamin A–deficient with vitamin supplementation.<a id="cross-ref-bib33" name="back-bib33" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib33"><sup>33</sup></a> The effect of vitamin A on cytokine production and shifting the body to a T<sub>H</sub>2  state has implications in common variable immunodeficiency. Two studies  have shown that supplementation with vitamin A improved antibody  production.<a id="cross-ref-bib34" name="back-bib34" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib34"><sup>34</sup></a>, <a id="cross-ref-bib35" name="back-bib35" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib35"><sup>35</sup></a></p>
<p><a name="sec5.4"></a></p>
<h3>Vitamin C</h3>
<p>Vitamin  C is an antioxidant necessary in some species that have lost the  ability to synthesize it on their own. The implication that vitamin C is  an important mediator of the immune response with an effect on  ameliorating the common cold is an idea that stretches back decades,  although early studies<a id="cross-ref-bib36" name="back-bib36" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib36"><sup>36</sup></a>, <a id="cross-ref-bib37" name="back-bib37" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib37"><sup>37</sup></a> never demonstrated an effect on the duration or intensity of the common  cold in patients supplemented with vitamin C. The connection between  vitamin C and asthma has also been of interest to researchers; however,  the results have not shown much effect of vitamin C on the pathogenesis  of asthma.<a id="cross-ref-bib38" name="back-bib38" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib38"><sup>38</sup></a>, <a id="cross-ref-bib39" name="back-bib39" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib39"><sup>39</sup></a> In a large study by Fogarty et al,<a id="cross-ref-bib40" name="back-bib40" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib40"><sup>40</sup></a> supplementation with vitamin C and magnesium had no effect on asthma symptoms. This was borne out by a recent review<a id="cross-ref-bib41" name="back-bib41" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib41"><sup>41</sup></a> of clinical trials looking at vitamin C supplementation and asthma, with most trials showing no benefit.</p>
<p><a name="sec6"></a></p>
<p id="back-to-article-outline-link"><a href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#article-outline">Back to Article Outline</a></p>
<h2>Herbal medicines and potential mechanisms of action</h2>
<p>The  potency of different herbal remedies will ultimately be related to  their individual mechanisms of action that have been scrupulously  explored over the past decade. A primary focus has been on their ability  to interact with transcription factors: the nuclear factor-κB (NF-κB)  pathway, the JAK/signal transducer and activator of transcription (STAT)  pathway, and the GATA-3 pathway (<a id="cross-ref-fig5" name="back-fig5" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#fig5">Fig 5</a>).</p>
<ul>
<li><a name="fig5"><img src="http://download.journals.elsevierhealth.com/images/journalimages/0091-6749/PIIS0091674908024391.gr5.sml.gif" alt="View full-size image." /></a>
<ul id="image-list">
<li><a name="fig5"> View Large Image </a></li>
<li><a name="fig5" href="http://download.journals.elsevierhealth.com/ppt/journals/0091-6749/PIIS0091674908024391.ppt?ll=gr5"> Download to PowerPoint </a></li>
</ul>
</li>
<li>
<h5>Fig 5.</h5>
<p>Herbal  medicines and potential mechanisms of action. NF-κB is an enzyme that  is at the center of an evolutionarily conserved proinflammatory cascade.  Initiation of the NF-κB system begins through receptors such as TNF-α  and TLR4. The inactivated NF-κB is complexed with an inhibitory protein,  IκB, which, after activation of cell membrane receptor, is a target of  phosphorylation and ubiquitination. This allows NF-κB to translocate to  the nucleus and bind to DNA. This allows transcription of  proinflammatory genes for such proteins as TNF-α, IL-1, MMP-9, IL-8,  monocyte chemoattractant protein 1 (MCP), macrophage inflammatory  protein 1α (MIP), and inducible NOS. The JAK pathway is initiated with  cytokine binding to its receptor, particularly the IFN-γ cytokine. The  receptor then dimerizes and turns on a member of the STAT family, of  which 7 have been described in human beings. This enzyme then  translocates to the nucleus and begins transcribing proteins such as  IFNs, IL-2, IL-4, and IL-12. Of interest, one of the regulators of the  STAT pathway is the suppressor of cytokine signaling family (SOCS), and  the SOCS3 enzyme has been implicated in the propagation of allergic  responses with increased expression of SOCS3, resulting in greater T<sub>H</sub>2 differentiation.<a id="cross-ref-bib105" name="back-bib105" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib105"><sup>105</sup></a>, <a id="cross-ref-bib106" name="back-bib106" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib106"><sup>106</sup></a>, <a id="cross-ref-bib107" name="back-bib107" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib107"><sup>107</sup></a> A final biochemical pathway for the JAK/STAT pathway includes the GATA  transcription family. Activation of STAT6 leads to expression of GATA-3,  which in turn will transform naive CD4<sup>+</sup> T cells into the T<sub>H</sub>2  subtype. This activation of the GATA-3 pathways has been implicated in  asthma and other allergic disorders independent of the SOCS pathway.<a id="cross-ref-bib108" name="back-bib108" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib108"><sup>108</sup></a>, <a id="cross-ref-bib109" name="back-bib109" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib109"><sup>109</sup></a> <em>ASHMI,</em> Antiasthma herbal medicine intervention; <em>EGCG</em>, epigallocatechin gallate; <em>TRAD</em>, TNF-α recepter associated death domain; <em>TRAF</em>, TNF-α receptor associated factor; <em>RelA</em>, reticuloendotheliosis viral oncogene homolog A; <em>STAT</em>, signal transducers and activators of transcription protein; <em>NOS</em>, nitric oxide synthase.</li>
</ul>
<p><a name="sec6.1"></a></p>
<h3>Magnolol</h3>
<p>One  of the many plant polyphenols that are present in herbal remedies and  have been shown to have action against NF-κB is magnolol, a constituent  of the Chinese herb Hou p&#8217;u (<em>Magnolia officinalis</em>).<a id="cross-ref-bib42" name="back-bib42" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib42"><sup>42</sup></a>, <a id="cross-ref-bib43" name="back-bib43" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib43"><sup>43</sup></a> By using an elegant assay that monitors the production of NF-κB  transcriptional products through activation via TNF-α, Chen et al<a id="cross-ref-bib42" name="back-bib42" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib42"><sup>42</sup></a> have shown that magnolol suppresses inhibitor of nuclear factor-κB  kinase β subunit activity, and thus decreases degradation of the  inhibitor of κβ enzyme. In another study, the researchers showed that  magnolol has effects beyond the IKKB activity and in fact can inhibit  activation of the STAT3/JAK pathway in IL-6–treated cells.</p>
<p><a name="sec6.2"></a></p>
<h3>Quercetin</h3>
<p>Quercetin  is a ubiquitous flavonoid found in a variety of foods, from raspberries  and apples to onions and capers. In a 2003 article, Cho et al<a id="cross-ref-bib44" name="back-bib44" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib44"><sup>44</sup></a> showed that Quercetin reduces LPS-mediated cytokine production through  NF-κB and in particular in the IKB degradation pathway. This is similar  in nature to the cascade suppression previously shown in curcumin and  magnolol.<a id="cross-ref-bib45" name="back-bib45" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib45"><sup>45</sup></a> Of interest, Quercetin has also been shown to have antiangiogenic effects <em>in vitro</em>,<a id="cross-ref-bib46" name="back-bib46" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib46"><sup>46</sup></a> as well as effects in preventing IL-1–mediated mast cell release of IL-6 without degranulation.</p>
<p><a name="sec6.3"></a></p>
<h3>Antiasthma herbal medicine interventions</h3>
<p>As  opposed to a single herbal intervention, antiasthma herbal medicine  interventions Mt Sinai School of Medicine formula 02 and food allergy  herbal formula, refined 2, are proprietary formulas containing anywhere  from 3 to 14 different herbs. In a randomized clinical trial published  in 2005, Wen et al<a id="cross-ref-bib47" name="back-bib47" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib47"><sup>47</sup></a> showed that antiasthma herbal medicine interventions produced significant improvement in FEV<sub>1</sub>,  peak expiratory flow, self-reported symptoms, and β-agonist use, and  was not associated with either adrenal dysfunction or IFN-γ suppression.  In a study in 2004,<a id="cross-ref-bib48" name="back-bib48" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib48"><sup>48</sup></a> a group studying Mt Sinai School of Medicine formula 02 showed similar  results with a decrease in IL-4 and IL-5 production, without a decrease  in IFN-γ, thus suggesting that these herbal formulas can help switch  individuals from a predominantly T<sub>H</sub>2 to a T<sub>H</sub>1 phenotype through the potential suppression of GATA-3.</p>
<p><a name="sec6.4"></a></p>
<h3>Resveratrol</h3>
<p>Resveratrol is a phytoalexin found in large amounts in the traditional Japanese and Chinese medicinal herb <em>Polygonum cuspidatum</em>,  as well as in grape skin extracts and red wine. Resveratrol is  synthesized in plant cells whenever stress (particularly fungal  invasion) or nutrient depletion occurs. Interest in resveratrol as a  nutritional supplement grew when an article published in <em>Science</em> in 1997<a id="cross-ref-bib49" name="back-bib49" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib49"><sup>49</sup></a> showed that resveratrol has potent cancer chemoprotective activity with  remarkable ability to inhibit COX-1 and COX-2. Two later studies  published in <em>Nature</em><a id="cross-ref-bib50" name="back-bib50" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib50"><sup>50</sup></a>, <a id="cross-ref-bib51" name="back-bib51" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib51"><sup>51</sup></a> further increased interest because resveratrol supplementation demonstrated an increased lifespan in <em>Caenorhabditis elegans</em> and <em>Drosophila melanogaster</em>.  In 2000, the activity of resveratrol at NF-κB was discovered to block  NF-κB reporter gene activation through inhibition of phosphorylation of  p65.<a id="cross-ref-bib52" name="back-bib52" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib52"><sup>52</sup></a> No activity at inhibitor of κβ subunit α was found. Subsequent studies  have shown that resveratrol blocks the TIR-domain–containing  adapter-inducing INF-β (TRIF) pathway, not the MyD88 pathway, in  Toll-like receptor (TLR)–dependent NF-κB activation.<a id="cross-ref-bib53" name="back-bib53" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib53"><sup>53</sup></a></p>
<p><a name="sec6.5"></a></p>
<h3>Ma huang (<em>Ephedrine sinica</em>)</h3>
<p><em>Ephedrine sinica</em> has been used for &gt;5000 years in the form of teas in TCM to treat  respiratory conditions such as asthma. In the United States, however, it  was being used for weight reduction, energy boosting, and enhancement  of physical performance by athletes. Because of its sympathomimetic  properties on α-adrenergic and β-adrenergic receptors, it became popular  as an illicit street drug with amphetamine-like effects and was abused  in the form of “ecstasy.” Ma huang is composed of 6 ephedrine alkaloids,  although the indications for its use in the United States were not  described in TCM, despite a meta-analysis in 2003 by the FDA  demonstrating its short-term effectiveness in promoting weight loss. In  2003, this agent was removed from the market after r&gt;3000 cases were  reported to the FDA, of which 30% resulted in serious adverse events  (chest pain, hypertension, myocardial infarctions, strokes, arrhythmia,  psychiatric disturbances, and death), and many involved young healthy  individuals. The safe use of this herb for decades in Chinese medicine  compared with its use in the United States was thought to be a result of  the differences in the indications for its use and the careful  combination of ma huang with synergistic herbs in Chinese herbal  concoctions, namely licorice, ginger, honey, cinnamon, and apricot  seeds, which also act to reduce its side effects. Others have proposed  that extrinsic factors including inadequate chemical analysis of  extracts, inconsistent herbal compositions, variations in herb sources,  and other idiosyncratic reactions resulted in toxicity despite use at  recommended doses, which were determined on the basis of ephedrine  content without accounting for the other undefined potent ingredients.<a id="cross-ref-bib54" name="back-bib54" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib54"><sup>54</sup></a> A new assay has since been established that uses reverse-phase HPLC to determine the exact species of <em>Ephedra</em> present in a herbal extract.<a id="cross-ref-bib55" name="back-bib55" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib55"><sup>55</sup></a> By chemically fingerprinting in this manner, one can now authenticate  ground plant materials and ensure that the active component is the plant  extract expected. In this manner, one can prevent surreptitious  inclusion of ephedra in unexpected herbal remedies. Because several  other herbal remedies have gained popularity in the treatment of atopic  diseases, many options are available for those seeking CAM discussed in  the Clinical Applications for the Practicing Allergist section below.</p>
<p><a name="sec7"></a></p>
<p id="back-to-article-outline-link"><a href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#article-outline">Back to Article Outline</a></p>
<h2>Clinical applications for the practicing allergist</h2>
<p>To  explain the biological mechanisms and provide clinical evidence of the  effectiveness of CAM remedies, 3 common atopic disease processes are  reviewed.</p>
<p><a name="sec7.1"></a></p>
<h3>Asthma</h3>
<p>Asthma is a chronic  inflammatory disease characterized by bronchial inflammation, bronchial  constriction, and increased mucus production. Although effective  conventional remedies are available, a large population (as high as 65%  among black subjects, poor subjects, less educated parents, and children  with persistent symptoms) exists that uses complementary medicines  adjunctively to minimize the need for conventional therapies and hence  avoid the profound side-effect profiles.<a id="cross-ref-bib56" name="back-bib56" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib56"><sup>56</sup></a>, <a id="cross-ref-bib57" name="back-bib57" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib57"><sup>57</sup></a> These complementary treatments for asthma fall into 1 of 5 main  categories: herbal, antioxidants, vitamins, fatty acids, and probiotics.</p>
<p>Although  several herbs have reportedly been used for the treatment of asthma, a  Cochrane Review recently conducted with 21 herbs showed mixed benefits.  For instance, <em>Tylophora indica</em> produced improvements in symptom scores &gt;50% from baseline after 1 week<a id="cross-ref-bib58" name="back-bib58" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib58"><sup>58</sup></a>, <a id="cross-ref-bib59" name="back-bib59" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib59"><sup>59</sup></a> and decreased the frequency of attacks by 50%.<a id="cross-ref-bib59" name="back-bib59" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib59"><sup>59</sup></a>, <a id="cross-ref-bib60" name="back-bib60" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib60"><sup>60</sup></a>, <a id="cross-ref-bib61" name="back-bib61" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib61"><sup>61</sup></a> Unfortunately, these effects were short-lived and were no longer  evidenced after 12 weeks of treatment. Similarly, ginger improved  symptoms by providing relief from chest tightness,<a id="cross-ref-bib62" name="back-bib62" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib62"><sup>62</sup></a> whereas pulmoflex, an Ayurvedic polyherbal formulation, provided relief to “patients experiencing deterioration.”<a id="cross-ref-bib63" name="back-bib63" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib63"><sup>63</sup></a> <em>Eucalyptol</em> demonstrated a steroid-sparing effect in a single case, although its mucolytic effect has been known for many years.<a id="cross-ref-bib64" name="back-bib64" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib64"><sup>64</sup></a> Contrary to limited subjective reports, objective measures of  improvement have been clearly reported with boswellia, a gummy resin of  the <em>Boswellia</em> tree with a long history of use in Indian herbal medicine, improving FEV<sub>1</sub><a id="cross-ref-bib65" name="back-bib65" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib65"><sup>65</sup></a> and peak expiratory flow rate (PEFR)<a id="cross-ref-bib66" name="back-bib66" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib66"><sup>66</sup></a> in adults; propolis, a resinous mixture collected by bees from various botanical sources, improved PEFR in adults.<a id="cross-ref-bib67" name="back-bib67" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib67"><sup>67</sup></a> Pycnogenol (Horphag Research, Geneva, Switzerland), a water extract of the bark of the French maritime pine (<em>Pinus pinaster</em> ssp Atlantica) containing oligomeric proanthocyanidins and bioflavonoids, had similar effects in children.<a id="cross-ref-bib68" name="back-bib68" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib68"><sup>68</sup></a> However, because of the measurements in percent of predicted FEV<sub>1</sub> and PEFR, these improvements equate to only minimal changes in actual FEV<sub>1</sub> and PEFR, and hence their clinical benefit remains undetermined.</p>
<p>The majority of CAM literature associated with allergy and asthma (<a id="cross-ref-fig2" name="back-fig2" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#fig2">Fig 2</a>) seems to focus on the effects of antioxidants and probiotics. However, 1 study<a id="cross-ref-bib69" name="back-bib69" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib69"><sup>69</sup></a> on fatty acids reported a 30% to 50% reduction in childhood asthma just  by incorporating fish, which is high in ω-3, into the child&#8217;s regular  diet. Although anecdotal, such dramatic results warrant further studies  because it is from these anecdotal reports that many of the current  studies have found their origin.<a id="cross-ref-bib70" name="back-bib70" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib70"><sup>70</sup></a> As for the antioxidants, although the list is mostly made up of vitamins and minerals (<a id="cross-ref-appseca1" name="back-appseca1" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#appseca1">Table E1</a>), there are some vitamins, such as <em>v</em>itamins A and D, that have no antioxidant affects but rather affect immune function. A recent animal model<a id="cross-ref-bib71" name="back-bib71" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib71"><sup>71</sup></a> reported that contrary to previous claims that vitamin A negatively correlated with asthma severity,<a id="cross-ref-bib72" name="back-bib72" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib72"><sup>72</sup></a> the excessive intake of vitamin A demonstrated a shift toward T<sub>H</sub>2,  resulting in pulmonary hyperresponsiveness and more deaths from asthma  in the United States compared with Third World countries, where vitamin A  deficiency resulted in death from infection.<a id="cross-ref-bib71" name="back-bib71" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib71"><sup>71</sup></a> This observation was supported by the decreased IL-4 and IL-5 levels in  bronchoalveolar lavage fluid, pulmonary eosinophilia, and suppressed  IgE and IgG<sub>1</sub> responses measured  in deficient patients. Of the vitamins that have antioxidant properties,  vitamin C is the most recognized in regard to asthma. A bivariable  analysis of children noted that despite controlling for several  potential confounding variables, of the antioxidants, children with  asthma lacked vitamin C and α-carotene.<a id="cross-ref-bib73" name="back-bib73" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib73"><sup>73</sup></a> It is proposed that perhaps the oxidative stress from the generation of  reactive oxygen and free radicals causes bronchial inflammation and  hyperreactivity, which results in a decrease in the cell&#8217;s reducing  capacity, leading to the development of asthma.<a id="cross-ref-bib74" name="back-bib74" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib74"><sup>74</sup></a>, <a id="cross-ref-bib75" name="back-bib75" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib75"><sup>75</sup></a> Moreover, it seems that although introducing fresh fruits and  vegetables after age 1 year reduced the risk of developing asthma, early  supplementation within the first 6 months actually increased the  child&#8217;s allergic sensitization to house dust mite on skin prick testing  and thereby increased the risk of developing asthma.<a id="cross-ref-bib76" name="back-bib76" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib76"><sup>76</sup></a> This effect was most prevalent among black children.<a id="cross-ref-bib77" name="back-bib77" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib77"><sup>77</sup></a> Finally, in 2007, <em>Lactobacillus</em> gained interest as a probiotic with effective therapeutic potential in allergic diseases. Because there are several strains of <em>Lactobacillus</em>, conflicting reports of its efficacy exist. Two groups found no objective evidence of beneficial effects with <em>Lactobacillus</em> GG given to marathon runners during pollen season<a id="cross-ref-bib78" name="back-bib78" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib78"><sup>78</sup></a> or with <em>Lactobacillus casei</em> given to preschool children to decrease the frequency of attacks.  However, 2 other groups used mouse models and found significant  improvements with live oral <em>Lactobacillus reuteri</em>, <em>Lactobacillus rhamnosus</em> GG, and <em>Bifidobacterium lactis</em> (Bb-12). With such mixed data on the subject, further studies are  needed to distinguish the mechanisms of action and efficacy of the  various probiotic strains before any definitive conclusions can be made.  However, one thing is clear: probiotics are vital to the healthy  maturation of the immune system after birth,<a id="cross-ref-bib79" name="back-bib79" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib79"><sup>79</sup></a> as has been demonstrated in patients with atopic dermatitis.<a id="cross-ref-bib80" name="back-bib80" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib80"><sup>80</sup></a>, <a id="cross-ref-bib81" name="back-bib81" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib81"><sup>81</sup></a></p>
<p><a name="sec7.2"></a></p>
<h3>Atopic dermatitis</h3>
<p>Atopic  dermatitis is an inflammatory cutaneous disease characterized by atopic  eczema and pruritus and is occasionally complicated by superimposed  bacterial skin infections. Like asthma, although many complementary  therapies exist for the treatment of atopic dermatitis, only a few have  been researched in terms of their efficacy, safety, and mechanism of  action. In <a id="cross-ref-appseca1" name="back-appseca1" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#appseca1">Table E1</a>,  an extensive list of complementary treatments associated with this  disease process is presented. However, even with such limited knowledge  about these alternative treatments, their popularity is worldwide, and  they are being used without inhibition.</p>
<p>Herbal remedies  predominate in the literature, whereas of the fatty acids, ω-6 fatty  acid and γ-linolenic acid, found in evening primrose (<em>Oenothera biennis</em>), is the primary agent to have therapeutic and prophylactic effects in atopic dermatitis,<a id="cross-ref-bib82" name="back-bib82" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib82"><sup>82</sup></a> associated with decreasing the redness, scaling, and itching from the lesions and preventing future exacerbations. Likewise, <em>Rumex japonicus Houtt</em><a id="cross-ref-bib83" name="back-bib83" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib83"><sup>83</sup></a> has been shown to have some efficacy in a hapten-induced mouse model of  atopic dermatitis. This herb demonstrated anti-inflammatory,  antioxidant, and antibacterial properties. By inhibiting the  histological changes in the skin (decreasing the hypertrophy,  hyperkeratosis, and infiltration of inflammatory cells in the skin), <em>R japonicus Houtt</em> decreased the development of eczematous skin lesions, and by decreasing the colonization of the skin by <em>Staphylococcus aureus</em>, it decreased scratching behavior and the frequency of exacerbations as well.</p>
<p>A  more detailed review of 12 herbs has demonstrated some effect in atopic  skin disorders. Butterbur, like montelukast, had no significant effect  on either the histamine or allergen-induced cutaneous wheal and flare  response compared with fexofenadine.<a id="cross-ref-bib84" name="back-bib84" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib84"><sup>84</sup></a> In an animal model, <em>Actinidia arguta</em> improved dermatitis skin lesions in magnesium-deficient hairless rats  by decreasing infiltration of the skin by inflammatory cells and  preventing histopathological remodeling of the dermis and epidermis  while preventing transepidermal water loss.<a id="cross-ref-bib85" name="back-bib85" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib85"><sup>85</sup></a> <em>Saururus chinensis</em>, described by the same group,<a id="cross-ref-bib86" name="back-bib86" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib86"><sup>86</sup></a> demonstrated similar anti-inflammatory effects to <em>A arguta</em>,  resulting in decreased hypertrophy and hyperkeratosis of the dermis and  epidermis and decreased itching behavior in the atopic subjects. In  addition, they demonstrated a shift toward the T<sub>H</sub>1 cell pathway with no effect demonstrated on T<sub>H</sub>2. <em>Mahonia aquifolium</em> demonstrated contrasting results: in an open-label trial in adults,  significant improvements were reported in eczema area, severity index  scores, and patient satisfaction on the basis of a posttreatment  questionnaire,<a id="cross-ref-bib87" name="back-bib87" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib87"><sup>87</sup></a> whereas a randomized, double-blind, vehicle-controlled, half-side comparison with an herbal ointment containing <em>M aquifolium, Viola tricolor</em>, and <em>Centella asiatica</em> reported no statistical improvement compared with placebo in either  primary skin symptoms or secondary assessment of pruritus,  effectiveness, and tolerability.<a id="cross-ref-bib88" name="back-bib88" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib88"><sup>88</sup></a> <em>Lyophyllum decastes</em> extracted from Hatakeshimeji mushrooms effectively lowered total skin  severity scores and serum IgE levels through its inhibitory action on  the T<sub>H</sub>2 immune response.<a id="cross-ref-bib89" name="back-bib89" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib89"><sup>89</sup></a> Konjac ceramide orally administered favored a shift toward the T<sub>H</sub>1  pathway and demonstrated improvements in the Score of Atopic Dermatitis  for skin symptoms, decreased skin responses to skin prick testing, and  decreased dust mite specific IgE production.<a id="cross-ref-bib90" name="back-bib90" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib90"><sup>90</sup></a> A randomized, double-blind, placebo-controlled monocentric trial of St  John&#8217;s wort cream containing 1.5% hyperforin (the main active  ingredient) showed effective anti-inflammatory properties resulting in  an improved appearance of the skin in patients with mild-moderate atopic  dermatitis in addition to antibacterial effects with decreased skin  colonization by <em>S aureus.</em><a id="cross-ref-bib91" name="back-bib91" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib91"><sup>91</sup></a> Persimmon leaf extract was evaluated over a period of 4 weeks by  administering 1.5 mg/kg/day of its major flavonoid astragalin. Results  showed both prophylactic and therapeutic efficacy in decreasing severity  of exacerbations of atopic dermatitis with decreased scratching  behavior, decreased transepidermal water loss, and decreased serum IgE,  and with prophylactic daily dosing there was a demonstrable decrease in  the onset and progression of exacerbations.<a id="cross-ref-bib92" name="back-bib92" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib92"><sup>92</sup></a></p>
<p>TCM  polyherbal remedies have been implicated for the treatment of atopic  dermatitis. One such formula containing 5 different herbs was  investigated<a id="cross-ref-bib21" name="back-bib21" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib21"><sup>21</sup></a> in children with moderate-severe atopic dermatitis and demonstrated a  significant decrease in corticosteroid use by one third and an  improvement in the dermatology quality of life score, although no  significant difference was noted in the allergic rhinitis score or the  Score of Atopic Dermatitis. Zemaphyte (Phytofarm Plc, London, United  Kingdom), a Chinese herb, also demonstrated clinical improvements in  atopic dermatitis with decreased erythema, decreased surface damage, and  decreased itching of the skin with few minor gastrointestinal side  effects. Bhu-zong-yi-qi-tang is a polyherbal compound made up of 10  herbs with effectiveness as a prophylactic agent in allergic rhinitis  and also therapeutic potential in atopic dermatitis because it decreased  serum IgE levels in a mouse model. Finally, BSASM is also a  multicompound preparation with anti-inflammatory effects in atopic  dermatitis demonstrated by improvements in pruritus, transepidermal  water loss, and eczema area severity index scores. It is thought to act  by inducing NF-κB activation, reducing IL-8 and TNF-α production, and  inhibiting IL-2 production in Jurkat T cells, although the true  mechanism is still under investigation. One thing is clear: the  effectiveness of such polyherbal formulas, whether it is BSASM or  bu-zhong-yi-qi-tang, is attributed to the synergistic effects of their  individual components, which exemplifies the tenet that the whole  exceeds sum of the parts—that is, the synergistic effects of these  components, although they are a strong force together (the whole), have  only a fraction of the efficacy when tried individually (the parts).</p>
<p><a name="sec7.3"></a></p>
<h3>Allergic rhinitis</h3>
<p>A  large proportion of the literature in CAM and allergy clinical studies  has been focused on the impact of multiple herbal remedies on allergic  rhinitis<a id="cross-ref-bib2" name="back-bib2" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib2"><sup>2</sup></a> (<a id="cross-ref-appseca1" name="back-appseca1" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#appseca1">Table E1</a>).</p>
<p>Butterbur  is a perennial shrub whose root contains the active compound petasins.  Adult studies showed butterbur proved efficacious compared with placebo  in sustaining nasal inspiratory flow while being challenged with a  potent nasal congestant, adenosine monophosphate,<a id="cross-ref-bib93" name="back-bib93" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib93"><sup>93</sup></a> and when compared with fexofenadine, it provided equally significant  effective relief from intermittent allergic rhinitis both by subjective  patient ratings and by the physician&#8217;s global assessment.<a id="cross-ref-bib94" name="back-bib94" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib94"><sup>94</sup></a> <em>Urtica dioica</em> is a plant whose leaf, flower, seed, and root each contain different  chemical constituents, including histamine, thus the common name  stinging nettle. Medicinal extracts contain polysaccharides and caffeic  malic acid, found in all parts of nettle, which relieved most of the  rhinoconjunctivitis symptoms in 58% of subjects and provided greater  efficacy than over-the-counter remedies in 48%.<a id="cross-ref-bib95" name="back-bib95" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib95"><sup>95</sup></a> Citrus unshiu powder demonstrated relief from seasonal allergic  rhinitis to Japanese cedar pollen with dose-dependent inhibition of  histamine and β-hexosaminidase, a marker for mast cell degranulation.<a id="cross-ref-bib96" name="back-bib96" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib96"><sup>96</sup></a> The 3 flavonoids credited for these effects are hesperetin, hesperidin, and nobiletin. Both <em>Lycopus lucidus</em> plant extract<a id="cross-ref-bib97" name="back-bib97" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib97"><sup>97</sup></a> and <em>Amomum xanthiodes</em><a id="cross-ref-bib98" name="back-bib98" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib98"><sup>98</sup></a> have demonstrated antihistamine and anti-inflammatory potential to  prevent fatal systemic allergic reactions and IgE-induced passive  cutaneous anaphylaxis in mice. Although the objective data are  significantly favorable for CAM, one must consider the data in context,  keeping in mind that the study of <em>U dioica</em> is an open-trial study, and no quantitative data were measured. As for citrus unshiu powder, <em>L lucidus</em>, and <em>A xanthiodes</em>, <em>in vivo</em> trials are needed to determine whether the findings from the rat models  can be accurately extrapolated to real clinical practices.</p>
<p>Likewise,  dietary products like grape seed extract, tomato extract, dietary  spirulina, and cellulose powder have been suggested for the treatment of  allergic rhinitis. Unfortunately, no evidence was found to support the  efficacy of grape seed extract,<a id="cross-ref-bib99" name="back-bib99" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib99"><sup>99</sup></a> and only an insignificant downward trend in serum-measured eosinophil  cationic protein concentrations was seen with tomato extract.<a id="cross-ref-bib100" name="back-bib100" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib100"><sup>100</sup></a> However, dietary <em>Spirulina</em>,  a filamentous blue-green alga, with its main active ingredient  C-phycocyanin, did demonstrate antiallergic effects by inhibiting  histamine release from mast cell–mediated allergic reactions and by  suppressing IL-4, thereby inhibiting the T<sub>H</sub>2 synthesis of IgE.<a id="cross-ref-bib101" name="back-bib101" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib101"><sup>101</sup></a> Likewise, cellulose powder administered to the nasal mucosa proved  beneficial in enhancing the filtration of allergens and irritants from  inhaled air, similar to one&#8217;s normal mucus providing complete resolution  of rhinoconjunctivitis in 77% of subjects.<a id="cross-ref-bib102" name="back-bib102" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib102"><sup>102</sup></a> Although the trials investigating dietary supplements are designed in a  randomized double-blind manner, the data are qualitative, measuring  subjective symptom scores and quality of life questionnaires. More  objective endpoint measurements and large-scale studies are needed to  lend internal and external validity to the conclusions drawn.</p>
<p><a name="sec7.4"></a></p>
<h3>Indian Ayurvedic medicine</h3>
<p>The 2 most studied regimens in this group include a polyherbal formula called Aller-7 and <em>Tinospora cordifolia</em>.  Aller-7 has demonstrated anti-inflammatory properties in rat models and  has shown improvement in rhinitis and total nasal symptom scores that  correlate with objective measurements.<a id="cross-ref-bib103" name="back-bib103" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib103"><sup>103</sup></a> Similarly, <em>T cordifolia</em> provided significant relief from sneezing, nasal discharge, nasal  obstruction, and nasal pruritus compared with placebo with consistent  improvements on examination of the nasal smears and nasal mucosa.<a id="cross-ref-bib104" name="back-bib104" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib104"><sup>104</sup></a></p>
<p><a name="sec7.5"></a></p>
<h3>TCM</h3>
<p>As mentioned, Bhu-zong-yi-qi-tang has shown proven effects in both allergic rhinitis<a id="cross-ref-bib105" name="back-bib105" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib105"><sup>105</sup></a> and atopic dermatitis. Another polyherbal formula important to the  treatment of allergic rhinitis is biminne, made of 11 constituents, each  with anti-inflammatory, antioxidant, and antiallergic properties.  Although the mechanism of action is unclear, there are subjective  reports of improvement in symptoms that correlate with total serum IgE  levels, physician evaluations, and sustained effects after 1 year.<a id="cross-ref-bib106" name="back-bib106" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib106"><sup>106</sup></a> Last, Shi-Bi-Lin, a modified form of Cang Er Zi San, has proven to be  an effective therapeutic choice with its anti-inflammatory effects on  the suppression of IL-4, TNF-α, and IL-6 production.<a id="cross-ref-bib107" name="back-bib107" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib107"><sup>107</sup></a> No effect was demonstrated on the messenger RNA sequence for these  cytokines, so the mechanism of cytokine modulation remains unknown.</p>
<p><a name="sec7.6"></a></p>
<h3>Kampo medicine (Japanese)</h3>
<p>Kampo  agents Sho-seiryu-to and rosmarinic acid are the main CAM agents used  in Japanese culture. Sho-seiryu-to is a polyherbal formula with evidence  of shifting toward a T<sub>H</sub>2  response, resulting in decreased IL-4 and allergen-specific IgE  production consistent with the improvement in allergen-specific sneezing  in mice. No effect was seen on IFN-α.<a id="cross-ref-bib108" name="back-bib108" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib108"><sup>108</sup></a> Rosmarinic acid, on the other hand, decreased leukocyte infiltration in  the nostrils, demonstrated by subjective improvements in symptoms that  correlate with improvements seen by nasal lavage. Polyherbal  preparations as seen with Ayurvedic, Kampo, and TCM require carefully  designed intricate studies to understand the mechanism of action and the  active ingredients responsible for their efficacy. The polyherbal  formulas reviewed in this article are all investigated via high-quality  randomized trials with reliable reproducible results. Future studies  should build on the results of these trials with the aim to follow  long-term outcomes via prospective trials.</p>
<p>In conclusion, the data  on complementary remedies are extensive but as of yet remain  scientifically unclear because there are conflicting results about  efficacy, and well controlled trials with reliable data are limited.  More independently funded replications of the isolated randomized  controlled trials published are needed to confirm the accuracy and  validity of the study findings. The National Institutes of Health  establishing the National Center for Alternative and Complementary  Medicine is a major step forward to unraveling the science of CAM and  assisting in integrating those interventions that have passed not just  the test of time but also the test of validation. Future trials should  include larger studies to account for the subject variations in the  extent of allergen exposure and sensitization and disease severity to  avoid any confounding variables. Also, better documentation of the  methods of randomization and blinding to ensure appropriate allocation  concealment will lend strength to the conclusions drawn. Last, reliable  subjective and valid objective measurement outcomes are key to confirm  the data and conclusions of any study design are trustworthy, even more  so in the study of medicine.</p>
<p><a name="sec7.7"></a></p>
<h3>Conclusions</h3>
<p>&nbsp;</p>
<div>•Further  studies are required using larger sample sizes, longer study durations,  comparable absolute measures, and well constructed study designs that  control for biases. Incorporating these changes will increase the power  and validity of the results so the validated CAM interventions can be  integrated into the general treatment of patients with asthma and  allergies.</div>
<div>•Although  many herbs are listed in the treatment of atopic disorders, few have  actually been investigated with well controlled clinical trials.</div>
<div>•One mechanistic theme that has been found in many of the trials is the suppression of the T<sub>H</sub>2 cytokine pathway involving IL-4 and IL-13, which promote IgE synthesis, or enhancing the T<sub>H</sub>1 cytokine pathway, increasing IFN-γ synthesis, which inhibits IgE synthesis.</div>
<div>•A  major tenet that seems to be true is that the whole exceeds sum of the  parts. The synergistic effects of individual components of polyherbal  formulations have a concatenate effect together, but may have only a  fraction of the efficacy when assessed individually.</div>
<p><a name="sec7.8"></a></p>
<h3>What do we know?</h3>
<p>&nbsp;</p>
<div>•CAM  is made up of 5 domains: alternative medical systems, biologically  based therapies, manipulative therapies, mind-body therapies, and energy  therapies.</div>
<div>•The  popularity of CAM among the public sector is rapidly increasing, as  evidenced by the increased expenditure on CAM and increased use reported  by patients to their physicians.</div>
<div>•Some  CAM practices can favorably work in a complementary fashion (not as an  alternative) in treating symptoms of allergic and immune disorders.</div>
<p><a name="sec7.9"></a></p>
<h3>What is still unknown?</h3>
<p>&nbsp;</p>
<div>•The true efficacy and safety of CAM therapies</div>
<div>•The efficacy of CAM therapies alone (as alternatives) in the treatment of various disorders</div>
<div>•The individual CAM therapeutic mechanism of effects (some may be multiple)</div>
<div>•The active component of individual CAM therapies.</div>
<div>•The potential drug-drug and drug-herb-phytochemical and vitamin interactions</div>
<p id="appendices"><a name="appseca1"></a></p>
<p id="back-to-article-outline-link"><a href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#article-outline">Back to Article Outline</a></p>
<h2>Table E1.</h2>
<h5 id="table-heading-">Clinical evidence of CAM safety and efficacy in asthma and allergy</h5>
<div>
<table>
<thead>
<tr>
<th>Remedy</th>
<th>Mechanism of action</th>
<th>Adverse events</th>
<th>Clinical evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin A<a id="cross-ref-E1" name="back-E1" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E1"><sup>E1</sup></a>, <a id="cross-ref-E2" name="back-E2" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E2"><sup>E2</sup></a></td>
<td>
<div>Immunomodulatory vitamin</div>
<div>Deficiency causes decreased serum IgE and IgG<sub>1</sub></div>
<div>Excess promotes T<sub>H</sub>2 response with pulmonary eosinophilia and increased IL-4 and IL-5 in bronchoalveolar lavage fluid (BAL)</div>
</td>
<td>Severe prolonged deficiency causes xerophthalmia</td>
<td>
<div>Deficiency in Third World countries causes death from infection</div>
<div>Excess in United States causes death from pulmonary hyperresponsiveness and asthma exacerbations</div>
<div>Vitamin A has negative correlation with asthma severity</div>
<div>Children with asthma have 4× higher risk for vitamin on A deficiency</div>
</td>
</tr>
<tr>
<td>Vitamin C<a id="cross-ref-E2" name="back-E2" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E2"><sup>E2</sup></a>, <a id="cross-ref-E3" name="back-E3" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E3"><sup>E3</sup></a>, <a id="cross-ref-E4" name="back-E4" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E4"><sup>E4</sup></a>, <a id="cross-ref-E5" name="back-E5" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E5"><sup>E5</sup></a></td>
<td>
<div>Antioxidant vitamin found in fresh fruits, vegetables, and whole grains</div>
<div>Oxidative  stress from the generation of reactive oxygen and free radicals causes  bronchial inflammation and hyperreactivity, which results in a decrease  in the cell&#8217;s reducing capacity and the development of asthma</div>
</td>
<td>Nausea, vomiting, and diarrhea at high doses</td>
<td>
<div>A  bivariable analysis of &gt;4000 children showed subjects with asthma  had significantly decreased levels of serum vitamin C, α-carotene,  β-carotene, and β-cryptoxanthin; after controlling for confounding  variables including age, body mass index, socioeconomic status,  antioxidant levels, parental asthma, and household smoking, only vitamin  C and α-carotene were deficient</div>
<div>A  case-control study demonstrated subjects with asthma to have a lower  level of serum vitamin A and plasma lycopene with no effects noted on  vitamin E or β-carotene levels</div>
</td>
</tr>
<tr>
<td>Vitamin B6, B12, and E<a id="cross-ref-E6" name="back-E6" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E6"><sup>E6</sup></a></td>
<td>
<div>Antioxidant vitamin</div>
<div>Same mechanism as above</div>
</td>
<td>No serious side effect reported</td>
<td>Decreased  levels of vitamins B1and B6 were measured in children with asthma being  treated with theophylline with a negative dose-dependent relationship  between vitamin B6 and theophylline; no effects were seen on vitamin A,  B2, B12, or C</td>
</tr>
<tr>
<td><em>Rumex japonicus Houtt</em><a id="cross-ref-E7" name="back-E7" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E7"><sup>E7</sup></a></td>
<td>
<div>Antioxidant</div>
<div>Antiinflammatory</div>
<div>Antibacterial</div>
<div>Suppresses T<sub>H</sub>2 cells, which in turn decrease serum IL-4 levels and reduce the total IgE levels</div>
<div>No effect on IFN-γ or the T<sub>H</sub>1 pathway</div>
</td>
<td>None</td>
<td>
<div>Anti-inflammatory:  prevents histological skin changes of atopic dermatitis (hypertrophy,  hyperkeratosis, and infiltration of inflammatory cells)</div>
<div>Antibacterial: decreased pruritus and skin colonization by <em>S aureus</em></div>
</td>
</tr>
<tr>
<td>ω-3<a id="cross-ref-E8" name="back-E8" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E8"><sup>E8</sup></a></td>
<td>Fatty acid</td>
<td>No serious events reported</td>
<td>30% to 50% reduction in childhood asthma just by incorporating fish into child&#8217;s diet</td>
</tr>
<tr>
<td>ω-6<a id="cross-ref-E9" name="back-E9" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E9"><sup>E9</sup></a></td>
<td>Fatty acid</td>
<td>No serious events reported</td>
<td>Supposed  to reduce the severity of atopic dermatitis by decreasing the redness,  scaling, and itching of the skin and prevent future exacerbations but  has not yet been scientifically confirmed with controlled trials</td>
</tr>
<tr>
<td></td>
<td>The oil extracted from the seeds of the evening primrose is applied to the skin as an emollient</td>
<td></td>
<td>Claims that ω-6-fatty acid is deficient in subjects with asthma are unproven</td>
</tr>
<tr>
<td><em>Lactobacillus</em><a id="cross-ref-E10" name="back-E10" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E10"><sup>E10</sup></a>, <a id="cross-ref-E11" name="back-E11" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E11"><sup>E11</sup></a>, <a id="cross-ref-E12" name="back-E12" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E12"><sup>E12</sup></a>, <a id="cross-ref-E13" name="back-E13" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E13"><sup>E13</sup></a></td>
<td>
<div>Probiotic</div>
<div>Inhibits eosinophil influx to the airway lumen and parenchyma</div>
<div>Decreases levels of TNF, monocyte chemoattractant protein 1, IL-5, and IL-13 in bronchoalveolar lavage fluid</div>
</td>
<td>None</td>
<td>
<div><em>Lactobacillus</em> GG did not decrease allergic markers like serum eosinophilia, total IgE, or serum eosinophil cationic protein</div>
<div><em>L casei</em> showed no improvement in the frequency of asthma attacks in children but did decrease the annual number of rhinitis episodes</div>
<div>Mice with antigen-challenged allergic airway inflammation treated with oral live <em>L reuteri</em> inhibited the T<sub>H</sub>2  pathway, resulting in decreased IL-5 and IL-13 in addition to showing  inhibitory effects on proinflammatory chemokines TNF and monocyte  chemoattractant protein 1; the killed strain had no affect on eotaxin or  IL-10</div>
<div><em>L rhamnosus</em> GG and <em>B lactis</em> (Bb-12) treatment in newborn mice decreased antigen specific IgE and decreased pulmonary eosinophilia; <em>L rhamnosus</em> also inhibited the T<sub>H</sub>2  response, resulting in decreased IL-4, IL-5, and IL-10 production in  addition to increasing the production of TGF-β–secreting CD4<sup>+</sup>CD3<sup>+</sup> cells</div>
</td>
</tr>
<tr>
<td>Butterbur<a id="cross-ref-E14" name="back-E14" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E14"><sup>E14</sup></a>, <a id="cross-ref-E15" name="back-E15" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E15"><sup>E15</sup></a>, <a id="cross-ref-E16" name="back-E16" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E16"><sup>E16</sup></a>, <a id="cross-ref-E17" name="back-E17" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E17"><sup>E17</sup></a></td>
<td>
<div>Inhibits  mast cell stimulation, possibly through the leukotriene pathway,  causing decreased production and release of histamines and leukotrienes;  mechanism is still unclear.</div>
<div>Inhibits <em>in vitro</em> synthesis of leukotrienes in human eosinophils, neutrophils, and macrophages</div>
<div>Decreases intracellular calcium concentration and mobilization</div>
</td>
<td>
<div>Unpurified  form (pyrrolizidine alkaloid compound) is hepatotoxic and carcinogenic  and causes decreased testosterone levels in rats; purified form is safe  with unaffected liver biochemistry after 2 weeks of treatment</div>
<div>20% belching</div>
<div>3.8% nausea, abdominal pain</div>
</td>
<td>
<div>Atopic  dermatitis: no significant effect on immediate histamine and allergen  cutaneous response in double-blind, double-dummy, cross-over study  against placebo, fexofenadine, and montelukast</div>
<div>Allergic  rhinitis: faster recovery time and less drop in peak nasal expiratory  flow scores after nasal adenosine monophosphate challenge with butterbur</div>
<div>Butterbur  and fexofenadine equally significant, effective relief for seasonal  allergic rhinitis based on subjective symptom score and physician&#8217;s  global assessment</div>
</td>
</tr>
<tr>
<td><em>A arguta</em><a id="cross-ref-E18" name="back-E18" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E18"><sup>E18</sup></a></td>
<td>
<div>Anti-inflammatory effects on skin</div>
<div>Prevents histological remodeling and water loss from the upper skin layers</div>
<div>DA-9102 isolated from <em>A</em></div>
<div><em>arguta</em> showed suppression of T<sub>H</sub>2 cytokine pathway with decreased IL-4 and IL-10 and resulting in decreased IgE synthesis</div>
</td>
<td>None</td>
<td>
<div>Magnesium-deficient,  hairless rats treated with 100 mg/day showed effective resolution of  dermatitis by decreasing infiltration of the skin by inflammatory cells,  preventing histopathological remodeling of the dermis and epidermis,  and preventing transepidermal water loss</div>
<div>Flow cytometry showed:</div>
<div>•Decreased CD45RA<sup>+</sup> cells resulting in decreased serum IgE</div>
<div>•Decreased CD11b<sup>+</sup> cells in the skin and periphery</div>
<div>•Decreased serum nitric oxide and leukotriene B4</div>
<div>•Decreased T<sub>H</sub>2 mRNA expression resulting in decreased IL-4 and IL-10 cytokines and hence decreased IgE synthesis</div>
</td>
</tr>
<tr>
<td><em>S chinensis</em><a id="cross-ref-E19" name="back-E19" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E19"><sup>E19</sup></a></td>
<td>Promoted a shift toward the T<sub>H</sub>1 cell response pathway with increased IFN-γ mRNA expression, whereas no effect was seen on IL-4 mRNA associated with T<sub>H</sub>2</td>
<td>No serious adverse events</td>
<td>Administered  subcutaneously 5 days a week × 8 weeks; showed decreased infiltration  of inflammatory cells into the skin, decreased hypertrophy and  hyperkeratosis of the dermis and epidermis, and decreased itching  behavior in the atopic subjects; objectively decreased serum IgE levels  were measured</td>
</tr>
<tr>
<td><em>M aquifolium</em><a id="cross-ref-E19" name="back-E19" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E19"><sup>E19</sup></a>, <a id="cross-ref-E20" name="back-E20" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E20"><sup>E20</sup></a>, <a id="cross-ref-E21" name="back-E21" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E21"><sup>E21</sup></a></td>
<td>Topical application</td>
<td>Itching or burning sensation</td>
<td>Open-label  trial in adults over a period of 12 weeks demonstrated significant  improvements in eczema area and severity index scores with ointment, and  posttreatment subjective questionnaire revealed confirmatory reports of  improvement in itching, appearance of skin lesions, and effectiveness  of the ointment</td>
</tr>
<tr>
<td></td>
<td>Not described in the study</td>
<td></td>
<td>Randomized, double-blind, vehicle-controlled, half-side comparison of ointment containing <em>M aquifolium</em>, <em>V tricolor</em>, and <em>C asiatica</em> showed no statistical improvement in primary outcomes (erythema, edema,  papulation, oozing, crust, excoriation and lichenification) or  secondary outcomes (pruritus severity and a global assessment of  effectiveness and tolerance)</td>
</tr>
<tr>
<td><em>L decastes</em><a id="cross-ref-E22" name="back-E22" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E22"><sup>E22</sup></a></td>
<td>
<div>Extracted from Hatakeshimeji mushrooms</div>
<div>Inhibits T<sub>H</sub>2 immune response, IL-4 expression, and hence serum IgE</div>
<div>No effect on IFN-γ expression</div>
</td>
<td>No serious adverse events</td>
<td>Atopic  dermatitis-like skin lesions induced by repeated application of picryl  chloride in NC/Nga mice demonstrated lower total skin severity scores  and decreased serum IgE after oral herbal treatment</td>
</tr>
<tr>
<td>Konjac ceramide<a id="cross-ref-E23" name="back-E23" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E23"><sup>E23</sup></a></td>
<td>
<div>Favors the inhibitory T<sub>H</sub>1 cytokine pathway involving increased IFN-γ and IL-12</div>
<div>T<sub>H</sub>2 pathway was notably inhibited with decreased levels of IL-4 and IL-13</div>
</td>
<td>No serious events noted</td>
<td>Konjac  ceramide 1.8 mg/day administered orally for 2 weeks to atopic patients  with house dust mite allergy demonstrated improvements in the Score of  Atopic Dermatitis for skin symptoms, decreased skin responses to skin  prick testing, and decreased dust mite specific IgE</td>
</tr>
<tr>
<td>St John&#8217;s wort<a id="cross-ref-E24" name="back-E24" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E24"><sup>E24</sup></a></td>
<td>
<div>Anti-inflammatory</div>
<div>Antibacterial</div>
<div>Main active ingredient = hyperforin</div>
</td>
<td>None reported</td>
<td>A  randomized, double-blind, placebo-controlled monocentric trial in  patients with mild-moderate atopic dermatitis applying St John&#8217;s wort  ointment containing 1.5% hyperforin vs placebo twice a day for 4 weeks  showed that the eczematous lesions improved superiorly compared with  placebo on all follow-ups day 7, 14, and 28, and it proved to be an  effective antibacterial agent by decreasing the skin colonization by <em>S aureus</em></td>
</tr>
<tr>
<td>Persimmon leaf extract<a id="cross-ref-E25" name="back-E25" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E25"><sup>E25</sup></a></td>
<td>
<div>Major flavonoid = astragalin</div>
<div>Inhibits histamine release from basophils</div>
</td>
<td>None reported</td>
<td>Astragalin  1.5 mg/kg administered for 4 weeks proved demonstrable effects in the  treatment and prophylaxis of atopic dermatitis with decreased skin  severity including scratching behavior, decreased transepidermal water  loss, and decreased serum IgE; daily dosing showed prophylactic effect  of decreasing the onset and development of exacerbations</td>
</tr>
<tr>
<td>Zemaphyte<a id="cross-ref-E26" name="back-E26" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E26"><sup>E26</sup></a></td>
<td>
<div>Antioxidant</div>
<div>Not described but may inhibit IL-4</div>
<div>No longer manufactured</div>
</td>
<td>
<div>No major changes were observed in blood, renal, and liver function tests</div>
<div>Minor:  dizziness, gastrointestinal discomfort (mild nausea, loose bowels,  flatulence), headache, urticaria, photosensitivity, exacerbation of  eczema, night diuresis, discoloration of teeth, and both bilirubin and  creatinine values outside normal limits</div>
</td>
<td>Four  randomized clinical trials each lasting 8 weeks were evaluated by  Cochrane Review; of these, 3 trials were of a cross-over design, with 2  trials reporting improvements in the eczematous skin lesions measured by  decreased erythema and decreased surface damage; 1 trial reported  decreased itching; the fourth trial was an open-label trial that  compared herbal Zemaphyte with a freeze-dried preparation; both forms  demonstrated decreased erythema and skin surface damage, although the 2  forms were not compared against each other</td>
</tr>
<tr>
<td>TCM polyherbal formula<a id="cross-ref-E27" name="back-E27" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E27"><sup>E27</sup></a></td>
<td>
<div>Consists of 5 herbs (total 9 g of raw herbs):</div>
<div>•<em>Flos lonicerae</em> (Jinyinhua) 2 g</div>
<div>•Herba menthae (Bohe) 1 g</div>
<div>•Cortex moutan (Danpi) 2 g</div>
<div>•Rhizoma atractylodis (Cangzhu) 2 g</div>
<div>•Cortex phellodendri (Huangbai) 2 g</div>
</td>
<td>No serious adverse effects</td>
<td>The  study trial took place over 12 weeks with treatments of 3 tablets twice  a day administered to subjects with moderate-severe atopic dermatitis;  every 4 weeks for 4 months, the requirement for topical corticosteroid  and oral antihistamine was assessed and values were recorded for Score  of Atopic Dermatitis symptoms, Children&#8217;s Dermatology Life Quality  Index, and the allergic rhinitis score; although no significant  difference was found in any of the scores between placebo and treatment  groups, in the fourth month a significant improvement was reported in  the Dermatology Life Quality Index score, and a significant reduction by  one third was reported by the treatment group for corticosteroid use</td>
</tr>
<tr>
<td>Bu-zhong-yi-qi-tang<a id="cross-ref-E28" name="back-E28" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E28"><sup>E28</sup></a>, <a id="cross-ref-E29" name="back-E29" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E29"><sup>E29</sup></a></td>
<td>
<div>Composed of 10 herbs:</div>
<div>•<em>Astragalus mongholicus</em></div>
<div>•<em>Citrus reticulata</em></div>
<div>•<em>Panax ginseng</em></div>
<div>•<em>Atractylodes macrocephala</em></div>
<div>•<em>Angelica dahurica</em></div>
<div>•<em>Cimicifuga foetida</em></div>
<div>•<em>Bupleurum chinense</em></div>
<div>•<em>Zingiber officinale</em></div>
<div>•<em>Ziziphus jujuba</em></div>
<div>•<em>Glycyrrhiza uralensis</em></div>
<div>Mechanism of action is not clear</div>
</td>
<td>Not addressed</td>
<td>
<div>Improved nasal symptom scores in treated group while no change in symptoms with placebo</div>
<div>Total serum IgE and IL-4–stimulated prostaglandin E<sub>2</sub> and leukotriene C<sub>4</sub> production by polymorphonuclear neutrophilic leukocyte suppressed with Bu-zhong-yi-qi-tang (BZYQT)</div>
<div>COX-2 mRNA expression ameliorated with BZYQT</div>
<div>Demonstrated  the ability to suppress spontaneous atopic dermatitis and decrease  serum IgE levels in NC/Nga mice with intractable atopic dermatitis when  administered in the oral form</div>
</td>
</tr>
<tr>
<td>BSASM<a id="cross-ref-E30" name="back-E30" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E30"><sup>E30</sup></a></td>
<td>
<div>Anti-inflammatory</div>
<div>Blocks T-cell–mediated immune response</div>
<div>Inhibited LPS-induced NF-κB activation</div>
<div>Reduced LPS-induced production of IL-8 and TNF-α</div>
<div>Inhibited IL-2 production in Jurkat T cells</div>
<div>Mechanism of action not yet clearly defined</div>
</td>
<td>No serious adverse reactions</td>
<td>Demonstrated  a reduction of eczema area severity index score, decrease of pruritus,  and decrease of transepidermal water loss both on the antecubital fossa  and abdomen</td>
</tr>
<tr>
<td><em>U dioica</em><a id="cross-ref-E31" name="back-E31" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E31"><sup>E31</sup></a></td>
<td>
<div>Polysaccharides stimulate T-lymphocyte activity and complement activation <em>in vitro</em></div>
<div>Polysaccharides and caffeic malic acid demonstrate anti-inflammatory activity <em>in vitro</em> and in animal models via COX and lipoxygenase inhibition</div>
</td>
<td>
<div>The nettle leaf contains histamine causing erythematous macules and itching.</div>
<div>(wheals and flares)</div>
</td>
<td>Open trial: 58% relief of most symptoms, 48% greater efficacy than over-the-counter remedies</td>
</tr>
<tr>
<td>Citrus unshiu powder<a id="cross-ref-E32" name="back-E32" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E32"><sup>E32</sup></a></td>
<td>
<div>Flavonoids  hesperidin and nobiletin inhibit histamine and β-hexosaminidase, a  molecular marker from mast cell degranulation; hesperidin was the more  potent of the 2</div>
<div>Flavonoid  hesperidin suppressed phosphorylation of Akt, a serine/threonine kinase  and direct effector of PI3-K that is involved in IgE-mediated basophil  stimulation</div>
<div>Hesperidin showed no effect on mast cell degranulation</div>
</td>
<td>Not addressed in study</td>
<td>
<div>Decreased histamine release from basophils at 1.6 mg/mL; degree of inhibition is patient-dependent</div>
<div>Decreased β-hexosaminidase between 8 mg/mL and 16 mg/mL</div>
<div>Histamine and β-hexosaminidase inhibited with 100 μM hesperidin and 500 μM nobelitin</div>
<div>Hesperidin  had no effect on mast cell degranulation, but it does suppress  phosphorylation of Akt, a serine/threonine kinase and direct effector of  PI3-K, and thus inhibits IgE-mediated basophil stimulation</div>
<div>Hesperidin  is absorbed in its intact form and detectable in plasma and urine,  whereas hesperidin is metabolized to hesperidin glycoside in the  intestinal tract</div>
</td>
</tr>
<tr>
<td><em>L lucidus</em> plant extract<a id="cross-ref-E33" name="back-E33" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E33"><sup>E33</sup></a></td>
<td>Inhibits  synthetic compound 48/80 causing inhibition of intracellular calcium  mobilization and interrupting mast cell degranulation cascade, resulting  in inhibition of histamine release</td>
<td>Not addressed in study</td>
<td>Dose-dependent  inhibition of 48/80 synthetically induced allergic reaction with  inhibition of intracellular calcium mobilization, mast cell  degranulation, and histamine release</td>
</tr>
<tr>
<td></td>
<td>Inhibits  p38-mitogen-activated protein kinase (MAPK), necessary for expression  of inflammatory cytokines, and prevents NF-κB DNA binding, resulting in  decreased expression of proinflammatory cytokines TNF-α and IL-6,  thereby inhibiting inflammatory cascade</td>
<td></td>
<td>Inhibition of p38-MAPK and prevention of NF-κB DNA binding causing decreased expression of TNF-α and IL-6 inflammatory cytokine</td>
</tr>
<tr>
<td><em>Amomum xanthiodes</em><a id="cross-ref-E34" name="back-E34" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E34"><sup>E34</sup></a></td>
<td>Inhibits  48/80-induced histamine release from mast cells via inhibition of  intracellular calcium resulting in decreased IgE-mediated passive  cutaneous anaphylaxis (PCA) reaction and inhibited p38-MAPK and hence  decreased TNF-α production</td>
<td>Not addressed in study</td>
<td>
<div>Same findings as <em>L lucidus</em></div>
<div>Also decreased IgE-mediated PCA reaction</div>
</td>
</tr>
<tr>
<td>Grape seed extract<a id="cross-ref-E35" name="back-E35" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E35"><sup>E35</sup></a></td>
<td>
<div>Contains catechins, epicatechins, proanthocyanidins, and polyphenolic bioflavonoid antioxidants</div>
<div>Catechin monomers inhibit allergen-induced histamine release in passively sensitized rat peritoneal mast cells</div>
</td>
<td>No laboratory abnormalities detected</td>
<td>No significant difference in symptom scores, rhinitis quality of life scores, or use of rescue chlorpheniramine</td>
</tr>
<tr>
<td>Tomato extract<a id="cross-ref-E28" name="back-E28" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E28"><sup>E28</sup></a></td>
<td>
<div>Contains  the polyphenol naringenin chalcone, the main active component  responsible for the antiallergic property of tomato extract</div>
<div>ECP is an allergy pathway mediator whose production is dependent on the number and activity of eosinophils in the serum</div>
<div>Decreased  ECP concentrations in the treatment group suggests that tomatoes act by  decreasing the number of eosinophils present, thereby decreasing the  quantity of histamine released</div>
</td>
<td>
<div>No  serious adverse effects were observed; cold and diarrhea were reported  by some but spontaneously resolved during the study and were of  questionable relation to the study extract</div>
<div>No significant changes noted in urinalysis, blood, or biochemistry in either study group</div>
</td>
<td>
<div>Significant improvement in total nasal symptom scores (sneezing, rhinorrhea, and nasal obstruction)</div>
<div>Sneezing score returned to baseline 1 week after study completion</div>
<div>Patient quality of life score improved in treatment group</div>
<div>Physician  examination showed no significant intergroup difference and no  significant difference in serum IgE levels, nasal discharge eosinophil  counts, or serum ECP levels, although a downward trend in ECP was noted;  ECP is a mediator released from eosinophils in quantities based on the  activity and number of eosinophils present</div>
</td>
</tr>
<tr>
<td>Dietary spirulina<a id="cross-ref-E36" name="back-E36" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E36"><sup>E36</sup></a></td>
<td>Inhibits secretion of IL-4 and thus suppresses the pathway leading to T<sub>H</sub>2-committed cells</td>
<td>Not addressed in the study</td>
<td>Dose-dependent (2000 mg) decrease in IL-4 levels by 32%, resulting in suppression of T<sub>H</sub>2 differentiation</td>
</tr>
<tr>
<td></td>
<td>C-phycocyanin  is the active ingredient with COX-2 inhibitory activity and  anitoxidative effects and acts as free radical scavenger</td>
<td></td>
<td>No change in secretion of T<sub>H</sub>1 cytokines IFN-γ and IL-2</td>
</tr>
<tr>
<td>Cellulose powder<a id="cross-ref-bib102" name="back-bib102" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#bib102"><sup>102</sup></a></td>
<td>
<div>Inhibits bacterial growth</div>
<div>Turns  into gel in nasal cavity and serves like mucous to filter out allergens  from inhaled air to ensure clean air is supplied to the lungs</div>
</td>
<td>
<div>In  week 1 of study, 10% reported uncomfortable sensation in back of  throat, which authors think may have been a result of hay fever</div>
<div>One person reported itchy eyes and 1 reported sore throat</div>
<div>In 1 subject who ran out of cellulose powder, serious hay fever symptoms occurred immediately</div>
</td>
<td>Completely  relieved hay fever symptoms within minutes to hours of administration  with a success rate of 77% of patients as per subjective patient reports  on questionnaire</td>
</tr>
<tr>
<td>Aller-7<a id="cross-ref-E37" name="back-E37" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E37"><sup>E37</sup></a>, <a id="cross-ref-E38" name="back-E38" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E38"><sup>E38</sup></a></td>
<td>
<div>Mast cell stabilization</div>
<div>Lipoxygenase and hyaluronidase inhibition</div>
<div>Antihistamine and antispasmodic activity</div>
<div>Antioxidant</div>
<div>Anti-inflammatory potential</div>
</td>
<td>
<div>Proven safety in acute, subacute, subchronic, reproductive, and teratogenic toxicity studies</div>
<div>All biochemical and histological parameters remained within normal limits</div>
</td>
<td>
<div>Aller-7  (250 mg/kg) had greater efficacy than prednisolone (14 mg/kg) in  reducing 48/80-induced paw edema in Balb/c mice, 62.55% compared with  44.7%, respectively</div>
<div>In  Swiss albino mice, Aller-7 showed its most potent anti-inflammatory  effect at a dose of 225 mg/kg, compared with 175 and 275 mg/kg</div>
<div>In  carrageenan-induced paw edema, Aller-7 (120 mg/kg) showed comparative  efficacy to ibuprofen (50 mg/kg) with 31.3% inhibition of inflammation  compared with 68.1% by ibuprofen</div>
<div>Dose-dependent inhibition of arthritis inflammation, although less effective than prednisolone in this case</div>
<div>In  open trial, noted &gt;40% improvement in sneezing, rhinorrhea, and  nasal congestion after 6 weeks with further improvement by 12 weeks</div>
<div>In  randomized group, improvement in total nasal symptoms at 6 weeks  (83.5%) with greater improvement at 12 weeks (91.1%) noted in treated  group, whereas placebo had no further improvement after 6 weeks (75% at 6  weeks, 65.2% at 12 weeks)</div>
<div>Absolute  eosinophil count decreased in treatment group, whereas mucociliary time  improved (average 79.4 seconds; Aller-7 at 6 weeks, 75.7 seconds, and  12 weeks, 32.5 seconds)</div>
<div>Improved  peak expiratory flow rate (average 451 L/min, Aller-7 at 6 weeks 491  L/min, and at 12 weeks, 486 L/min), but not statistically different,  perhaps because of normal flow rate at baseline</div>
<div>Improved  nasal obstruction with peak nasal flow rate increase from 119.3 to 156  L/min correlating with subjective symptom improvement</div>
</td>
</tr>
<tr>
<td><em>T cordifolia</em><a id="cross-ref-E39" name="back-E39" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E39"><sup>E39</sup></a></td>
<td>
<div>Immunostimulant because it increases leukocyte counts and ablates neutropenia</div>
<div>Immunoprotective because it improves phagocytic and bactericidal capacity of polymorphs; primary target is the macrophages.</div>
<div>Anti-inflammatory effects suggested by decreased neutrophils in nasal smears</div>
<div>Antiallergic  effects indicated by decreased number of goblet cells and eosinophils  in nasal smears; previous studies also showed decreased  histamine-induced bronchospasms in pigs, decreased capillary  permeability in mice, and reduced number of disrupted mast cells in rats</div>
</td>
<td>Out of 36 treated patients, 2 had nasal pain and 1 had headache, although they were still able to complete the study</td>
<td>
<div>Sneezing significantly relieved in 83% with <em>T cordifolia</em> and 21% placebo</div>
<div>Nasal discharge significantly relieved in 69% with TC and 3% placebo</div>
<div>Nasal obstruction significantly relieved in 61% with TC and 83% placebo</div>
<div>Nasal pruritus significantly relieved in 71% with TC and 12% placebo</div>
<div>Total leukocyte count increased significantly in 69% with TC and 11% with placebo</div>
<div>Nasal  smear in TC group showed decreased neutrophils and eosinophils with  absent goblet cells; placebo group showed marginal decrease in  eosinophils, neutrophils, and goblet cells</div>
<div>Change in nasal mucosa color from blue to pink in 69% treated with TC</div>
</td>
</tr>
<tr>
<td>Biminne<a id="cross-ref-E40" name="back-E40" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E40"><sup>E40</sup></a></td>
<td>
<div>Composed of 11 herbs:</div>
<div>•<em>Rehmannia glutinosa</em></div>
<div>•<em>Scutellaria baicalensis</em></div>
<div>•<em>Polygonatum sibiricum</em></div>
<div>•<em>Ginkgo biloba</em></div>
<div>•<em>Epimedium sagittatum</em></div>
<div>•<em>Psoralea corylifolia</em></div>
<div>•<em>Schisandra chinensis</em></div>
<div>•Pulp of <em>Prunus mume</em></div>
<div>•<em>Ledebouriella divaricata</em></div>
<div>•<em>Angelica dahurica</em></div>
<div>•<em>Astragalus membranaceus</em></div>
<div>Mechanism  of action is not yet understood but is thought to be attributed to the  composition of the mixture and the proportion of each constituent</div>
</td>
<td>
<div>No adverse events detected</div>
<div>As with any herbal medication, possible side effects include nonspecific complaints of nausea, bloating, or skin rash</div>
<div>One has to be careful of dose-dependent or allergic reactions to a particular constituent when using polyherbal formulas</div>
<div>Also,  potential for herb interactions with food, conventional medications,  and even other herbs needs to be monitored carefully when administering  this form of treatment</div>
</td>
<td>
<div>Subjective improvements in daily symptoms, overall quality of life, and visual analog scale scores of symptoms</div>
<div>Statistically significant improvement in sneezing, itchy nose, and inability to sleep</div>
<div>Similar efficacy as antihistamine on physician&#8217;s overall evaluation and use of relief medication</div>
<div>&gt;50% maintained improvement in visual analog scale scores at 1-year follow-up</div>
<div>Total serum IgE was decreased</div>
</td>
</tr>
<tr>
<td>Shi-bi-lin<a id="cross-ref-E26" name="back-E26" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E26"><sup>E26</sup></a></td>
<td>
<div>Modulates cytokine production, although the exact mechanism is not yet understood</div>
<div>Inhibits nitric oxide synthase and release of thromboxane B2 from endothelial cells</div>
<div>Modified form of a 700-year-old herbal formula named Cang Er Zi San</div>
<div>Human mast cell line 1 (HMC-1) cells exposed to different concentrations of formula for different lengths of time</div>
<div>Composed of 6 raw herbs:</div>
<div>•<em>Fructus xanthii</em></div>
<div>•Radix Angelicae Dahuricae</div>
<div>•Radix Saposhnikoviae</div>
<div>•Flos Magnoliae</div>
<div>•Radix Gentianae</div>
<div>•Herba Verbenae</div>
</td>
<td>Not discussed</td>
<td>
<div>Potent inhibition of IL-4 and TNF-α.</div>
<div>Inhibits TNF-α, a potent stimulator of inflammatory markers from airway epithelial cells</div>
<div>Stimulates  IL-6 at concentration of 0.05 mg/mL in early incubation otherwise  inhibitory effect on this cytokine which normally induces IgG, IgM, and  IgA secretion and synergistically works with IL-4 as a proinflammatory  agent</div>
<div>Stimulatory effect on IL-8 at low concentration, but overall no prominent effect</div>
<div>No detected effect on cytokine mRNA expression by RT-PCR</div>
</td>
</tr>
<tr>
<td>Sho-seiryu-to<a id="cross-ref-E41" name="back-E41" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E41"><sup>E41</sup></a></td>
<td>
<div>Polyherbal formula with 8 herbs:</div>
<div>•Hange (Pinelliae Tuber)</div>
<div>•Kanzo (Glycyr-rhizae Radix)</div>
<div>•Keihi (Cinnamomi Cortex)</div>
<div>•Gomishi (Schisandrae Fructus)</div>
<div>•Mao (Ephedra Herba)</div>
<div>•Saishin (Asiasari Radix)</div>
<div>•Shakuaku (Paconiae Radix)</div>
<div>•Kakyo (Zingiberis Siccatum)</div>
<div>Of these constituents, mao-containing alkaloids have adrenergic effects that alter the balance of T<sub>H</sub>1/T<sub>H</sub>2 via the α-adrenergic receptor on CD4 T-cells</div>
<div>Modulates cytokine production, although exact mechanism is not yet understood</div>
<div>Inhibits nitric oxide synthase and release of thromboxane B2 from endothelial cells</div>
</td>
<td>Not discussed</td>
<td>
<div>Decreased ovalbumin-induced sneezing</div>
<div>Decreased total and ovalbumin-specific IgE levels from T cells</div>
<div>Decreased IL-4 producing CD4 T<sub>H</sub>2 cells, although no effect on IFN-γ production from T<sub>H</sub>1 cells</div>
<div>In type 1 allergic reactions, CD86 is upregulated and differentiates naive CD4 T cells (T<sub>H</sub>0) into T<sub>H</sub>2 cells producing the IL-4–mediated IgE response; decreased CD86<sup>+</sup>MHC class II cells and CD28<sup>+</sup>CD4 T cells seen with Sho-seiryu-to (SST) inhibit this anti-inflammatory effect</div>
<div>No effect on CD80 MHCII, CD40 MHCII, and CD154CD4 T cells</div>
<div>No effect on B-cell production of</div>
<div>cytokine IL-4 or IgE</div>
</td>
</tr>
<tr>
<td>Rosmarinic acid<a id="cross-ref-E42" name="back-E42" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E42"><sup>E42</sup></a>, <a id="cross-ref-E43" name="back-E43" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#E43"><sup>E43</sup></a></td>
<td>
<div>Extracted rosmarinic acid from <em>Perilla frutescens</em>, a popular Japanese garnish, to evaluate effects on</div>
<div>seasonal allergic rhinitis to Japanese cedar pollen</div>
<div>A polyphenol phytochemical from the plant genus Lamiaceae; found in various herbs including basil, sage, mint, rosemary, and <em>Perilla frutescens</em></div>
<div>Inhibition  of locally expressed proinflammatory cytokines and chemokines IL-1b,  IL-8, and eotaxin results in inhibition of local PMNL (neutrophils and  eosinophils) infiltration</div>
<div>Mast cell stabilization</div>
<div>Lipoxygenase and hyaluronidase inhibition</div>
<div>Antioxidant properties</div>
<div>Previous reports suggest antihistaminic activity, although these reports not confirmed in other trials</div>
<div>Previous  studies have shown inhibitory effects of pollen-specific IgE production  from B cells, although this too is controversial</div>
</td>
<td>No  significant abnormalities were detected by routine blood tests at the  end of the study; routine tests included complete blood cell counts,  hepatic and renal function tests, total protein and proteinogram,  electrolytes, lipids, uric acid, and concentration of creatine  phosphokinase</td>
<td>
<div>Decreased neutrophils and eosinophils in nasal lavage on days 0 and 3 of treatment</div>
<div>Initially  the 50-mg dose lost effectiveness over nasal eosinophil infiltration,  and by day 21, even the 200-mg dose was not effective at suppressing  proinflammatory cytokines that activate the polymorphonuclear leukocytes  (PML) infiltration</div>
<div>Neither serum IgE nor nasal eotaxin, IL-1β, IL-8 or histamine levels were ever significantly different among the groups</div>
<div>Decreased subjective recording of symptoms</div>
<div>Decrease number of neutrophils and eosinophils in nasal lavage</div>
<div>Both anti-inflammatory and antioxidant effects were noted in the animal model</div>
<div>In  the animal model, RA treatment produced marked reductions in  intercellular adhesion molecule 1, vascular cell adhesion molecule 1,  COX-2, and macrophage inflammatory protein 2 (adhesion molecules,  chemokine and eicosanoid synthesis)</div>
<div>Also  in animal models, decreased reactive oxygen radical production was seen  with RA treatment measured by decreased thiobarbituric acid reactive  substance, lipid peroxide, and 8-hydroxy-2□deoxyguanosine</div>
</td>
</tr>
</tbody>
</table>
</div>
<p><em>ECP,</em> Eosinophil cationic protein.</p>
<table>
<tfoot></tfoot>
</table>
<p><a name="bibliography"></a></p>
<p id="back-to-article-outline-link"><a href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#article-outline">Back to Article Outline</a></p>
<h2>References</h2>
<ol id="referenceList"><a name="bib1"></a>&nbsp;</p>
<li id="reference-bib1">Angell M, Kassirer JP. <strong>Alternative medicine—the risks of untested and unregulated remedies. </strong><em>N Engl J Med</em>. 1998;339:839–841
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib1">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00284793_339_839">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib2"></a></p>
<li id="reference-bib2">Resnick ES, Bielory BP, Bielory L. <strong>Complementary therapy in allergic rhinitis. </strong><em>Curr Allergy Asthma Rep</em>. 2008;8:118–125
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib2">View In Article</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib3"></a></p>
<li id="reference-bib3">Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002.
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib3">View In Article</a></li>
</ul>
</li>
<p><a name="bib4"></a></p>
<li id="reference-bib4">Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. <strong>Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. </strong><em>JAMA</em>. 1998;280:1569–1575
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib4">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00987484_280_1569">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib5"></a></p>
<li id="reference-bib5">Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. <strong>Unconventional medicine in the United States: prevalence, costs, and patterns of use. </strong><em>N Engl J Med</em>. 1993;328:246–252
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib5">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00284793_328_246">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib6"></a></p>
<li id="reference-bib6">WHO . <strong>Traditional medicine. </strong>Geneva, Switzerland: World Health Organization; 2003;
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib6">View In Article</a></li>
</ul>
</li>
<p><a name="bib7"></a></p>
<li id="reference-bib7">Myers SP, Cheras PA, Myers SP, Cheras PA. <strong>The other side of the coin: safety of complementary and alternative medicine. </strong><em>Med J Aust</em>. 2004;181:222–225
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib7">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_0025729X_181_222">MEDLINE</a></li>
</ul>
</li>
<p><a name="bib8"></a></p>
<li id="reference-bib8">Heimall J, Bielory L. <strong>Defining complementary and alternative medicine in allergies and asthma: benefits and risks. </strong><em>Clin Rev Allergy Immunol</em>. 2004;27:93–103
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib8">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_10800549_27_93">MEDLINE</a></li>
</ul>
</li>
<p><a name="bib9"></a></p>
<li id="reference-bib9">Studdert DM, Eisenberg DM, Miller FH, Curto DA, Kaptchuk TJ, Brennan TA. <strong>Medical malpractice implications of alternative medicine. </strong><em>JAMA</em>. 1998;280:1610–1615
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib9">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00987484_280_1610">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib10"></a></p>
<li id="reference-bib10">Chen C, Biller J, Willing SJ, Lopez AM. <strong>Ischemic stroke after using over the counter products containing ephedra. </strong><em>J Neurol Sci</em>. 2004;217:55–60
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib10">View In Article</a></li>
<li><a id="abstract-link" href="http://www.jns-journal.com/article/S0022-510X%2803%2900262-4/abstract?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Abstract</a></li>
<li><a id="fulltext-link" href="http://www.jns-journal.com/article/S0022-510X%2803%2900262-4/fulltext?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Full Text</a></li>
<li><a id="pdf-link" href="http://download.journals.elsevierhealth.com/pdfs/journals/0022-510X/PIIS0022510X03002624.pdf?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749&amp;mis=.pdf"> Full-Text PDF (463 KB) </a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib11"></a></p>
<li id="reference-bib11">Samenuk D, Link MS, Homoud MK, Contreras R, Theoharides TC, Wang PJ, et al. <strong>Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. </strong><em>Mayo Clin Proc</em>. 2002;77:12–16
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib11">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00256196_77_12">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib12"></a></p>
<li id="reference-bib12">Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. <strong>Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. </strong><em>N Engl J Med</em>. 1996;334:1150–1155
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib12">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00284793_334_1150">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib13"></a></p>
<li id="reference-bib13">Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. <strong>Mortality  in randomized trials of antioxidant supplements for primary and  secondary prevention: systematic review and meta-analysis. </strong><em>JAMA</em>. 2007;297:842–857
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib13">View In Article</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib14"></a></p>
<li id="reference-bib14">Saper RB, Kales SN, Paquin J, Burns MJ, Eisenberg DM, Davis RB, et al. <strong>Heavy metal content of Ayurvedic herbal medicine products. </strong><em>JAMA</em>. 2004;292:2868–2873
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib14">View In Article</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib15"></a></p>
<li id="reference-bib15">Saper RB, Phillips RS, Sehgal A, Khouri N, Davis RB, Paquin J, et al. <strong>Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. </strong><em>JAMA</em>. 2008;300:915–923
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib15">View In Article</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib16"></a></p>
<li id="reference-bib16">Fugh-Berman A, Ernst E. <strong>Herb-drug interactions: review and assessment of report reliability. </strong><em>Br J Clin Pharmacol</em>. 2001;52:587–595
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib16">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_03065251_52_587">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib17"></a></p>
<li id="reference-bib17">Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. <strong>Acute heart transplant rejection due to Saint John&#8217;s wort. </strong><em>Lancet</em>. 2000;355:548–549
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib17">View In Article</a></li>
<li><a id="abstract-link" href="http://www.thelancet.com/journals/lancet/article/S0140-6736%2899%2905467-7/abstract?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Abstract</a></li>
<li><a id="fulltext-link" href="http://www.thelancet.com/journals/lancet/article/S0140-6736%2899%2905467-7/fulltext?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Full Text</a></li>
<li><a id="pdf-link" href="http://download.journals.elsevierhealth.com/pdfs/journals/0140-6736/PIIS0140673699054677.pdf?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749&amp;mis=.pdf"> Full-Text PDF (57 KB) </a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib18"></a></p>
<li id="reference-bib18">Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. <strong>Indinavir concentrations and St John&#8217;s wort. </strong><em>Lancet</em>. 2000;355:547–548
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib18">View In Article</a></li>
<li><a id="abstract-link" href="http://www.thelancet.com/journals/lancet/article/S0140-6736%2899%2905712-8/abstract?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Abstract</a></li>
<li><a id="fulltext-link" href="http://www.thelancet.com/journals/lancet/article/S0140-6736%2899%2905712-8/fulltext?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Full Text</a></li>
<li><a id="pdf-link" href="http://download.journals.elsevierhealth.com/pdfs/journals/0140-6736/PIIS0140673699057128.pdf?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749&amp;mis=.pdf"> Full-Text PDF (57 KB) </a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib19"></a></p>
<li id="reference-bib19">Wood B, Wishart J. <strong>Potent topical steroid in a Chinese herbal cream. </strong><em>N Z Med J</em>. 1997;110:420–421
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib19">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00288446_110_420">MEDLINE</a></li>
</ul>
</li>
<p><a name="bib20"></a></p>
<li id="reference-bib20">Hon KL, Lee VW, Leung TF, Lee KK, Chan AK, Fok TF, et al. <strong>Corticosteroids are not present in a traditional Chinese medicine formulation for atopic dermatitis in children. </strong><em>Ann Acad Med Sing</em>. 2006;35:759–763
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib20">View In Article</a></li>
</ul>
</li>
<p><a name="bib21"></a></p>
<li id="reference-bib21">Hon KL, Leung TF, Ng PC, Lam MC, Kam WY, Wong KY, et al. <strong>Efficacy  and tolerability of a Chinese herbal medicine concoction for treatment  of atopic dermatitis: a randomized, double-blind, placebo-controlled  study. </strong><em>Br J Dermatol</em>. 2007;157:357–363
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib21">View In Article</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib22"></a></p>
<li id="reference-bib22">Critchley JA, Zhang Y, Suthisisang CC, Chan TY, Tomlinson B. <strong>Alternative  therapies and medical science: designing clinical trials of  alternative/complementary medicines—is evidence-based traditional  Chinese medicine attainable?. </strong><em>J Clin Pharmacol</em>. 2000;40:462–467
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib22">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00912700_40_462">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib23"></a></p>
<li id="reference-bib23">Nagpal S, Na S, Rathnachalam R. <strong>Noncalcemic actions of vitamin D receptor ligands. </strong><em>Endocr Rev</em>. 2005;26:662–687
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib23">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_0163769X_26_662">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib24"></a></p>
<li id="reference-bib24">Rigby WF, Stacy T, Fanger MW. <strong>Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). </strong><em>J Clin Invest</em>. 1984;74:1451–1455
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib24">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00219738_74_1451">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib25"></a></p>
<li id="reference-bib25">Thien R, Baier K, Pietschmann P, Peterlik M, Willheim M. <strong>Interactions of 1 alpha,25-dihydroxyvitamin D3 with IL-12 and IL-4 on cytokine expression of human T lymphocytes. </strong><em>J Allergy Clin Immunol</em>. 2005;116:683–689
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib25">View In Article</a></li>
<li><a id="abstract-link" href="http://www.jacionline.org/article/S0091-6749%2805%2901308-4/abstract?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Abstract</a></li>
<li><a id="fulltext-link" href="http://www.jacionline.org/article/S0091-6749%2805%2901308-4/fulltext?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Full Text</a></li>
<li><a id="pdf-link" href="http://download.journals.elsevierhealth.com/pdfs/journals/0091-6749/PIIS0091674905013084.pdf?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749&amp;mis=.pdf"> Full-Text PDF (231 KB) </a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib26"></a></p>
<li id="reference-bib26">van Etten E, Mathieu C. <strong>Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. </strong><em>J Steroid Biochem Mol Biol</em>. 2005;97:93–101
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib26">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_09600760_97_93">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib27"></a></p>
<li id="reference-bib27">Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. <strong>Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. </strong><em>JAMA</em>. 2006;296:2832–2838
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib27">View In Article</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib28"></a></p>
<li id="reference-bib28">Munger KL, Zhang SM, O&#8217;Reilly E, Hernan MA, Olek MJ, Willett WC, et al. <strong>Vitamin D intake and incidence of multiple sclerosis. </strong><em>Neurology</em>. 2004;62:60–65
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib28">View In Article</a></li>
</ul>
</li>
<p><a name="bib29"></a></p>
<li id="reference-bib29">Zingg JM. <strong>Vitamin E and mast cells. </strong><em>Vitam Horm</em>. 2007;76:393–418
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib29">View In Article</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib30"></a></p>
<li id="reference-bib30">Kempna P, Reiter E, Arock M, Azzi A, Zingg JM. <strong>Inhibition of HMC-1 mast cell proliferation by vitamin E: involvement of the protein kinase B pathway. </strong><em>J Biol Chem</em>. 2004;279:50700–50709
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib30">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00219258_279_50700">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib31"></a></p>
<li id="reference-bib31">Wagner JG, Jiang Q, Harkema JR, Ames BN, Illek B, Roubey RA, et al. <strong>Gamma-tocopherol  prevents airway eosinophilia and mucous cell hyperplasia in  experimentally induced allergic rhinitis and asthma. </strong><em>Clin Exp Allergy</em>. 2008;38:501–511
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib31">View In Article</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib32"></a></p>
<li id="reference-bib32">Schuster GU, Kenyon NJ, Stephensen CB. <strong>Vitamin A deficiency decreases and high dietary vitamin A increases disease severity in the mouse model of asthma. </strong><em>J Immunol</em>. 2008;180:1834–1842
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib32">View In Article</a></li>
</ul>
</li>
<p><a name="bib33"></a></p>
<li id="reference-bib33">Ross AC. <strong>Vitamin A supplementation and retinoic acid treatment in the regulation of antibody responses in vivo. </strong><em>Vitam Horm</em>. 2007;75:197–222
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib33">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00836729_75_197">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib34"></a></p>
<li id="reference-bib34">Saxon A, Keld B, Braun J, Dotson A, Sidell N. <strong>Long-term  administration of 13-cis retinoic acid in common variable  immunodeficiency: circulating interleukin-6 levels, B-cell surface  molecule display, and in vitro and in vivo B-cell antibody production. </strong><em>Immunology</em>. 1993;80:477–487
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib34">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00192805_80_477">MEDLINE</a></li>
</ul>
</li>
<p><a name="bib35"></a></p>
<li id="reference-bib35">Zhang JG, Morgan L, Spickett GP. <strong>The  effects of vitamin A derivatives on in vitro antibody production by  peripheral blood mononuclear cells (PBMC) from normal blood donors and  patients with common variable immunodeficiency (CVID). </strong><em>Clin Exp Immunol</em>. 1997;107:57–60
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib35">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00099104_107_57">MEDLINE</a></li>
</ul>
</li>
<p><a name="bib36"></a></p>
<li id="reference-bib36">Karlowski TR, Chalmers TC, Frenkel LD, Kapikian AZ, Lewis TL, Lynch JM. <strong>Ascorbic acid for the common cold: a prophylactic and therapeutic trial. </strong><em>JAMA</em>. 1975;231:1038–1042
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib36">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00987484_231_1038">MEDLINE</a></li>
</ul>
</li>
<p><a name="bib37"></a></p>
<li id="reference-bib37">Dykes MH, Meier P. <strong>Ascorbic acid and the common cold: evaluation of its efficacy and toxicity. </strong><em>JAMA</em>. 1975;231:1073–1079
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib37">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00987484_231_1073">MEDLINE</a></li>
</ul>
</li>
<p><a name="bib38"></a></p>
<li id="reference-bib38">Bielory L, Gandhi R. <strong>Asthma and vitamin C. </strong><em>Ann Allergy</em>. 1994;73:89–96quiz -100
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib38">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00034738_73_89">MEDLINE</a></li>
</ul>
</li>
<p><a name="bib39"></a></p>
<li id="reference-bib39">Bielory L, Lupoli K. <strong>Herbal interventions in asthma and allergy. </strong><em>J Asthma</em>. 1999;36:1–65
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib39">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_02770903_36_1">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib40"></a></p>
<li id="reference-bib40">Fogarty A, Lewis SA, Scrivener SL, Antoniak M, Pacey S, Pringle M, et al. <strong>Oral magnesium and vitamin C supplements in asthma: a parallel group randomized placebo-controlled trial. </strong><em>Clin Exp Allergy</em>. 2003;33:1355–1359
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib40">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_09547894_33_1355">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib41"></a></p>
<li id="reference-bib41">Ram FS, Rowe BH, Kaur B. <strong>Vitamin C supplementation for asthma. </strong><em>Cochrane Database Syst Rev</em>. 2004;CD000993
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib41">View In Article</a></li>
</ul>
</li>
<p><a name="bib42"></a></p>
<li id="reference-bib42">Chen SC, Chang YL, Wang DL, Cheng JJ. <strong>Herbal remedy magnolol suppresses IL-6-induced STAT3 activation and gene expression in endothelial cells. </strong><em>Br J Pharmacol</em>. 2006;148:226–232
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib42">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00071188_148_226">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib43"></a></p>
<li id="reference-bib43">Tse AK, Wan CK, Zhu GY, Shen XL, Cheung HY, Yang M, et al. <strong>Magnolol  suppresses NF-kappaB activation and NF-kappaB regulated gene expression  through inhibition of IkappaB kinase activation. </strong><em>Mol Immunol</em>. 2007;44:2647–2658
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib43">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_01615890_44_2647">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib44"></a></p>
<li id="reference-bib44">Cho SY, Park SJ, Kwon MJ, Jeong TS, Bok SH, Choi WY, et al. <strong>Quercetin  suppresses proinflammatory cytokines production through MAP kinases and  NF-kappaB pathway in lipopolysaccharide-stimulated macrophage. </strong><em>Mol Cell Biochem</em>. 2003;243:153–160
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib44">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_03008177_243_153">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib45"></a></p>
<li id="reference-bib45">Ruiz PA, Braune A, Holzlwimmer G, Quintanilla-Fend L, Haller D. <strong>Quercetin  inhibits TNF-induced NF-kappaB transcription factor recruitment to  proinflammatory gene promoters in murine intestinal epithelial cells. </strong><em>J Nutr</em>. 2007;137:1208–1215
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib45">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00223166_137_1208">MEDLINE</a></li>
</ul>
</li>
<p><a name="bib46"></a></p>
<li id="reference-bib46">Tan WF, Lin LP, Li MH, Zhang YX, Tong YG, Xiao D, et al. <strong>Quercetin, a dietary-derived flavonoid, possesses antiangiogenic potential. </strong><em>Eur J Pharmacol</em>. 2003;459:255–262
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib46">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00142999_459_255">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib47"></a></p>
<li id="reference-bib47">Wen MC, Wei CH, Hu ZQ, Srivastava K, Ko J, Xi ST, et al. <strong>Efficacy and tolerability of anti-asthma herbal medicine intervention in adult patients with moderate-severe allergic asthma. </strong><em>J Allergy Clin Immunol</em>. 2005;116:517–524
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib47">View In Article</a></li>
<li><a id="abstract-link" href="http://www.jacionline.org/article/S0091-6749%2805%2901358-8/abstract?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Abstract</a></li>
<li><a id="fulltext-link" href="http://www.jacionline.org/article/S0091-6749%2805%2901358-8/fulltext?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Full Text</a></li>
<li><a id="pdf-link" href="http://download.journals.elsevierhealth.com/pdfs/journals/0091-6749/PIIS0091674905013588.pdf?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749&amp;mis=.pdf"> Full-Text PDF (228 KB) </a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib48"></a></p>
<li id="reference-bib48">Srivastava K, Teper AA, Zhang TF, Li S, Walsh MJ, Huang CK, et al. <strong>Immunomodulatory effect of the antiasthma Chinese herbal formula MSSM-002 on T<sub>H</sub>2 cells. </strong><em>J Allergy Clin Immunol</em>. 2004;113:268–276
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib48">View In Article</a></li>
<li><a id="abstract-link" href="http://www.jacionline.org/article/S0091-6749%2803%2902557-0/abstract?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Abstract</a></li>
<li><a id="fulltext-link" href="http://www.jacionline.org/article/S0091-6749%2803%2902557-0/fulltext?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Full Text</a></li>
<li><a id="pdf-link" href="http://download.journals.elsevierhealth.com/pdfs/journals/0091-6749/PIIS0091674903025570.pdf?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749&amp;mis=.pdf"> Full-Text PDF (414 KB) </a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib49"></a></p>
<li id="reference-bib49">Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. <strong>Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. </strong><em>Science</em>. 1997;275:218–220
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib49">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00368075_275_218">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib50"></a></p>
<li id="reference-bib50">Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. <strong>Resveratrol improves health and survival of mice on a high-calorie diet. </strong><em>Nature</em>. 2006;444:337–342
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib50">View In Article</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib51"></a></p>
<li id="reference-bib51">Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, et al. <strong>Sirtuin activators mimic caloric restriction and delay ageing in metazoans. </strong><em>Nature</em>. 2004;430:686–689
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib51">View In Article</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib52"></a></p>
<li id="reference-bib52">Manna SK, Mukhopadhyay A, Aggarwal BB. <strong>Resveratrol  suppresses TNF-induced activation of nuclear transcription factors  NF-kappa B, activator protein-1, and apoptosis: potential role of  reactive oxygen intermediates and lipid peroxidation. </strong><em>J Immunol</em>. 2000;164:6509–6519
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib52">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00221767_164_6509">MEDLINE</a></li>
</ul>
</li>
<p><a name="bib53"></a></p>
<li id="reference-bib53">Youn HS, Lee JY, Fitzgerald KA, Young HA, Akira S, Hwang DH. <strong>Specific  inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by  resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. </strong><em>J Immunol</em>. 2005;175:3339–3346
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib53">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00221767_175_3339">MEDLINE</a></li>
</ul>
</li>
<p><a name="bib54"></a></p>
<li id="reference-bib54">Mehendale SR, Bauer BA, Yuan CS, Mehendale SR, Bauer BA. <strong>Yuan C-S. Ephedra-containing dietary supplements in the US versus ephedra as a Chinese medicine. </strong><em>Am J Chin Med</em>. 2004;32:1–10
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib54">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_0192415X_32_1">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib55"></a></p>
<li id="reference-bib55">Schaneberg BT, Crockett S, Bedir E, Khan IA, Schaneberg BT, Crockett S, et al. <strong>The role of chemical fingerprinting: application to ephedra. </strong><em>Phytochemistry</em>. 2003;62:911–918
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib55">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00319422_62_911">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib56"></a></p>
<li id="reference-bib56">Schafer T. <strong>Epidemiology of complementary alternative medicine for asthma and allergy in Europe and Germany. </strong><em>Ann Allergy Asthma Immunol</em>. 2004;93:S5–S10
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib56">View In Article</a></li>
<li><a id="abstract-link" href="http://www.annallergy.org/article/S1081-1206%2810%2961481-0/abstract?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Abstract</a></li>
<li><a id="pdf-link" href="http://download.journals.elsevierhealth.com/pdfs/journals/1081-1206/PIIS1081120610614810.pdf?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749&amp;mis=.pdf"> Full-Text PDF (382 KB) </a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib57"></a></p>
<li id="reference-bib57">Sidora-Arcoleo K, Yoos HL, McMullen A, Kitzman H. <strong>Complementary and alternative medicine use in children with asthma: prevalence and sociodemographic profile of users. </strong><em>J Asthma</em>. 2007;44:169–175
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib57">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_02770903_44_169">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib58"></a></p>
<li id="reference-bib58">Gupta S, George P, Gupta V, Tandon VR, Sundaram KR. <strong>Tylophora indica in bronchial asthma—a double blind study. </strong><em>Ind J Med Res</em>. 1979;69:981–989
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib58">View In Article</a></li>
</ul>
</li>
<p><a name="bib59"></a></p>
<li id="reference-bib59">Mathew K, Shipvuri D. <strong>Treatment of asthma with alkaloids of Tylophora indica: double blind study. </strong><em>Aspects Allergy Appl Immunol</em>. 1974;7:166–178
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib59">View In Article</a></li>
</ul>
</li>
<p><a name="bib60"></a></p>
<li id="reference-bib60">Shivpuri D, Menon M, Prakash D. <strong>A crossover double-blind study on Tylophora indica in the treatment of asthma and allergic rhinitis. </strong><em>J Allergy Clin Immunol</em>. 1969;43:145–150
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib60">View In Article</a></li>
</ul>
</li>
<p><a name="bib61"></a></p>
<li id="reference-bib61">Shivpuri DN, Singhal SC, Parkash D. <strong>Treatment of asthma with an alcoholic extract of Tylophora indica: a cross-over, double-blind study. </strong><em>Ann Allergy</em>. 1972;30:407–412
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib61">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00034738_30_407">MEDLINE</a></li>
</ul>
</li>
<p><a name="bib62"></a></p>
<li id="reference-bib62">Rouhi H, Ganji F, Nasri H. <strong>Effects of ginger on the improvement of asthma [the evaluation of its treatmental effects]. </strong><em>Pak J Nutr</em>. 2006;5:373–376
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib62">View In Article</a></li>
</ul>
</li>
<p><a name="bib63"></a></p>
<li id="reference-bib63">Gabrielian E, Narimanian M, Aslanian G, Amroyan E, Panossian A. <strong>A placebo controlled double blind study with an Ayurvedic drug PulmoFlex in bronchial asthma. </strong><em>Phytomedica</em>. 2004;5:113–120
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib63">View In Article</a></li>
</ul>
</li>
<p><a name="bib64"></a></p>
<li id="reference-bib64">Juergens UR, Dethlefsen U, Steinkamp G, Gillissen A, Repges R, Vetter H. <strong>Anti-inflammatory activity of 1.8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial. </strong><em>Respir Med</em>. 2003;97:250–256
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib64">View In Article</a></li>
<li><a id="abstract-link" href="http://www.resmedjournal.com/article/S0954-6111%2803%2991432-6/abstract?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Abstract</a></li>
<li><a id="pdf-link" href="http://download.journals.elsevierhealth.com/pdfs/journals/0954-6111/PIIS0954611103914326.pdf?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749&amp;mis=.pdf"> Full-Text PDF (147 KB) </a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib65"></a></p>
<li id="reference-bib65">Badria F, Mohammed E, El-Badrawy M, El-Desouky M. <strong>Natural leukotriene inhibitor from Boswellia: a potential new alternative for treating bronchial asthma. </strong><em>Alt Compl Ther</em>. 2004;10:257–265
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib65">View In Article</a></li>
</ul>
</li>
<p><a name="bib66"></a></p>
<li id="reference-bib66">Gupta I, Gupta V, Pariha RA, Gupta S, Ludtke R, Safayhi H. <strong>Effects  of Boswellia serrata gum resin in patients with bronchial asthma:  results of a double-blind, placebo-controlled, 6-week clinical study. </strong><em>Eur J Med Res</em>. 1998;3:511–514
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib66">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_09492321_3_511">MEDLINE</a></li>
</ul>
</li>
<p><a name="bib67"></a></p>
<li id="reference-bib67">Khayyal M, el-Ghazaly M, el-Khatib A, Hatem A, de Vries P, el-Shafei S. <strong>A  clinical pharmacological study of the potential beneficial effects of a  propolis food product as an adjuvant in asthmatic patients. </strong><em>Fund Clin Pharmacol</em>. 2003;17:93–102
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib67">View In Article</a></li>
</ul>
</li>
<p><a name="bib68"></a></p>
<li id="reference-bib68">Lau BH, Wong DS, Slater JM. <strong>Effect of acupuncture on allergic rhinitis: clinical and laboratory evaluations. </strong><em>Am J Chin Med</em>. 1975;3:263–270
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib68">View In Article</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib69"></a></p>
<li id="reference-bib69">Mellis CM. <strong>Is asthma prevention possible with dietary manipulation?. </strong><em>Med J Aust</em>. 2002;177(suppl):S78–S80
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib69">View In Article</a></li>
</ul>
</li>
<p><a name="bib70"></a></p>
<li id="reference-bib70">Theoharides TC, Bielory L. <strong>Mast cells and mast cell mediators as targets of dietary supplements. </strong><em>Ann Allergy Asthma Immunol</em>. 2004;93:S24–S34
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib70">View In Article</a></li>
<li><a id="abstract-link" href="http://www.annallergy.org/article/S1081-1206%2810%2961484-6/abstract?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Abstract</a></li>
<li><a id="pdf-link" href="http://download.journals.elsevierhealth.com/pdfs/journals/1081-1206/PIIS1081120610614846.pdf?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749&amp;mis=.pdf"> Full-Text PDF (630 KB) </a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib71"></a></p>
<li id="reference-bib71">Schuster GU, Kenyon NJ, Stephensen CB. <strong>Vitamin A deficiency decreases and high dietary vitamin A increases disease severity in the mouse model of asthma. </strong><em>J Immunol</em>. 2008;180:1834–1842
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib71">View In Article</a></li>
</ul>
</li>
<p><a name="bib72"></a></p>
<li id="reference-bib72">Arora P, Kumar V, Batra S. <strong>Vitamin A status in children with asthma. </strong><em>Pediatr Allergy Immunol</em>. 2002;13:223–226
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib72">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_09056157_13_223">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib73"></a></p>
<li id="reference-bib73">Harik-Khan RI, Muller DC, Wise RA. <strong>Serum vitamin levels and the risk of asthma in children. </strong><em>Am J Epidemiol</em>. 2004;159:351–357
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib73">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00029262_159_351">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib74"></a></p>
<li id="reference-bib74">Riccioni G, Barbara M, Bucciarelli T, di Ilio C, D&#8217;Orazio N. <strong>Antioxidant vitamin supplementation in asthma. </strong><em>Ann Clin Lab Sci</em>. 2007;37:96–101
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib74">View In Article</a></li>
</ul>
</li>
<p><a name="bib75"></a></p>
<li id="reference-bib75">Riccioni G, D&#8217;Orazio N. <strong>The  role of selenium, zinc and antioxidant vitamin supplementation in the  treatment of bronchial asthma: adjuvant therapy or not?. </strong><em>Exp Opin Investig Drugs</em>. 2005;14:1145–1155
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib75">View In Article</a></li>
</ul>
</li>
<p><a name="bib76"></a></p>
<li id="reference-bib76">Nja F, Nystad W, Lodrup Carlsen KC, Hetlevik O, Carlsen K-H. <strong>Effects of early intake of fruit or vegetables in relation to later asthma and allergic sensitization in school-age children. </strong><em>Acta Paediatr</em>. 2005;94:147–154
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib76">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_08035253_94_147">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib77"></a></p>
<li id="reference-bib77">Milner JD, Stein DM, McCarter R, Moon RY. <strong>Early infant multivitamin supplementation is associated with increased risk for food allergy and asthma. </strong><em>Pediatrics</em>. 2004;114:27–32
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib77">View In Article</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib78"></a></p>
<li id="reference-bib78">Moreira A, Kekkonen R, Korpela R, Delgado L, Haahtela T. <strong>Allergy in marathon runners and effect of Lactobacillus GG supplementation on allergic inflammatory markers. </strong><em>Respir Med</em>. 2007;101:1123–1131
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib78">View In Article</a></li>
<li><a id="abstract-link" href="http://www.resmedjournal.com/article/S0954-6111%2806%2900602-0/abstract?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Abstract</a></li>
<li><a id="fulltext-link" href="http://www.resmedjournal.com/article/S0954-6111%2806%2900602-0/fulltext?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Full Text</a></li>
<li><a id="pdf-link" href="http://download.journals.elsevierhealth.com/pdfs/journals/0954-6111/PIIS0954611106006020.pdf?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749&amp;mis=.pdf"> Full-Text PDF (533 KB) </a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib79"></a></p>
<li id="reference-bib79">Mizuno Y, Furusho T, Yoshida A, Nakamura H, Matsuura T, Eto Y. <strong>Serum vitamin A concentrations in asthmatic children in Japan. </strong><em>Pediatr Int</em>. 2006;48:261–264
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib79">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_13288067_48_261">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib80"></a></p>
<li id="reference-bib80">Lee J, Seto D, Bielory L. <strong>Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. </strong><em>J Allergy Clin Immunol</em>. 2008;121:116–121e11
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib80">View In Article</a></li>
<li><a id="abstract-link" href="http://www.jacionline.org/article/S0091-6749%2807%2902172-0/abstract?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Abstract</a></li>
<li><a id="fulltext-link" href="http://www.jacionline.org/article/S0091-6749%2807%2902172-0/fulltext?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Full Text</a></li>
<li><a id="pdf-link" href="http://download.journals.elsevierhealth.com/pdfs/journals/0091-6749/PIIS0091674907021720.pdf?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749&amp;mis=.pdf"> Full-Text PDF (1198 KB) </a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib81"></a></p>
<li id="reference-bib81">Ogden NS, Bielory L. <strong>Probiotics: a complementary approach in the treatment and prevention of pediatric atopic disease. </strong><em>Curr Opin Allergy Clin Immunol</em>. 2005;5:179–184
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib81">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_15284050_5_179">MEDLINE</a></li>
</ul>
</li>
<p><a name="bib82"></a></p>
<li id="reference-bib82">Stonemetz D. <strong>A review of the clinical efficacy of evening primrose. </strong><em>Holist Nurs Pract</em>. 2008;22:171–174
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib82">View In Article</a></li>
</ul>
</li>
<p><a name="bib83"></a></p>
<li id="reference-bib83">Lee HS, Kim SK, Han JB, Choi HM, Park JH, Kim EC, et al. <strong>Inhibitory effects of Rumex japonicus Houtt on the development of atopic dermatitis-like skin lesions in NC/Nga mice. </strong><em>Br J Dermatol</em>. 2006;155:33–38
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib83">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00070963_155_33">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib84"></a></p>
<li id="reference-bib84">Jackson CM, Lee DK, Lipworth BJ. <strong>The effects of butterbur on the histamine and allergen cutaneous response. </strong><em>Ann Allergy Asthma Immunol</em>. 2004;92:250–254
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib84">View In Article</a></li>
<li><a id="abstract-link" href="http://www.annallergy.org/article/S1081-1206%2810%2961556-6/abstract?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Abstract</a></li>
<li><a id="pdf-link" href="http://download.journals.elsevierhealth.com/pdfs/journals/1081-1206/PIIS1081120610615566.pdf?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749&amp;mis=.pdf"> Full-Text PDF (165 KB) </a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib85"></a></p>
<li id="reference-bib85">Choi JJ, Park B, Kim DH, Pyo M-Y, Choi S, Son M, et al. <strong>Blockade  of atopic dermatitis-like skin lesions by DA-9102, a natural medicine  isolated from Actinidia arguta, in the Mg-deficiency induced dermatitis  model of hairless rats. </strong><em>Exp Biol Med</em>. 2008;233:1026–1034
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib85">View In Article</a></li>
</ul>
</li>
<p><a name="bib86"></a></p>
<li id="reference-bib86">Choi MS, Kim EC, Lee HS, Kim SK, Choi HM, Park JH, et al. <strong>Inhibitory  effects of Saururus chinensis (LOUR.) BAILL on the development of  atopic dermatitis-like skin lesions in NC/Nga mice. </strong><em>Biol Pharm Bull</em>. 2008;31:51–56
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib86">View In Article</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib87"></a></p>
<li id="reference-bib87">Donsky H, Clarke D. <strong>Relieva, a Mahonia aquifolium extract for the treatment of adult patients with atopic dermatitis. </strong><em>Am J Ther</em>. 2007;14:442–446
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib87">View In Article</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib88"></a></p>
<li id="reference-bib88">Klovekorn W, Tepe A, Danesch U. <strong>A  randomized, double-blind, vehicle-controlled, half-side comparison with  a herbal ointment containing Mahonia aquifolium, Viola tricolor and  Centella asiatica for the treatment of mild-to-moderate atopic  dermatitis. </strong><em>Int J Clin Pharmacol Ther</em>. 2007;45:583–591
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib88">View In Article</a></li>
</ul>
</li>
<p><a name="bib89"></a></p>
<li id="reference-bib89">Ukawa Y, Izumi Y, Ohbuchi T, Takahashi T, Ikemizu S, Kojima Y. <strong>Oral  administration of the extract from Hatakeshimeji (Lyophyllum decastes  sing.) mushroom inhibits the development of atopic dermatitis-like skin  lesions in NC/Nga mice. </strong><em>J Nutr Sci Vitaminol</em>. 2007;53:293–296
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib89">View In Article</a></li>
</ul>
</li>
<p><a name="bib90"></a></p>
<li id="reference-bib90">Kimata H. <strong>Improvement of atopic dermatitis and reduction of skin allergic responses by oral intake of konjac ceramide. </strong><em>Pediatr Dermatol</em>. 2006;23:386–389
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib90">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_07368046_23_386">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib91"></a></p>
<li id="reference-bib91">Schempp CM, Windeck T, Hezel S, Simon JC. <strong>Topical  treatment of atopic dermatitis with St. John&#8217;s wort cream—a randomized,  placebo controlled, double blind half-side comparison. </strong><em>Phytomedicine</em>. 2003;10(suppl 4):31–37
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib91">View In Article</a></li>
<li><a id="abstract-link" href="http://www.phytomedicinejournal.com/article/S0944-7113%2804%2970349-9/abstract?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Abstract</a></li>
<li><a id="pdf-link" href="http://download.journals.elsevierhealth.com/pdfs/journals/0944-7113/PIIS0944711304703499.pdf?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749&amp;mis=.pdf"> Full-Text PDF (113 KB) </a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib92"></a></p>
<li id="reference-bib92">Matsumoto T, Shibata T. <strong>The ex vivo effect of the herbal medicine sho-saiko-to on histamine release from rat mast cells. </strong><em>Eur Arch Otorhinolaryngol</em>. 1998;255:359–364
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib92">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_09374477_255_359">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib93"></a></p>
<li id="reference-bib93">Lee DKC, Carstairs IJ, Haggart K, Jackson CM, Currie GP, Lipworth BJ. <strong>Butterbur, a herbal remedy, attenuates adenosine monophosphate induced nasal responsiveness in seasonal allergic rhinitis. </strong><em>Clin Exp Allergy</em>. 2003;33:882–886
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib93">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_09547894_33_882">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib94"></a></p>
<li id="reference-bib94">Schapowal A. <strong>Treating  intermittent allergic rhinitis: a prospective, randomized, placebo and  antihistamine-controlled study of Butterbur extract Ze 339. </strong><em>Phytother Res</em>. 2005;19:530–537
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib94">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_0951418X_19_530">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib95"></a></p>
<li id="reference-bib95"><strong>Urtica dioica; Urtica urens (nettle). </strong>[monograph] <em>Alt Med Rev</em>. 2007;12:280–284
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib95">View In Article</a></li>
</ul>
</li>
<p><a name="bib96"></a></p>
<li id="reference-bib96">Kobayashi S, Tanabe S. <strong>Evaluation  of the anti-allergic activity of Citrus unshiu using rat basophilic  leukemia RBL-2H3 cells as well as basophils of patients with seasonal  allergic rhinitis to pollen. </strong><em>Int J Mol Med</em>. 2006;17:511–515
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib96">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_11073756_17_511">MEDLINE</a></li>
</ul>
</li>
<p><a name="bib97"></a></p>
<li id="reference-bib97">Shin TY, Kim SH, Suk K, Ha JH, Kim I, Lee MG, et al. <strong>Anti-allergic effects of Lycopus lucidus on mast cell-mediated allergy model. </strong><em>Toxicol Appl Pharmacol</em>. 2005;209:255–262
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib97">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_0041008X_209_255">MEDLINE</a></li>
</ul>
</li>
<p><a name="bib98"></a></p>
<li id="reference-bib98">Kim S-H, Lee S, Kim IK, Kwon TK, Moon J-Y, Park W-H, et al. <strong>Suppression of mast cell-mediated allergic reaction by Amomum xanthiodes. </strong><em>Food Chem Toxicol</em>. 2007;45:2138–2144
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib98">View In Article</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib99"></a></p>
<li id="reference-bib99">Bernstein DI, Bernstein CK, Deng C, Murphy KJ, Bernstein IL, Bernstein JA, et al. <strong>Evaluation  of the clinical efficacy and safety of grapeseed extract in the  treatment of fall seasonal allergic rhinitis: a pilot study. </strong><em>Ann Allergy Asthma Immunol</em>. 2002;88:272–278
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib99">View In Article</a></li>
<li><a id="abstract-link" href="http://www.annallergy.org/article/S1081-1206%2810%2962008-X/abstract?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Abstract</a></li>
<li><a id="pdf-link" href="http://download.journals.elsevierhealth.com/pdfs/journals/1081-1206/PIIS108112061062008X.pdf?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749&amp;mis=.pdf"> Full-Text PDF (173 KB) </a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib100"></a></p>
<li id="reference-bib100">Yoshimura M, Enomoto T, Dake Y, Okuno Y, Ikeda H, Cheng L, et al. <strong>An evaluation of the clinical efficacy of tomato extract for perennial allergic rhinitis. </strong><em>Allergol Int</em>. 2007;56:225–230
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib100">View In Article</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib101"></a></p>
<li id="reference-bib101">Mao TK, Van de Water J, Gershwin ME. <strong>Effects of a spirulina-based dietary supplement on cytokine production from allergic rhinitis patients. </strong><em>J Med Food</em>. 2005;8:27–30
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib101">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_1096620X_8_27">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib102"></a></p>
<li id="reference-bib102">Josling P, Steadman S. <strong>Use of cellulose powder for the treatment of seasonal allergic rhinitis. </strong><em>Adv Ther</em>. 2003;20:213–219
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib102">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_0741238X_20_213">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib103"></a></p>
<li id="reference-bib103">Saxena VS, Venkateshwarlu K, Nadig P, Barbhaiya HC, Bhatia N, Borkar DM, et al. <strong>Multicenter clinical trials on a novel polyherbal formulation in allergic rhinitis. </strong><em>Int J Clin Pharmacol Res</em>. 2004;24:79–94
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib103">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_02511649_24_79">MEDLINE</a></li>
</ul>
</li>
<p><a name="bib104"></a></p>
<li id="reference-bib104">Badar VA, Thawani VR, Wakode PT, Shrivastava MP, Gharpure KJ, Hingorani LL, et al. <strong>Efficacy of Tinospora cordifolia in allergic rhinitis. </strong><em>J Ethnopharmacol</em>. 2005;96:445–449
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib104">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_03788741_96_445">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib105"></a></p>
<li id="reference-bib105">Yang SH, Yu CL. <strong>Antiinflammatory effects of Bu-zhong-yi-qi-tang in patients with perennial allergic rhinitis. </strong><em>J Ethnopharmacol</em>. 2008;115:104–109
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib105">View In Article</a></li>
</ul>
</li>
<p><a name="bib106"></a></p>
<li id="reference-bib106">Hu G, Walls RS, Bass D, Ramon B, Grayson D, Jones M, et al. <strong>The  Chinese herbal formulation biminne in management of perennial allergic  rhinitis: a randomized, double-blind, placebo-controlled, 12-week  clinical trial. </strong><em>Ann Allergy Asthma Immunol</em>. 2002;88:478–487
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib106">View In Article</a></li>
<li><a id="abstract-link" href="http://www.annallergy.org/article/S1081-1206%2810%2962386-1/abstract?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Abstract</a></li>
<li><a id="pdf-link" href="http://download.journals.elsevierhealth.com/pdfs/journals/1081-1206/PIIS1081120610623861.pdf?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749&amp;mis=.pdf"> Full-Text PDF (599 KB) </a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib107"></a></p>
<li id="reference-bib107">Zhao Y, van Hasselt CA, Woo JK, Chen GG, Wong YO, Wang LH, et al. <strong>Effects of the Chinese herbal formula Shi-Bi-Lin on cytokine release from the human mast cell line. </strong><em>Ann Allergy Asthma Immunol</em>. 2005;95:79–85
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib107">View In Article</a></li>
<li><a id="abstract-link" href="http://www.annallergy.org/article/S1081-1206%2810%2961192-1/abstract?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749">Abstract</a></li>
<li><a id="pdf-link" href="http://download.journals.elsevierhealth.com/pdfs/journals/1081-1206/PIIS1081120610611921.pdf?refuid=S0091-6749%2808%2902439-1&amp;refissn=0091-6749&amp;mis=.pdf"> Full-Text PDF (282 KB) </a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib108"></a></p>
<li id="reference-bib108">Ikeda Y, Kaneko A, Yamamoto M, Ishige A, Sasaki H. <strong>Possible involvement of suppression of Th2 differentiation in the anti-allergic effect of sho-seiryu-to in mice. </strong><em>Jpn J Pharmacol</em>. 2002;90:328–336
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib108">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_00215198_90_328">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
<p><a name="bib109"></a></p>
<li id="reference-bib109">Denny SI, Thompson RL, Margetts BM. <strong>Dietary factors in the pathogenesis of asthma and chronic obstructive pulmonary disease. </strong><em>Curr Allergy Asthma Rep</em>. 2003;3:130–136
<ul>
<li><a id="back-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#back-bib109">View In Article</a></li>
<li><a id="medline-link" href="http://www.jacionline.org/medline/record/ivp_15297322_3_130">MEDLINE</a></li>
<li><a id="cross-ref-link" href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">CrossRef</a></li>
</ul>
</li>
</ol>
<p><a name="further-reading"></a></p>
<p id="back-to-article-outline-link"><a href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#article-outline">Back to Article Outline</a></p>
<h2>References</h2>
<ol id="referenceList"><a name="E1"></a>&nbsp;</p>
<li id="reference-E1">Schuster GU, Kenyon NJ, Stephensen CB. <strong>Vitamin A deficiency decreases and high dietary vitamin A increases disease severity in the mouse model of asthma. </strong><em>J Immunol</em>. 2008;180:1834–1842</li>
<p><a name="E2"></a></p>
<li id="reference-E2">Arora P, Kumar V, Batra S. <strong>Vitamin A status in children with asthma. </strong><em>Pediatr Allergy Immunol</em>. 2002;13:223–226</li>
<p><a name="E3"></a></p>
<li id="reference-E3">Harik-Khan RI, Muller DC, Wise RA. <strong>Serum vitamin levels and the risk of asthma in children. </strong><em>Am J Epidemiol</em>. 2004;159:351–357</li>
<p><a name="E4"></a></p>
<li id="reference-E4">Riccioni G, Barbara M, Bucciarelli T, di Ilio C, D&#8217;Orazio N. <strong>Antioxidant vitamin supplementation in asthma. </strong><em>Ann Clin Lab Sci</em>. 2007;37:96–101</li>
<p><a name="E5"></a></p>
<li id="reference-E5">Denny SI, Thompson RL, Margetts BM. <strong>Dietary factors in the pathogenesis of asthma and chronic obstructive pulmonary disease. </strong><em>Curr Allergy Asthma Rep</em>. 2003;3:130–136</li>
<p><a name="E6"></a></p>
<li id="reference-E6">Shimizu T, Maeda S, Arakawa H, Mochizuki H, Tokuyama K, Morikawa A. <strong>Relation between theophylline and circulating vitamin levels in children with asthma. </strong><em>Pharmacology</em>. 1996;53:384–389</li>
<p><a name="E7"></a></p>
<li id="reference-E7">Lee HS, Kim SK, Han JB, Choi HM, Park JH, Kim EC, et al. <strong>Inhibitory effects of Rumex japonicus Houtt on the development of atopic dermatitis-like skin lesions in NC/Nga mice. </strong><em>Br J Dermatol</em>. 2006;155:33–38</li>
<p><a name="E8"></a></p>
<li id="reference-E8">Mellis CM. <strong>Is asthma prevention possible with dietary manipulation?. </strong><em>Med J Aust</em>. 2002;177(suppl):S78–S80</li>
<p><a name="E9"></a></p>
<li id="reference-E9">Stonemetz D. <strong>A review of the clinical efficacy of evening primrose. </strong><em>Holist Nurs Pract</em>. 2008;22:171–174</li>
<p><a name="E10"></a></p>
<li id="reference-E10">Moreira A, Kekkonen R, Korpela R, Delgado L, Haahtela T. <strong>Allergy in marathon runners and effect of Lactobacillus GG supplementation on allergic inflammatory markers. </strong><em>Respir Med</em>. 2007;101:1123–1131</li>
<p><a name="E11"></a></p>
<li id="reference-E11">Feleszko W, Jaworska J, Rha RD, Steinhausen S, Avagyan A, Jaudszus A, et al. <strong>Probiotic-induced  suppression of allergic sensitization and airway inflammation is  associated with an increase of T regulatory-dependent mechanisms in a  murine model of asthma. </strong><em>Clin Exp Allergy</em>. 2007;37:498–505</li>
<p><a name="E12"></a></p>
<li id="reference-E12">Forsythe P, Inman MD, Bienenstock J. <strong>Oral treatment with live Lactobacillus reuteri inhibits the allergic airway response in mice. </strong><em>Am J Respir Crit Care Med</em>. 2007;175:561–569</li>
<p><a name="E13"></a></p>
<li id="reference-E13">Giovannini M, Agostoni C, Riva E, Salvini F, Ruscitto A, Zuccotti GV, et al. <strong>A  randomized prospective double blind controlled trial on effects of  long-term consumption of fermented milk containing Lactobacillus casei  in pre-school children with allergic asthma and/or rhinitis. </strong><em>Pediatr Res</em>. 2007;62:215–220</li>
<p><a name="E14"></a></p>
<li id="reference-E14">Lee DKC, Carstairs IJ, Haggart K, Jackson CM, Currie GP, Lipworth BJ. <strong>Butterbur, a herbal remedy, attenuates adenosine monophosphate induced nasal responsiveness in seasonal allergic rhinitis. </strong><em>Clin Exp Allergy</em>. 2003;33:882–886</li>
<p><a name="E15"></a></p>
<li id="reference-E15">Schapowal A. <strong>Treating  intermittent allergic rhinitis: a prospective, randomized, placebo and  antihistamine-controlled study of Butterbur extract Ze 339. </strong><em>Phytother Res</em>. 2005;19:530–537</li>
<p><a name="E16"></a></p>
<li id="reference-E16">Gray RD, Haggart K, Lee DKC, Cull S, Lipworth BJ. <strong>Effects of butterbur treatment in intermittent allergic rhinitis: a placebo-controlled evaluation. </strong><em>Ann Allergy Asthma Immunol</em>. 2004;93:56–60</li>
<p><a name="E17"></a></p>
<li id="reference-E17">Jackson CM, Lee DKC, Lipworth BJ. <strong>The effects of butterbur on the histamine and allergen cutaneous response. </strong><em>Ann Allergy Asthma Immunol</em>. 2004;92:250–254</li>
<p><a name="E18"></a></p>
<li id="reference-E18">Choi JJ, Park B, Kim DH, Pyo M-Y, Choi S, Son M, et al. <strong>Blockade  of atopic dermatitis-like skin lesions by DA-9102, a natural medicine  isolated from Actinidia arguta, in the Mg-deficiency induced dermatitis  model of hairless rats. </strong><em>Exp Biol Med</em>. 2008;233:1026–1034</li>
<p><a name="E19"></a></p>
<li id="reference-E19">Choi MS, Kim EC, Lee HS, Kim SK, Choi HM, Park JH, et al. <strong>Inhibitory  effects of Saururus chinensis (LOUR.) BAILL on the development of  atopic dermatitis-like skin lesions in NC/Nga mice. </strong><em>Biol Pharm Bull</em>. 2008;31:51–56</li>
<p><a name="E20"></a></p>
<li id="reference-E20">Donsky H, Clarke D. <strong>Relieva, a Mahonia aquifolium extract for the treatment of adult patients with atopic dermatitis. </strong><em>Am J Ther</em>. 2007;14:442–446</li>
<p><a name="E21"></a></p>
<li id="reference-E21">Klovekorn W, Tepe A, Danesch U. <strong>A  randomized, double-blind, vehicle-controlled, half-side comparison with  a herbal ointment containing Mahonia aquifolium, Viola tricolor and  Centella asiatica for the treatment of mild-to-moderate atopic  dermatitis. </strong><em>Int J Clin Pharmacol Ther</em>. 2007;45:583–591</li>
<p><a name="E22"></a></p>
<li id="reference-E22">Ukawa Y, Izumi Y, Ohbuchi T, Takahashi T, Ikemizu S, Kojima Y. <strong>Oral  administration of the extract from Hatakeshimeji (Lyophyllum decastes  sing.) mushroom inhibits the development of atopic dermatitis-like skin  lesions in NC/Nga mice. </strong><em>J Nutr Sci Vitaminol</em>. 2007;53:293–296</li>
<p><a name="E23"></a></p>
<li id="reference-E23">Kimata H. <strong>Improvement of atopic dermatitis and reduction of skin allergic responses by oral intake of konjac ceramide. </strong><em>Pediatr Dermatol</em>. 2006;23:386–389</li>
<p><a name="E24"></a></p>
<li id="reference-E24">Schempp CM, Windeck T, Hezel S, Simon JC. <strong>Topical  treatment of atopic dermatitis with St. John&#8217;s wort cream—a randomized,  placebo controlled, double blind half-side comparison. </strong><em>Phytomedicine</em>. 2003;10(suppl 4):31–37</li>
<p><a name="E25"></a></p>
<li id="reference-E25">Matsumoto M, Kotani M, Fujita A, Higa S, Kishimoto T, Suemura M, et al. <strong>Oral  administration of persimmon leaf extract ameliorates skin symptoms and  transepidermal water loss in atopic dermatitis model mice, NC/Nga. </strong><em>Br J Dermatol</em>. 2002;146:221–227</li>
<p><a name="E26"></a></p>
<li id="reference-E26">Zhao Y, van Hasselt CA, Woo JK, Chen GG, Wong YO, Wang LH, et al. <strong>Effects of the Chinese herbal formula Shi-Bi-Lin on cytokine release from the human mast cell line. </strong><em>Ann Allergy Asthma Immunol</em>. 2005;95:79–85</li>
<p><a name="E27"></a></p>
<li id="reference-E27">Hon KLE, Leung TF, Ng PC, Lam MCA, Kam WYC, Wong KY, et al. <strong>Efficacy  and tolerability of a Chinese herbal medicine concoction for treatment  of atopic dermatitis: a randomized, double-blind, placebo-controlled  study. </strong><em>Br J Dermatol</em>. 2007;157:357–363</li>
<p><a name="E28"></a></p>
<li id="reference-E28">Yoshimura M, Enomoto T, Dake Y, Okuno Y, Ikeda H, Cheng L, et al. <strong>An evaluation of the clinical efficacy of tomato extract for perennial allergic rhinitis. </strong><em>Allergol Int</em>. 2007;56:225–230</li>
<p><a name="E29"></a></p>
<li id="reference-E29">Kobayashi H, Mizuno N, Kutsuna H, Teramae H, Ueoku S, Onoyama J, et al. <strong>Hochu-ekki-to suppresses development of dermatitis and elevation of serum IgE level in NC/Nga mice. </strong><em>Drugs Under Exp Clin Res</em>. 2003;29:81–84</li>
<p><a name="E30"></a></p>
<li id="reference-E30">Lee J, Jung E, Park B, Jung K, Park J, Kim K, et al. <strong>Evaluation of the anti-inflammatory and atopic dermatitis-mitigating effects of BSASM, a multicompound preparation. </strong><em>J Ethnopharmacol</em>. 2005;96:211–219</li>
<p><a name="E31"></a></p>
<li id="reference-E31"><strong>Urtica dioica; Urtica urens (nettle). </strong>[monograph] <em>Alt Med Rev</em>. 2007;12:280–284</li>
<p><a name="E32"></a></p>
<li id="reference-E32">Kobayashi S, Tanabe S. <strong>Evaluation  of the anti-allergic activity of Citrus unshiu using rat basophilic  leukemia RBL-2H3 cells as well as basophils of patients with seasonal  allergic rhinitis to pollen. </strong><em>Int J Mol Med</em>. 2006;17:511–515</li>
<p><a name="E33"></a></p>
<li id="reference-E33">Shin TY, Kim SH, Suk K, Ha JH, Kim I, Lee MG, et al. <strong>Anti-allergic effects of Lycopus lucidus on mast cell-mediated allergy model. </strong><em>Toxicol Appl Pharmacol</em>. 2005;209:255–262</li>
<p><a name="E34"></a></p>
<li id="reference-E34">Kim S-H, Lee S, Kim IK, Kwon TK, Moon J-Y, Park W-H, et al. <strong>Suppression of mast cell-mediated allergic reaction by Amomum xanthiodes. </strong><em>Food Chem Toxicol</em>. 2007;45:2138–2144</li>
<p><a name="E35"></a></p>
<li id="reference-E35">Bernstein DI, Bernstein CK, Deng C, Murphy KJ, Bernstein IL, Bernstein JA, et al. <strong>Evaluation  of the clinical efficacy and safety of grapeseed extract in the  treatment of fall seasonal allergic rhinitis: a pilot study. </strong><em>Ann Allergy Asthma Immunol</em>. 2002;88:272–278</li>
<p><a name="E36"></a></p>
<li id="reference-E36">Mao TK, Van de Water J, Gershwin ME. <strong>Effects of a spirulina-based dietary supplement on cytokine production from allergic rhinitis patients. </strong><em>J Med Food</em>. 2005;8:27–30</li>
<p><a name="E37"></a></p>
<li id="reference-E37">Saxena VS, Venkateshwarlu K, Nadig P, Barbhaiya HC, Bhatia N, Borkar DM, et al. <strong>Multicenter clinical trials on a novel polyherbal formulation in allergic rhinitis. </strong><em>Int J Clin Pharmacol Res</em>. 2004;24:79–94</li>
<p><a name="E38"></a></p>
<li id="reference-E38">Pratibha N, Saxena VS, Amit A, D&#8217;Souza P, Bagchi M, Bagchi D. <strong>Anti-inflammatory activities of Aller-7, a novel polyherbal formulation for allergic rhinitis. </strong><em>Int J Tissue React</em>. 2004;26:43–51</li>
<p><a name="E39"></a></p>
<li id="reference-E39">Badar VA, Thawani VR, Wakode PT, Shrivastava MP, Gharpure KJ, Hingorani LL, et al. <strong>Efficacy of Tinospora cordifolia in allergic rhinitis. </strong><em>J Ethnopharmacol</em>. 2005;96:445–449</li>
<p><a name="E40"></a></p>
<li id="reference-E40">Hu G, Walls RS, Bass D, Ramon B, Grayson D, Jones M, et al. <strong>The  Chinese herbal formulation biminne in management of perennial allergic  rhinitis: a randomized, double-blind, placebo-controlled, 12-week  clinical trial. </strong><em>Ann Allergy Asthma Immunol</em>. 2002;88:478–487</li>
<p><a name="E41"></a></p>
<li id="reference-E41">Ikeda Y, Kaneko A, Yamamoto M, Ishige A, Sasaki H. <strong>Possible involvement of suppression of Th2 differentiation in the anti-allergic effect of sho-seiryu-to in mice. </strong><em>Jpn J Pharmacol</em>. 2002;90:328–336</li>
<p><a name="E42"></a></p>
<li id="reference-E42">Osakabe N, Takano H, Sanbongi C, Yasuda A, Yanagisawa R, Inoue K, et al. <strong>Anti-inflammatory  and anti-allergic effect of rosmarinic acid (RA); inhibition of  seasonal allergic rhinoconjunctivitis (SAR) and its mechanism. </strong><em>Biofactors</em>. 2004;21:127–131</li>
<p><a name="E43"></a></p>
<li id="reference-E43">Takano H, Osakabe N, Sanbongi C, Yanagisawa R, Inoue K, Yasuda A, et al. <strong>Extract  of Perilla frutescens enriched for rosmarinic acid, a polyphenolic  phytochemical, inhibits seasonal allergic rhinoconjunctivitis in humans. </strong><em>Exp Biol Med</em>. 2004;229:247–254</li>
</ol>
</div>
<div>
<p id="article-footnote-1">Series editors: Donald Y. M. Leung, MD, PhD, and Dennis K. Ledford, MD</p>
<p id="pii">PII: S0091-6749(08)02439-1</p>
<p id="doi">doi:10.1016/j.jaci.2008.12.023</p>
<p id="copyright">© 2009 American Academy of Allergy, Asthma &amp; Immunology. Published by Elsevier Inc. All rights reserved.</p>
</div>
<div>
<div>
<div><a id="prevArticle" href="http://www.jacionline.org/article/S0091-6749%2809%2900046-3/fulltext">« Previous</a><a id="nextArticle" href="http://www.jacionline.org/article/S0091-6749%2808%2903478-7/fulltext">Next »</a><strong>The Journal of Allergy and Clinical Immunology</strong><br />
<a href="http://www.jacionline.org/issues?issue_key=S0091-6749%2809%29X0002-3">Volume 123, Issue 2</a> , Pages 283-294.e10, February 2009</div>
</div>
</div>
</div>
<div id="secondary">
<div id="social"><a id="utilShare" href="http://addthis.com/bookmark.php?v=250&amp;pub=xa-4b1d65bd00983246">Print or                         Share This Page</a></div>
<div id="thisArticleElsewhere_link">Access this article on <a href="http://linkinghub.elsevier.com/retrieve/pii/S0091-6749%2808%2902439-1?showall=true"> SciVerse ScienceDirect </a></div>
<div>
<div>
<h3>Article Tools</h3>
</div>
<div>
<ul>
<form>
<li id="download_powerpoint"><a id="download_powerpoint_link" href="http://download.journals.elsevierhealth.com/ppt/journals/0091-6749/PIIS0091674908024391.ppt"><img src="http://www.jacionline.org/webfiles/images/icons/disk.png" alt="Download" /> Download Images*</a></li>
<li id="email_colleague"><a><img src="http://www.jacionline.org/webfiles/images/icons/email_go.png" alt="Email Abstract" /> Email Abstract</a></li>
<li id="reading-list"><a><img src="http://www.jacionline.org/webfiles/images/icons/book_add.png" alt="Add to My Reading List" /> Add to My Reading List</a></li>
<li id="request_permission"><a><img src="http://www.jacionline.org/webfiles/images/icons/lock_open.png" alt="Rights and Permissions" /> Rights/Permissions</a></li>
<li id="request_permission"><a><img src="http://www.jacionline.org/webfiles/images/icons/report.png" alt="Request Reprints" /> Request Reprints</a></li>
<li id="related_articles"><a href="http://www.jacionline.org/article/PIIS0091674908024391/related?article_id=S0091-6749%2808%2902439-1"><img src="http://www.jacionline.org/webfiles/images/icons/page_link.png" alt="Related Articles" /> Related Articles</a></li>
<li id="scopus_link"><a><img src="http://www.jacionline.org/webfiles/images/scopus_logo.gif" alt="Scopus Citations" /> (33) Cited in Scopus</a></li>
<li id="export_citation"><a><img src="http://www.jacionline.org/webfiles/images/icons/text_list_numbers.png" alt="Export Citation List" /> Export Citation</a></li>
<li id="citation_alert"><a><img src="http://www.jacionline.org/webfiles/images/icons/cog_add.png" alt="Create Citation Alert" /> Create Citation Alert</a></li>
</form>
</ul>
<p>* 				<a id="imginfo">Image Usage &amp; Resolution</a></p>
</div>
</div>
</div>
<div id="footer"><a href="http://www.elsevier.com/"> Copyright © 2011 Elsevier, Inc. All rights reserved </a> | 	<a href="http://www.jacionline.org/misc/privacy">Privacy Policy</a> | 	<a href="http://www.jacionline.org/misc/terms">Terms &amp; Conditions</a> | 	<a href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">Feedback</a> | 	<a href="http://www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext#">About Us</a> | 	<a href="http://www.jacionline.org/webfiles/helpfiles/periodicals_help.htm">Help</a> | 	<a href="http://www.jacionline.org/contact">Contact Us</a><br />
The content on this site is intended for health professionals.Advertisements on this site do not constitute a  guarantee or endorsement by the journal, Association, or publisher of  the quality or value of such product or of the claims made for it by its  manufacturer.&nbsp;</p>
<p><img src="http://secure-us.imrworldwide.com/cgi-bin/m?rnd=1308527656694&amp;ci=us-elsevier&amp;cg=0&amp;cc=1&amp;sr=1024x768&amp;cd=24&amp;lg=en-US&amp;je=y&amp;ck=y&amp;tz=-7&amp;si=http%3A//www.jacionline.org/article/S0091-6749%2808%2902439-1/fulltext&amp;rp=http%3A//www.jacionline.org/article/S0091-6749%2808%2902439-1/abstract" alt="" width="1" height="1" /></p>
</div>
</div>
</div>
]]></content:encoded>
			<wfw:commentRss>http://defeatosteosarcoma.org/2011/06/2890/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Shiitake mushroom (Lentinula edodes)</title>
		<link>http://defeatosteosarcoma.org/2011/05/shiitake-mushroom-lentinula-edodes/</link>
		<comments>http://defeatosteosarcoma.org/2011/05/shiitake-mushroom-lentinula-edodes/#comments</comments>
		<pubDate>Thu, 19 May 2011 18:37:34 +0000</pubDate>
		<dc:creator>James Street</dc:creator>
				<category><![CDATA[General Cancer Research]]></category>
		<category><![CDATA[Natural Therapies]]></category>
		<category><![CDATA[Nutrition and Cancer]]></category>
		<category><![CDATA[Vitamins and Supplements]]></category>

		<guid isPermaLink="false">http://defeatosteosarcoma.org/?p=2545</guid>
		<description><![CDATA[ONCOLOGY. Vol. 25 No. 6 INTEGRATIVE ONCOLOGY Complementary Therapies, Herbs, and Other OTC Agents By Barrie Cassileth, PhD1 &#124; May 13, 2011 &#160; ALSO KNOWN AS: Forest mushroom, lentinula, black mushroom, hua gu. BACKGROUND: Shiitake, an edible mushroom indigenous to East Asia, is cultivated worldwide for its purported health benefits. The fresh and dried forms [...]]]></description>
			<content:encoded><![CDATA[<p>ONCOLOGY. Vol. 25 No. 6</p>
<div id="article-eyebrown">INTEGRATIVE ONCOLOGY</div>
<h2><em>Complementary Therapies, Herbs, and Other OTC Agents</em></h2>
<div id="article-byline">By Barrie Cassileth, PhD<sup>1</sup> | May 13, 2011</div>
<hr />
<p>&nbsp;</p>
<p><strong><img src="http://www.cancernetwork.com/image/image_gallery?img_id=1861205&amp;t=1305299662164" alt="" width="150" height="139" align="right" /></strong><strong>ALSO KNOWN AS</strong>: Forest mushroom, lentinula, black mushroom, hua gu.</p>
<p><strong>BACKGROUND</strong>:  Shiitake, an edible mushroom indigenous to East Asia, is cultivated  worldwide for its purported health benefits. The fresh and dried forms  of the mushroom are commonly used in East Asian cooking. It is also  valued as a medicinal mushroom. Shiitake is popular in many countries  around the world and is commonly found in supermarkets and Asian grocery  stores.</p>
<p>Lentinan ([1,3] beta-D-glucan), a polysaccharide  isolated from shiitake, is thought to be responsible for many of the  mushroom&#8217;s beneficial effects. An injectable form of lentinan is used  for cancer treatment in some countries, but it has not been evaluated in  large studies.</p>
<p><strong>RESEARCH:</strong> In vitro studies  conducted with lentinan have indicated its anticancer effects in colon  cancer cells;[1] these effects may result from its ability to suppress  cytochrome P450 1A enzymes that are known to metabolize pro-carcinogens  to active forms.[2]</p>
<p>Lentin, the protein component of  shiitake, exerts antifungal properties, inhibits proliferation of  leukemic cells, and suppresses the activity of HIV-1 reverse  transcriptase.[3]</p>
<p>Studies of shiitake extracts suggest  antiproliferative,[4] immunostimulatory,[4] hepatoprotective,[5]  antimutagenic,[6] and anticaries[7] effects in vitro and in mice. But a  clinical trial failed to show any benefit of an oral shiitake extract in  the treatment of prostate cancer.[8]</p>
<p>More recently, however,  improvements were reported in quality of life and survival with an oral  formulation of superfine dispersed lentinan in patients with  hepatocellular carcinoma,[9] gastric cancer,[10] colorectal cancer,[11]  and pancreatic cancer.[12] Larger, well-designed studies are needed to  determine whether oral lentinan is superior to the injectable form.</p>
<p><strong>ADVERSE REACTIONS:</strong> None have been reported at normal doses. However, there have been a  handful of case reports documenting adverse effects associated with  shiitake in some way. Chronic hypersensitivity pneumonitis was observed  in a lung cancer patient following exposure to shiitake spores.[13]  Prolonged consumption of shiitake powder has resulted in dermatitis,  photosensitivity,[14] eosinophilia, and gastrointestinal upset.[15]  Intermittent skin eruptions (dermatitis), over a period of 16 years,  were linked to consumption of shiitake mushrooms in a 45-year-old  male.[16] Food allergy manifesting as esophageal symptoms was reported  in a 37-year-old man following consumption of shiitake mushroom.[17]</p>
<div id="article-references">
<p><strong>REFERENCES</strong></p>
<p>1. Ng ML, Yap AT. Inhibition of human colon carcinoma development by  lentinan from shiitake mushrooms (Lentinus edodes). J Altern Complement  Med. 2002;8:581-9.</p>
<p>2. Okamoto T, Kodoi R, Nonaka Y, et al. Lentinan from shiitake  mushroom (Lentinus edodes) suppresses expression of cytochrome P450 1A  subfamily in the mouse liver. Biofactors. 2004;21:407-9.</p>
<p>3. Ngai PH, Ng TB. Lentin, a novel and potent antifungal protein from  shitake mushroom with inhibitory effects on activity of human  immunodeficiency virus-1 reverse transcriptase and proliferation of  leukemia cells. Life Sci. 2003;73:3363-74.</p>
<p>4. Israilides C, Kletsas D, Arapoglou D, et al. In vitro cytostatic  and immunomodulatory properties of the medicinal mushroom Lentinula  edodes. Phytomedicine. 2008;15:512-9.</p>
<p>5. Akamatsu S, Watanabe A, Tamesada M, et al. Hepatoprotective effect  of extracts from Lentinus edodes mycelia on dimethylnitrosamine-induced  liver injury. Biol Pharm Bull. 2004;27:1957-60.</p>
<p>6. de Lima PL, Delmanto RD, Sugui MM, et al. Letinula edodes (Berk.)  Pegler (Shiitake) modulates genotoxic and mutagenic effects induced by  alkylating agents in vivo. Mutat Res. 2001;496:23-32.</p>
<p>7. Shouji N, Takada K, Fukushima K, Hirasawa M. Anticaries effect of a  component from shiitake (an edible mushroom). Caries Res. 2000;34:94-8.</p>
<p>8. deVere White RW, Hackman RM, Soares SE, Beckett LA, Sun B. Effects  of a mushroom mycelium extract on the treatment of prostate cancer.  Urology. 2002;60:640-4.</p>
<p>9. Isoda N, Eguchi Y, Nukaya H, et al. Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan)<br />
in patients with hepatocellular carcinoma. Hepatogastroenterology. 2009;56:437-41.</p>
<p>10. Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Individual  patient based meta-analysis of lentinan for unresectable/recurrent  gastric cancer. Anticancer Res. 2009;29:2739-45.</p>
<p>11. Hazama S, Watanabe S, Ohashi M, et al. Efficacy of orally  administered superfine dispersed lentinan (beta-1,3-glucan) for the  treatment of advanced colorectal cancer. Anticancer Res. 2009;29:2611-7.</p>
<p>12. Shimizu K, Watanabe S, Watanabe S, et al. Efficacy of oral  administered superfine dispersed lentinan for advanced pancreatic  cancer. Hepatogastroenterology. 2009;56:240-4.</p>
<p>13. Suzuki K, Tanaka H, Sugawara H, et al. Chronic hypersensitivity  pneumonitis induced by Shiitake mushroom spores associated with lung  cancer. Intern Med. 2001;40:1132-5.</p>
<p>14. Hanada K, Hashimoto I. Flagellate mushroom (Shiitake) dermatitis and photosensitivity. Dermatology. 1998;197:255-7.</p>
<p>15. Levy AM, Kita H, Phillips SF, et al. Eosinophilia and  gastrointestinal symptoms after ingestion of shiitake mushrooms. J  Allergy Clin Immunol. 1998;101:613-20.</p>
<p>16. Garg S, Cockayne SE. Shiitake dermatitis diagnosed after 16 years! Arch Dermatol. 2008;144:1241-2.</p>
<p>17. Goikoetxea MJ, Fernández-Benítez M, Sanz ML. Food allergy to  Shiitake (Lentinus edodes) manifested as oesophageal symptoms in a  patient with probable eosinophilic oesophagitis. Allergol Immunopathol  (Madr). 2009;37:333-4.</p>
</div>
]]></content:encoded>
			<wfw:commentRss>http://defeatosteosarcoma.org/2011/05/shiitake-mushroom-lentinula-edodes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reduced Argininosuccinate Synthetase Is a Predictive Biomarker for the Development of Pulmonary Metastasis in Patients with Osteosarcoma</title>
		<link>http://defeatosteosarcoma.org/2011/05/reduced-argininosuccinate-synthetase-is-a-predictive-biomarker-for-the-development-of-pulmonary-metastasis-in-patients-with-osteosarcoma/</link>
		<comments>http://defeatosteosarcoma.org/2011/05/reduced-argininosuccinate-synthetase-is-a-predictive-biomarker-for-the-development-of-pulmonary-metastasis-in-patients-with-osteosarcoma/#comments</comments>
		<pubDate>Thu, 19 May 2011 06:55:23 +0000</pubDate>
		<dc:creator>James Street</dc:creator>
				<category><![CDATA[Lung Metastases]]></category>
		<category><![CDATA[Natural Therapies]]></category>
		<category><![CDATA[Nutrition and Cancer]]></category>
		<category><![CDATA[Vitamins and Supplements]]></category>

		<guid isPermaLink="false">http://defeatosteosarcoma.org/?p=2540</guid>
		<description><![CDATA[Auteur(s) / Author(s) KOBAYASHI Eisuke ; MASUDA Mari ; NAKAYAMA Robert ; ICHIKAWA Hitoshi ; SATOW Reiko ; SHITASHIGE Miki ; HONDA Kazufumi ; YAMAGUCHI Umio ; SHOJI Ayako ; TOCHIGI Naobumi ; MORIOKA Hideo ; TOYAMA Yoshiaki ; HIROHASHI Setsuo ; KAWAI Akira ; YAMADA Tesshi ; Résumé / Abstract Pulmonary metastasis is the most significant prognostic determinant for osteosarcoma, but methods for its prediction and treatment have not [...]]]></description>
			<content:encoded><![CDATA[<h3>Auteur(s) / Author(s)</h3>
<p><a href="http://www.refdoc.fr/?traduire=en&amp;FormRechercher=submit&amp;FormRechercher_Txt_Recherche_name_attr=auteursNom:%20%28KOBAYASHI%29">KOBAYASHI Eisuke</a> ;  <a href="http://www.refdoc.fr/?traduire=en&amp;FormRechercher=submit&amp;FormRechercher_Txt_Recherche_name_attr=auteursNom:%20%28MASUDA%29">MASUDA Mari</a> ;  <a href="http://www.refdoc.fr/?traduire=en&amp;FormRechercher=submit&amp;FormRechercher_Txt_Recherche_name_attr=auteursNom:%20%28NAKAYAMA%29">NAKAYAMA Robert</a> ;  <a href="http://www.refdoc.fr/?traduire=en&amp;FormRechercher=submit&amp;FormRechercher_Txt_Recherche_name_attr=auteursNom:%20%28ICHIKAWA%29">ICHIKAWA Hitoshi</a> ;  <a href="http://www.refdoc.fr/?traduire=en&amp;FormRechercher=submit&amp;FormRechercher_Txt_Recherche_name_attr=auteursNom:%20%28SATOW%29">SATOW Reiko</a> ;  <a href="http://www.refdoc.fr/?traduire=en&amp;FormRechercher=submit&amp;FormRechercher_Txt_Recherche_name_attr=auteursNom:%20%28SHITASHIGE%29">SHITASHIGE Miki</a> ;  <a href="http://www.refdoc.fr/?traduire=en&amp;FormRechercher=submit&amp;FormRechercher_Txt_Recherche_name_attr=auteursNom:%20%28HONDA%29">HONDA Kazufumi</a> ;  <a href="http://www.refdoc.fr/?traduire=en&amp;FormRechercher=submit&amp;FormRechercher_Txt_Recherche_name_attr=auteursNom:%20%28YAMAGUCHI%29">YAMAGUCHI Umio</a> ;  <a href="http://www.refdoc.fr/?traduire=en&amp;FormRechercher=submit&amp;FormRechercher_Txt_Recherche_name_attr=auteursNom:%20%28SHOJI%29">SHOJI Ayako</a> ;  <a href="http://www.refdoc.fr/?traduire=en&amp;FormRechercher=submit&amp;FormRechercher_Txt_Recherche_name_attr=auteursNom:%20%28TOCHIGI%29">TOCHIGI Naobumi</a> ;  <a href="http://www.refdoc.fr/?traduire=en&amp;FormRechercher=submit&amp;FormRechercher_Txt_Recherche_name_attr=auteursNom:%20%28MORIOKA%29">MORIOKA Hideo</a> ;  <a href="http://www.refdoc.fr/?traduire=en&amp;FormRechercher=submit&amp;FormRechercher_Txt_Recherche_name_attr=auteursNom:%20%28TOYAMA%29">TOYAMA Yoshiaki</a> ;  <a href="http://www.refdoc.fr/?traduire=en&amp;FormRechercher=submit&amp;FormRechercher_Txt_Recherche_name_attr=auteursNom:%20%28HIROHASHI%29">HIROHASHI Setsuo</a> ;  <a href="http://www.refdoc.fr/?traduire=en&amp;FormRechercher=submit&amp;FormRechercher_Txt_Recherche_name_attr=auteursNom:%20%28KAWAI%29">KAWAI Akira</a> ;  <a href="http://www.refdoc.fr/?traduire=en&amp;FormRechercher=submit&amp;FormRechercher_Txt_Recherche_name_attr=auteursNom:%20%28YAMADA%29">YAMADA Tesshi</a> ;</p>
<h3>Résumé / Abstract</h3>
<p>Pulmonary metastasis is the most significant  prognostic determinant for osteosarcoma, but methods for its prediction  and treatment have not been established. Using oligonucleotide  microarrays, we compared the global gene expression of biopsy samples  between seven osteosarcoma patients who developed pulmonary metastasis  within 4 years after neoadjuvant chemotherapy and curative resection,  and 12 patients who did not relapse. We identified argininosuccinate  synthetase (ASS) as a gene differentially expressed with the highest  statistical significance (Welch&#8217;s t test, P = 2.2 x 10<sup>-5</sup>).  Immunohistochemical analysis of an independent cohort of 62 osteosarcoma  cases confirmed that reduced expression of ASS protein was  significantly correlated with the development of pulmonary metastasis  after surgery (log-rank test, P &lt; 0.05). Cox regression analysis  revealed that ASS was the sole significant predictive factor (P = 0.039;  hazard ratio, 0.319; 95% confidence interval, 0.108-0.945). ASS is one  of the enzymes required for the production of a nonessential amino acid,  arginine. We showed that osteosarcoma cells lacking ASS expression were  auxotrophic for arginine and underwent G<sub>0</sub>-G<sub>1</sub> arrest in arginine-free medium, suggesting that an arginine deprivation  therapy could be effective in patients with osteosarcoma. Recently,  phase I and II clinical trials in patients with melanoma and  hepatocellular carcinoma have shown the safety and efficacy of plasma  arginine depletion by stabilized arginine deiminase. Our data indicate  that in patients with osteosarcoma, reduced expression of ASS is not  only a novel predictive biomarker for the development of metastasis, but  also a potential target for pharmacologic intervention.</p>
<h3>Revue / Journal Title</h3>
<p><a href="http://www.refdoc.fr/?traduire=en&amp;FormRechercher=submit&amp;FormRechercher_Txt_Recherche_name_attr=listeTitreSerie:%20%28Molecular%20cancer%20therapeutics%29">Molecular cancer therapeutics</a> <strong>ISSN</strong> <a href="http://www.refdoc.fr/?traduire=en&amp;FormRechercher=submit&amp;FormRechercher_Txt_Recherche_name_attr=identifiantsDoc:%20%281535-7163%29">1535-7163</a> <strong>CODEN</strong> MCTOCF</p>
<h3>Source / Source</h3>
<p>2010, vol. 9, n<sup>o</sup>3, pp. 535-544 [10 page(s) (article)]</p>
<h3>Langue / Language</h3>
<p>Anglais</p>
<h3>Editeur / Publisher</h3>
<p>American Association for Cancer Research, Philadelphia, PA, ETATS-UNIS  	 		(2001) 	 (Revue)</p>
<h3>Localisation / Location</h3>
<p>INIST-CNRS, Cote INIST : 27573, 35400018101874.0020</p>
<div>Nº notice refdoc (ud4) : 22638552</div>
]]></content:encoded>
			<wfw:commentRss>http://defeatosteosarcoma.org/2011/05/reduced-argininosuccinate-synthetase-is-a-predictive-biomarker-for-the-development-of-pulmonary-metastasis-in-patients-with-osteosarcoma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Anticancer effects of ginsenoside Rg1, cinnamic acid, and tanshinone IIA in osteosarcoma MG-63 cells: Nuclear matrix downregulation and cytoplasmic trafficking of nucleophosmin</title>
		<link>http://defeatosteosarcoma.org/2011/04/anticancer-effects-of-ginsenoside-rg1-cinnamic-acid-and-tanshinone-iia-in-osteosarcoma-mg-63-cells-nuclear-matrix-downregulation-and-cytoplasmic-trafficking-of-nucleophosmin/</link>
		<comments>http://defeatosteosarcoma.org/2011/04/anticancer-effects-of-ginsenoside-rg1-cinnamic-acid-and-tanshinone-iia-in-osteosarcoma-mg-63-cells-nuclear-matrix-downregulation-and-cytoplasmic-trafficking-of-nucleophosmin/#comments</comments>
		<pubDate>Fri, 15 Apr 2011 05:34:15 +0000</pubDate>
		<dc:creator>James Street</dc:creator>
				<category><![CDATA[Alternative Therapies]]></category>
		<category><![CDATA[Natural Therapies]]></category>
		<category><![CDATA[Nutrition and Cancer]]></category>
		<category><![CDATA[Osteosarcoma]]></category>
		<category><![CDATA[Vitamins and Supplements]]></category>

		<guid isPermaLink="false">http://defeatosteosarcoma.org/?p=2213</guid>
		<description><![CDATA[Purchase $ 41.95 References and further reading may be available for this article. To view references and further reading you must purchase this article. Qi-Fu Lia, , , Song-Lin Shia, Qing-Rong Liub, Jian Tanga, Jianye Songa and Ying Lianga a Key Laboratory of Ministry of Education for Cell Biology &#38; Tumor cell Engineering, School of [...]]]></description>
			<content:encoded><![CDATA[<div>
<div><a href="http://www.sciencedirect.com/science?_ob=ShoppingCartURL&amp;_method=add&amp;_udi=B6TCH-4RTM35H-3&amp;_acct=C000050221&amp;_version=1&amp;_userid=10&amp;_ts=1302806133&amp;md5=cc39ea29b9e5353bed187302361368b5"></p>
<div>
<div><img src="http://www.sciencedirect.com/scidirimg/pdf_icon.gif" alt="" /></div>
<div>
<div>Purchase</div>
<div>$  41.95</div>
</div>
</div>
<p></a></div>
<p><a id="dd_href" href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TCH-4RTM35H-3&amp;_user=10&amp;_coverDate=12%2F31%2F2008&amp;_rdoc=1&amp;_fmt=high&amp;_orig=gateway&amp;_origin=gateway&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_searchStrId=1718618618&amp;_rerunOrigin=scholar.google&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_userid=10&amp;md5=ecf0ee3f6c75831b4ba1310a79d3bee5&amp;searchtype=a#" target="DeepDyve"> <img id="dd_img" src="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TCH-4RTM35H-3&amp;_user=10&amp;_coverDate=12%2F31%2F2008&amp;_rdoc=1&amp;_fmt=high&amp;_orig=gateway&amp;_origin=gateway&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_searchStrId=1718618618&amp;_rerunOrigin=scholar.google&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_userid=10&amp;md5=ecf0ee3f6c75831b4ba1310a79d3bee5&amp;searchtype=a#" alt="" /> </a></div>
<div>
<p>References and further reading may be available for this article. To view references and further reading you must <a href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TCH-4RTM35H-3&amp;_user=10&amp;_coverDate=12%2F31%2F2008&amp;_rdoc=1&amp;_fmt=full&amp;_orig=gateway&amp;_origin=gateway&amp;_cdi=5171&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_searchStrId=1718618618&amp;_rerunOrigin=scholar.google&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_userid=10&amp;md5=fc1417c583e9c4bcad4c33b8eb188998&amp;searchtype=a">purchase</a> this article.</p>
</div>
<p><strong>Qi-Fu Li<a href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TCH-4RTM35H-3&amp;_user=10&amp;_coverDate=12%2F31%2F2008&amp;_rdoc=1&amp;_fmt=high&amp;_orig=gateway&amp;_origin=gateway&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_searchStrId=1718618618&amp;_rerunOrigin=scholar.google&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_userid=10&amp;md5=ecf0ee3f6c75831b4ba1310a79d3bee5&amp;searchtype=a#aff1"><sup>a</sup></a><sup>, </sup><a name="bcor1"></a><a href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TCH-4RTM35H-3&amp;_user=10&amp;_coverDate=12%2F31%2F2008&amp;_rdoc=1&amp;_fmt=high&amp;_orig=gateway&amp;_origin=gateway&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_searchStrId=1718618618&amp;_rerunOrigin=scholar.google&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_userid=10&amp;md5=ecf0ee3f6c75831b4ba1310a79d3bee5&amp;searchtype=a#cor1"><sup><img title="Corresponding Author Contact Information" src="http://www.sciencedirect.com/scidirimg/entities/REcor.gif" border="0" alt="Corresponding Author Contact Information" /></sup></a><sup>, </sup><a href="mailto:chifulee@xmu.edu.cn"><sup><img title="E-mail The Corresponding Author" src="http://www.sciencedirect.com/scidirimg/entities/REemail.gif" border="0" alt="E-mail The Corresponding Author" /></sup></a>, Song-Lin Shi<a href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TCH-4RTM35H-3&amp;_user=10&amp;_coverDate=12%2F31%2F2008&amp;_rdoc=1&amp;_fmt=high&amp;_orig=gateway&amp;_origin=gateway&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_searchStrId=1718618618&amp;_rerunOrigin=scholar.google&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_userid=10&amp;md5=ecf0ee3f6c75831b4ba1310a79d3bee5&amp;searchtype=a#aff1"><sup>a</sup></a>, Qing-Rong Liu<a href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TCH-4RTM35H-3&amp;_user=10&amp;_coverDate=12%2F31%2F2008&amp;_rdoc=1&amp;_fmt=high&amp;_orig=gateway&amp;_origin=gateway&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_searchStrId=1718618618&amp;_rerunOrigin=scholar.google&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_userid=10&amp;md5=ecf0ee3f6c75831b4ba1310a79d3bee5&amp;searchtype=a#aff2"><sup>b</sup></a>, Jian Tang<a href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TCH-4RTM35H-3&amp;_user=10&amp;_coverDate=12%2F31%2F2008&amp;_rdoc=1&amp;_fmt=high&amp;_orig=gateway&amp;_origin=gateway&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_searchStrId=1718618618&amp;_rerunOrigin=scholar.google&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_userid=10&amp;md5=ecf0ee3f6c75831b4ba1310a79d3bee5&amp;searchtype=a#aff1"><sup>a</sup></a>, Jianye Song<a href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TCH-4RTM35H-3&amp;_user=10&amp;_coverDate=12%2F31%2F2008&amp;_rdoc=1&amp;_fmt=high&amp;_orig=gateway&amp;_origin=gateway&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_searchStrId=1718618618&amp;_rerunOrigin=scholar.google&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_userid=10&amp;md5=ecf0ee3f6c75831b4ba1310a79d3bee5&amp;searchtype=a#aff1"><sup>a</sup></a> and Ying Liang<a href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TCH-4RTM35H-3&amp;_user=10&amp;_coverDate=12%2F31%2F2008&amp;_rdoc=1&amp;_fmt=high&amp;_orig=gateway&amp;_origin=gateway&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_searchStrId=1718618618&amp;_rerunOrigin=scholar.google&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_userid=10&amp;md5=ecf0ee3f6c75831b4ba1310a79d3bee5&amp;searchtype=a#aff1"><sup>a</sup></a></strong></p>
<div>
<div id="authorsAnchors">
<p><a name="aff1"></a><sup>a</sup> Key Laboratory of Ministry of  Education for Cell Biology &amp; Tumor cell Engineering, School of Life  Sciences, Xiamen University, Xiamen 361005, PR China</p>
<p><a name="aff2"></a><sup>b</sup> Molecular Neurobiology Branch, National Institute on Drug  Abuse-Intramural Research Program (NIDA-IRP), NIH, Department of Health  and Human Services (DHSS), 333 Cassell Drive, Baltimore, MD 21224, USA</p>
</div>
</div>
<div>Received 29 November 2007;</div>
<div>revised 28 January 2008;</div>
<div>accepted 29 January 2008.</div>
<div>Available online 12 February 2008.</div>
<p>&nbsp;</p>
<div>
<div>
<h3>Abstract</h3>
<p>Ginsenoside Rg1, cinnamic acid, and  tanshinone IIA are effective anticancer and antioxidant constituents of  traditional Chinese herbal medicines of Ginseng (<em>Panax ginseng</em>), Xuanshen (<em>Radix scrophulariae</em>), and Danshen (<em>Salvia mitiorrhiza</em>),  respectively. There was insufficient study on molecular mechanisms of  anticancer effects of those constituents and their targets were unknown.  We chose nucleophosmin as a candidate molecular target because it is  frequently mutated and upregulated in various cancer cells.  Nucleophosmin is a major nucleolus phosphoprotein that involves in rRNA  synthesis, maintaining genomic stability, and normal cell division and  its haploinsufficiency makes cell more susceptible to oncogenic assault.  Ginsenoside Rg1, cinnamic acid, and tanshinone IIA treatment of  osteosarcoma MG-63 cells decreased nucleophosmin expression in nuclear  matrix and induced nucleophosmin translocation from nucleolus to  nucleoplasm and cytoplasm, a process of dedifferentiating transformed  cells. Using immunogold electro-microscopy, we found at the first time  that nucleophosmin was localized on nuclear matrix intermediate  filaments that had undergone restorational changes after the treatments.  Nucleophosmin also functions as a molecular chaperone that might  interact with multiple oncogenes and tumor suppressor genes. We found  that oncogenes c-myc, c-fos and tumor suppressor genes, P53, Rb were  regulated by ginsenoside Rg1, cinnamic acid, and tanshinone IIA as well.  In present study, we identified nucleophosmin as a molecular target of  the effective anticancer constituents of t Ginseng, Xuanseng, and  Danseng that down-regulated nucleophosmin in nuclear matrix, changed its  trafficking from nucleolus to cytoplasm, and regulated several  oncogenes and tumor suppressor genes. Therefore, we postulate that  Ginsenoside Rg1, cinnamic acid, and tanshinone IIA could serve as  protective agents in cancer prevention and treatment.</p>
</div>
</div>
<div>
<p><strong>Keywords: </strong>Ginsenoside; Nucleophosmin; Human osteosarcoma; Nuclear matrix; Induced differentiation</p>
</div>
]]></content:encoded>
			<wfw:commentRss>http://defeatosteosarcoma.org/2011/04/anticancer-effects-of-ginsenoside-rg1-cinnamic-acid-and-tanshinone-iia-in-osteosarcoma-mg-63-cells-nuclear-matrix-downregulation-and-cytoplasmic-trafficking-of-nucleophosmin/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Strawberries may prevent esophageal cancer</title>
		<link>http://defeatosteosarcoma.org/2011/04/strawberries-may-prevent-esophageal-cancer/</link>
		<comments>http://defeatosteosarcoma.org/2011/04/strawberries-may-prevent-esophageal-cancer/#comments</comments>
		<pubDate>Thu, 07 Apr 2011 05:42:33 +0000</pubDate>
		<dc:creator>James Street</dc:creator>
				<category><![CDATA[Complementary Therapy]]></category>
		<category><![CDATA[Natural Therapies]]></category>
		<category><![CDATA[Nutrition and Cancer]]></category>
		<category><![CDATA[Prevention]]></category>
		<category><![CDATA[Vitamins and Supplements]]></category>

		<guid isPermaLink="false">http://defeatosteosarcoma.org/?p=2147</guid>
		<description><![CDATA[Thursday, April 07, 2011 by: S. L. Baker, features writer Learn more: http://www.naturalnews.com/031981_strawberries_esophageal_cancer.html#ixzz1IoTLzSzh (NaturalNews) According to the National Cancer Institute, about 16,700 new cases of esophageal cancer were diagnosed last year &#8212; and about 14,500 people died from the disease. Obviously, there&#8217;s no easy cure for this often fatal malignancy. So, as with any disease, [...]]]></description>
			<content:encoded><![CDATA[<p>Thursday, April 07, 2011 by: S. L. Baker, features writer</p>
<div>Learn more:  <a href="http://www.naturalnews.com/031981_strawberries_esophageal_cancer.html#ixzz1IoTLzSzh">http://www.naturalnews.com/031981_strawberries_esophageal_cancer.html#ixzz1IoTLzSzh</a></div>
<p>(NaturalNews) According to the National Cancer Institute, about 16,700  new cases of esophageal cancer were diagnosed last year &#8212; and about  14,500 people died from the disease. Obviously, there&#8217;s no easy cure for  this often fatal malignancy. So, as with any disease, it&#8217;s much better  to prevent getting it in the first place.</p>
<p>But how? Mainstream  medicine pushes Big Pharma drugs called H2 blockers and proton pump  inhibitors (PPIs) to calm gastroesophageal reflux disease (GERD) in  hopes of preventing Barrett&#8217;s esophagus, a complication of GERD that ups  the risk for esophageal cancer. But these meds are loaded with  potential side effects and there&#8217;s no strong evidence they really  prevent cancer.</p>
<p>However, a new study provides evidence there may  be a natural and tasty way to not only lower the odds of developing  esophageal cancer but to halt and perhaps reverse the progression of  precancerous lesions.</p>
<p>The powerful and delicious substance?  Strawberries, especially the freeze-dried variety.These findings were  just presented for the first time at the American Association for Cancer  Research&#8217;s (AACR) 102nd Annual Meeting 2011, held in Orlando.</p>
<p>&#8220;We  concluded from this study that six months of eating strawberries is  safe and easy to consume. In addition, our preliminary data suggests  that strawberries can decrease histological grade of precancerous  lesions and reduce cancer-related molecular events,&#8221; said lead  researcher Tong Chen, M.D., Ph.D., assistant professor, division of  medical oncology, department of internal medicine at Ohio State  University. Dr. Chen is also a member of the Molecular Carcinogenesis  and Chemoprevention Program in Ohio State University&#8217;s Comprehensive  Cancer Center.</p>
<p>She pointed out that esophageal cancer is the  third most common gastrointestinal cancer and the sixth most frequent  cause of cancer death in the world. Dr. Chen and her research team are  zeroing in on esophageal squamous cell carcinoma (SCC) which accounts  for 95 percent of cases of esophageal cancer worldwide.</p>
<p>In  earlier research, Dr. Chen&#8217;s research team discovered that freeze-dried  strawberries significantly inhibited esophageal tumor development in  rats. For the new study, the scientists launched a trial which included  participants with esophageal precancerous lesions who were at high risk  for developing full-blown esophageal cancer.</p>
<p>The research  subjects consumed 60 grams of freeze-dried strawberries every day for  six months. Freeze-dried strawberries were used because, by removing the  water from the berries, the natural cancer-preventive substances in the  strawberries soared by nearly 10-fold, according to Dr. Chen.</p>
<p>Biopsies  were taken before and after the six months of strawberry consumption.  The results showed that 29 out of 36 participants experienced a decrease  in the histological grade of their precancerous esophageal lesions  during the time they ate the strawberries.</p>
<p><em><strong>&#8220;Our study is  important because it shows that strawberries may slow the progression of  precancerous lesions in the esophagus. Strawberries may be an  alternative or work together with other chemopreventive drugs for the  prevention of esophageal cancer,&#8221;</strong></em> Dr. Chen stated.</p>
<div>Learn more:  <a href="http://www.naturalnews.com/031981_strawberries_esophageal_cancer.html#ixzz1IoTF4rok">http://www.naturalnews.com/031981_strawberries_esophageal_cancer.html#ixzz1IoTF4rok</a></div>
]]></content:encoded>
			<wfw:commentRss>http://defeatosteosarcoma.org/2011/04/strawberries-may-prevent-esophageal-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Peer Reviewed Publication Supporting Intravenous Vitamin C For Cancer Patients</title>
		<link>http://defeatosteosarcoma.org/2011/03/peer-reviewed-publication-supporting-intravenous-vitamin-c-for-cancer-patients/</link>
		<comments>http://defeatosteosarcoma.org/2011/03/peer-reviewed-publication-supporting-intravenous-vitamin-c-for-cancer-patients/#comments</comments>
		<pubDate>Fri, 01 Apr 2011 05:35:25 +0000</pubDate>
		<dc:creator>James Street</dc:creator>
				<category><![CDATA[Alternative Therapies]]></category>
		<category><![CDATA[Natural Therapies]]></category>
		<category><![CDATA[Nutrition and Cancer]]></category>
		<category><![CDATA[Vitamins and Supplements]]></category>

		<guid isPermaLink="false">http://defeatosteosarcoma.org/?p=2109</guid>
		<description><![CDATA[26 Mar 2011 The Riordan Clinic announced publication in the Journal of Translational Medicine results of a collaboration between oncologists, alternative medicine practitioners, and basic researchers, which proposes a new use of intravenous vitamin C for treatment of cancer. The rationale is provided that intravenous, but not oral, vitamin C may be capable of addressing [...]]]></description>
			<content:encoded><![CDATA[<p>26 Mar 2011   </p>
<p>The Riordan Clinic announced publication in the Journal of Translational Medicine results of a collaboration between oncologists, alternative medicine practitioners, and basic researchers, which proposes a new use of intravenous vitamin C for treatment of cancer.</p>
<p>The rationale is provided that intravenous, but not oral, vitamin C may be capable of addressing issues in cancer patients such as wasting (cachexia), immune suppression, and improving quality of life. Citing 246 references, the paper synthesized existing knowledge regarding the use of intravenous vitamin C for numerous medical conditions and seeks re-evaluation of the place of intravenous vitamin C in the context of conventional oncology practice.</p>
<p>&#8220;Currently there is a great divide in the way intravenous vitamin C is viewed,&#8221; said Thomas Ichim, Board Member of the Riordan Clinic and first author of the publication. &#8220;On the one hand, you have alternative medicine practitioners, who have been claiming very interesting results in practical treatment of cancer patients, but cannot explain any molecular rationale for its use or potential effects. On the other hand you have a great amount of scientific literature supporting possible relevance of this approach in cancer. This paper is a significant step towards closing the divide.&#8221;</p>
<p>In the past, the use of vitamin C in the treatment of cancer has been considered controversial since some studies have claimed excellent results in extending lifespan of cancer patients, whereas other studies have not seen any effects. The discrepancy seems to be explained by studies seeing positive effects utilizing intravenous vitamin C, whereas the failed studies used oral vitamin C. Scientists at the Riordan Clinic were the first to publish, and patent, that intravenous, but not oral vitamin C, can achieve significant concentration in the blood in order to selectively kill tumor cells.</p>
<p>&#8220;We are proud to have had such a multi-disciplinary collaboration as part of this team including scientists/doctors from University of Western Ontario, Canada, the Torrey Pines Research Institute, the University of Puerto Rico, University of Connecticut, University of Nebraska Medical Center, University of Latvia, the Lawson Health Research Institute, and Loma Linda University,&#8221; stated Brian Riordan, CEO of the Riordan Clinic. &#8220;The Riordan Clinic has been using intravenous vitamin C for decades; my personal mission is to seek input from colleagues in conventional oncology in order to figure out how we can collectively generate best treatment methods for our patients. This paper is a small step in what we anticipate will be many successful collaborations with our friends in conventional oncology practice.&#8221; Funding for the publication was provided by Allan P. Markin&#8217;s Pure North S&#8217;Energy Foundation.</p>
<p>Source: Bio-Communications Research Institute</p>
<p>Article URL: http://www.medicalnewstoday.com/articles/220327.php</p>
<p>Main News Category: Cancer / Oncology</p>
<p>Also Appears In:  Nutrition / Diet,  </p>
]]></content:encoded>
			<wfw:commentRss>http://defeatosteosarcoma.org/2011/03/peer-reviewed-publication-supporting-intravenous-vitamin-c-for-cancer-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Novel Curcumin Analog FLLL32 Decreases STAT3 DNA Binding Activity and Expression, and Induces Apoptosis in Osteosarcoma Cell Lines</title>
		<link>http://defeatosteosarcoma.org/2011/03/the-novel-curcumin-analog-flll32-decreases-stat3-dna-binding-activity-and-expression-and-induces-apoptosis-in-osteosarcoma-cell-lines/</link>
		<comments>http://defeatosteosarcoma.org/2011/03/the-novel-curcumin-analog-flll32-decreases-stat3-dna-binding-activity-and-expression-and-induces-apoptosis-in-osteosarcoma-cell-lines/#comments</comments>
		<pubDate>Tue, 29 Mar 2011 16:21:29 +0000</pubDate>
		<dc:creator>James Street</dc:creator>
				<category><![CDATA[Alternative Therapies]]></category>
		<category><![CDATA[antiangiogenesis]]></category>
		<category><![CDATA[Complementary Therapy]]></category>
		<category><![CDATA[experimental treatments]]></category>
		<category><![CDATA[Follow up Treatment]]></category>
		<category><![CDATA[Local Recurrence]]></category>
		<category><![CDATA[Lung Metastases]]></category>
		<category><![CDATA[Metastases]]></category>
		<category><![CDATA[Molecular Osteosarcoma Studies]]></category>
		<category><![CDATA[Natural Therapies]]></category>
		<category><![CDATA[Osteosarcoma]]></category>

		<guid isPermaLink="false">http://defeatosteosarcoma.org/?p=2086</guid>
		<description><![CDATA[Curcumin is a naturally occurring phenolic compound shown to have a wide variety of antitumor activities; however, it does not attain sufficient blood levels to do so when ingested. Using structure-based design, a novel compound, FLLL32, was generated from curcumin. FLLL32 possesses superior biochemical properties and more specifically targets STAT3, a transcription factor important in [...]]]></description>
			<content:encoded><![CDATA[<p>Curcumin is a naturally occurring phenolic compound shown to have a wide  variety of antitumor activities; however, it does not attain sufficient  blood levels to do so when ingested.  Using structure-based design, a  novel compound, FLLL32, was generated from curcumin.</p>
<p>FLLL32  possesses superior biochemical properties and more specifically targets  STAT3, a transcription factor important in tumor cell survival,  proliferation, metastasis, and chemotherapy resistance.  In our previous  work, we found that several canine and human osteosarcoma (OSA) cell  lines, but not normal osteoblasts, exhibit constitutive phosphorylation  of STAT3.</p>
<p>Compared to curcumin, we hypothesized that FLLL32  would be more efficient at inhibiting STAT3 function in OSA cells and  that this would result in enhanced downregulation of STAT3  transcriptional targets and subsequent death of OSA cells.</p>
<p>Methods:  Human and canine OSA cells were treated with vehicle, curcumin, or  FLLL32 and the effects on proliferation (CyQUANT(R)), apoptosis  (SensoLyte(R) Homogeneous AMC Caspase- 3/7 Assay kit, western blotting),  STAT3 DNA binding (EMSA), and vascular endothelial growth factor  (VEGF), survivin, and matrix metalloproteinase-2(MMP2) expression  (RT-PCR, western blotting) were measured.  STAT3 expression was measured  by RT-PCR, qRT- PCR, and western blotting.</p>
<p>Results:  Our data showed that FLLL32 decreased STAT3 DNA binding by EMSA.</p>
<p>FLLL32 promoted loss of cell proliferation at lower concentrations  than curcumin leading to caspase-3- dependent apoptosis, as evidenced by  PARP cleavage and increased caspase 3/7 activity; this could be  inhibited by treatment with the pan-caspase inhibitor Z-VAD-FMK.   Treatment of OSA cells with FLLL32 decreased expression of survivin,  VEGF, and MMP2 at both mRNA and protein levels with concurrent decreases  in phosphorylated and total STAT3; this loss of total STAT3 occurred,  in part, via the ubiquitin-proteasome pathway.</p>
<p>Conclusions:  These data demonstrate that the novel curcumin analog FLLL32 has  biologic activity against OSA cell lines through inhibition of STAT3  function and expression.</p>
<p>Future work with FLLL32 will define the therapeutic potential of this compound in vivo.</p>
<p>Author: Stacey FosseyMisty BearJiayuh LinChenglong LiEric  SchwartzPui-Kai LiJames FuchsJoelle FengerWilliam KisseberthCheryl  London<br />
Credits/Source: BMC Cancer 2011, 11:112</p>
]]></content:encoded>
			<wfw:commentRss>http://defeatosteosarcoma.org/2011/03/the-novel-curcumin-analog-flll32-decreases-stat3-dna-binding-activity-and-expression-and-induces-apoptosis-in-osteosarcoma-cell-lines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Curcumin Protects Against Cancer</title>
		<link>http://defeatosteosarcoma.org/2011/03/how-curcumin-protects-against-cancer/</link>
		<comments>http://defeatosteosarcoma.org/2011/03/how-curcumin-protects-against-cancer/#comments</comments>
		<pubDate>Sat, 26 Mar 2011 00:20:31 +0000</pubDate>
		<dc:creator>James Street</dc:creator>
				<category><![CDATA[antiinflammatory]]></category>
		<category><![CDATA[Combination Treatments]]></category>
		<category><![CDATA[Complementary Therapy]]></category>
		<category><![CDATA[Inflamation]]></category>
		<category><![CDATA[Natural Therapies]]></category>
		<category><![CDATA[Nutrition and Cancer]]></category>

		<guid isPermaLink="false">http://defeatosteosarcoma.org/?p=2052</guid>
		<description><![CDATA[Life Extension Magazine March 2011 Report By J. Everett Borger How Curcumin Protects Against Cancer According to the American Cancer Society,1 one out of every three women in the United States risks developing some form of cancer over the course of their lives. For men, that number rises to one in two. Since cancer is [...]]]></description>
			<content:encoded><![CDATA[<p>Life Extension Magazine March 2011<br />
Report</p>
<p>By J. Everett Borger<br />
How Curcumin Protects Against Cancer</p>
<p>According to the American Cancer Society,1 one out of every three women in the United States risks developing some form of cancer over the course of their lives. For men, that number rises to one in two. Since cancer is an age-related disease, the risk of diagnosis increases the longer one lives, making it the second leading cause of death in this country.2,3</p>
<p>These data underscore a stark reality. When it comes to cancer prevention, the medical establishment and drug company profiteers remain grossly negligent in protecting the public. The result is countless avoidable cancer deaths each year. There is an urgent need to provide aging individuals with validated interventions to target cancer’s multiple causative factors before they take hold.</p>
<p>Among the most compelling and underrecognized of these is curcumin. In contrast to mainstream oncology’s focus on single-agent toxic treatments, curcumin has emerged as a potent multimodal cancer-preventing agent, with 240 published studies appearing in the global scientific literature in the past year alone.</p>
<p>In this article, you will learn of the multiple factors involved in carcinogenesis (cancer development). You will discover up-to-date research demonstrating curcumin’s power to disrupt specific molecular mechanisms that lead to cancer—and to even treat the disease in many cases.<br />
System-Wide, Safe, Multimodal Defense</p>
<p>Curcumin is derived from the Indian spice turmeric and possesses several active components, all of which contribute to its anti-inflammatory and chemopreventive power.4-6 In fact, curcumin targets ten causative factors involved in cancer development.</p>
<p>Disrupting any one of these factors gives you a good chance of preventing cancer; disrupting several provides even greater protection, including the prevention of DNA damage.7</p>
<p>By blocking the inflammatory master molecule nuclear factor-kappaB (or NF-kB), curcumin blunts cancer-causing inflammation, slashing levels of inflammatory cytokines throughout the body.8,9 Curcumin also interferes with production of dangerous advanced glycation end products that trigger inflammation which can lead to cancerous mutation.10</p>
<p>Curcumin alters cellular signaling to enhance healthy control over cellular replication, which tightly regulates the cellular reproductive cycle, helping to stop uncontrolled proliferation of new tissue in tumors.11 It promotes apoptosis in rapidly reproducing cancer cells without affecting healthy tissue11-13 and reins in tumor growth by making tumors more vulnerable to pharmacologic cell-killing treatments.11,14</p>
<p>In addition, curcumin regulates tumor suppressor pathways and triggers mitochondrial-mediated death in tumor tissue, thereby increasing the death of cancer cells.11,15</p>
<p>Finally, curcumin interferes with tumor invasiveness and blocks molecules that would otherwise open pathways to penetration of tissue.2 It also helps to starve tumors of their vital blood supply and it can oppose many of the processes that permit metastases to spread.8,16,17 These multi-targeted actions are central to curcumin’s capacity to block multiple forms of cancer before they manifest.<br />
Combating Deadly Cancers in Women</p>
<p>Breast cancers vary widely in their responsiveness to standard treatment. Cancers that depend on the hormone estrogen for survival are more effectively treated with conventional methods. Those that lack receptors for female hormones are far more resistant to treatment. This is where curcumin’s value truly lies, because it has the ability to induce apoptosis (programmed cell death) in a variety of hormone-negative cancers.18-20 Remarkably, curcumin produces virtually no change in healthy breast cells, with very low toxicity even at doses as high as 8,000 mg daily.21</p>
<p>In human cancer patients, curcumin doses as high as 3,600 mg a day have been shown to induce the following favorable anti-cancer effects:</p>
<p>* Paraptosis. A process similar to apoptosis (programmed cell death), curcumin initiates paraptosis only in breast cancer cells, resulting in their rapid destruction.22<br />
* Targeted destruction of cancer-cell mitochondria (leaving mitochondria in healthy cells unaffected).22<br />
* Disruption of the cancer cell cycle. Curcumin can “suspend” cancerous cells in a non-reproductive state within their life cycle, thereby halting their replication.20,23-25<br />
* Cancer cell downregulation. Curcumin blocks a group of molecules vital to the process of metastasis. In animal models, it has been shown to reduce metastatic spread to the lungs via this pathway.17,26,27<br />
* Arrested stem cell development. Curcumin inhibits growth and renewal of so-called cancer stem cells, aberrant cells now believed to be at the root of many cancers, including breast cancer.3,28</p>
<p>Combating Deadly Cancers in Women</p>
<p>Curcumin has also been shown to effectively combat cervical cancer, a leading cause of cancer death in women in developing nations and a common cancer in this country.29 It is caused largely by infection with the human papilloma virus, or HPV. Curcumin’s anti-inflammatory effects break the link that triggers HPV-induced cancer development.29,30</p>
<p>Curcumin further promotes apoptosis of cancer cells within the lining of the uterus and reduces the growth rate of painful but non-malignant uterine leiomyomas (uterine fibroids). 31-34</p>
<p>Collectively, these effects make curcumin attractive both as a primary chemopreventive agent in women at risk for breast cancer and an adjuvant treatment option in those who have already developed the disease.20,21<br />
Prostate Cancer Defense</p>
<p>Prostate cancer is the second leading cause of cancer death in American men.35,44 Fortunately, its long latency period and slow growth rate make it a prime candidate for prevention.36 Curcumin strikes at multiple targets in prostate malignancies, interfering with the spread of cancer cells and regulating inflammatory responses through the master regulator NF-kB.36-38</p>
<p>Like certain breast cancers, prostate cancer is often dependent on sex hormones for its growth. Curcumin reduces expression of sex hormone receptors in the prostate, which speeds androgenic breakdown and impairs cancer cells’ ability to respond to the effects of testosterone.39-42 It also inhibits cancer initiation and promotion43 by blocking metastases from forming in the prostate and regulating enzymes required for tissue invasiveness.44<br />
Combating Gastrointestinal Cancers</p>
<p>Colorectal cancer is the third most common malignancy in adults and the second leading cause of cancer deaths.45,46 Despite aggressive surgical care and chemotherapy, nearly 50% of people with colorectal cancers develop recurrent tumors.47 This may be due in part to the survival of dangerous colon cancer stem cells that resist conventional chemotherapy and act as “seeds” for subsequent cancers.3,48,49</p>
<p>On the other hand, these cancers are excellent candidates for prevention, since they follow a predictable sequence from non-malignant polyps to full-blown cancerous growths, usually requiring a decade to develop.46</p>
<p>Much as with malignancies of the breast, cervix, and prostate, curcumin slows the progression from colon polyp to cancer by damping down the inflammatory cascade triggered by NF-kB and pro-inflammatory cytokines.6 This halts the growth of cancer cells before they can become detectable tumors via a host of interrelated molecular mechanisms.50,51</p>
<p>Curcumin also creates a gastrointestinal environment more favorable to optimal colon health by reducing levels of so-called secondary bile acids, natural secretions that contribute to colon cancer risk.52 That has a direct effect, inhibiting proliferation of cancer cells and further reducing their production.53</p>
<p>Curcumin also suppresses colon cancer when combined with other polyphenols such as resveratrol.46,54 The combination of curcumin with green tea extracts has prevented experimentally induced colon cancer in rats.55</p>
<p>Curcumin also synergizes with standard chemotherapy drugs, helping to boost their efficacy and potentially reduce the dose of toxic chemotherapy products, minimizing needless harm and suffering for cancer patients.45,47-49 Curcumin increases colon cancer cell response to radiation.56</p>
<p>A novel feature of curcumin is its ability to bind to and activate vitamin D receptors in colon cells.57 Vitamin D is known to exert potent anti-cancer properties.</p>
<p>Curcumin is equally powerful at preventing cancers in the stomach. It inhibits growth and proliferation of human gastric cancer cells in the laboratory and is particularly effective in stopping cancers that have become resistant to multiple drug treatment.58-60 Curcumin can prevent gastric cancer cells from progressing through their growth cycle, blocking further tumor growth.60</p>
<p>Infection with the bacterium Helicobacter pylori (H. pylori) is a known cause of gastritis, peptic ulcer, and gastric cancer.61 Curcumin blocks growth of H. pylori and reduces the rate at which stomach cells react by turning cancerous.61,62 This effect is again related to curcumin’s fundamental ability to block activation of inflammatory NF-kB.62<br />
What You Need to Know: Multimodal Anti-Cancer Power of Curcumin</p>
<p>*<br />
Multimodal Anti-Cancer Power of Curcumin<br />
Curcumin has emerged as a potent cancer-preventing agent, with 240 published studies appearing in the global scientific literature in the past year alone.<br />
* Its multimodal effects act to simultaneously counter ten discrete causative factors in cancer development.<br />
* It intervenes at each stage in the complex sequence of events that enable cancer cells to develop, proliferate, and metastasize.<br />
* Its multitargeted mechanisms of action have yielded compelling results in combating a remarkably broad array of cancers, including those of the breast, uterus, cervix, prostate, and GI tract.<br />
* A blossoming body of research reveals curcumin’s promise in countering cancers of the blood, brain, lung, and bladder as well.</p>
<p>Further Preventive Potential</p>
<p>Curcumin’s anti-inflammatory, antioxidant, and gene-regulating powers have been explored in preventing or treating cancers of the blood-forming system (leukemias, lymphomas, and myelomas) as well as those of the brain, lung, and bladder.12,13,63-81 Even aggressive tumors of the head and neck, often following years of smoking, are proving responsive to curcumin treatment.14,82-85 Curcumin is also emerging as a potentially effective intervention for pancreatic cancer—one of cancer’s most lethal and aggressive forms.86-90<br />
Further Preventive Potential<br />
Summary</p>
<p>Cancer is the second leading cause of death in the US, and the risk of developing the disease increases significantly as we age.</p>
<p>Curcumin has emerged as a potent cancer-preventing agent, with 240 published studies appearing in the global scientific literature in the past year. Curcumin’s multimodal effects act to simultaneously counter ten discrete causative factors in cancer development.</p>
<p>It intervenes at each stage in the complex sequence of events that must occur in order for a cancer to develop, progress, invade, and ultimately metastasize to healthy tissue.</p>
<p>The multi-targeted mechanisms of curcumin have yielded compelling results in combating a remarkably broad array of cancers, including those of the breast, uterus, cervix, prostate, and GI tract. A burgeoning body of research demonstrates curcumin’s potential to counter cancers of the blood, brain, lung, and bladder as well.</p>
<p>If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at<br />
1-866-864-3027.<br />
Ten Key Causative Factors in Cancer Development<br />
Ten Key Causative Factors in Cancer Development</p>
<p>More than many other age-related diseases, cancer results from the cumulative effect of years of discrete, small-scale assaults on the body. Oxidation, inflammation, stress, infection, and other physiological insults take their toll, inflicting lethal damage over time that sets abnormal cell proliferation in motion.91,92</p>
<p>1. DNA damage. Numerous biomolecular assaults strike at the “blueprint” that cells need in order to replicate themselves accurately. DNA damage is often referred to as the “initiator” in cancer development—the first step in the onset of most cancers.</p>
<p>2. Excessive or chronic inflammation. Inflammatory processes trigger the release of a host of disruptive cytokines (cell-signaling molecules) that affect virtually all cellular functions. Inflammation is commonly referred to as a cancer “promoter” for this reason.</p>
<p>3. Disruption of cell signaling pathways. Normal communication within and between cells assures proper regulation of their healthy function. These pathways are easily disrupted by adverse events such as inflammation.</p>
<p>4. Alterations in the cellular reproductive cycle. Cells undergo a four-stage process as they prepare to replicate themselves. The cell cycle itself is controlled by signaling pathways that can be altered or disrupted at each of these stages.</p>
<p>5. Abnormal regulation of apoptosis. Apoptosis is the process of naturally “pre-programmed” cell death that prevents overgrowth of tissue. When apoptosis fails, cells may undergo uncontrolled reproduction.</p>
<p>6. Altered survival pathways. The flip side of unregulated apoptosis: survival of too many healthy cells, paradoxically, can endanger the host by permitting a cancer to take hold by increasing the odds of mutation and proliferation.</p>
<p>7. Excessive cellular proliferation. Certain hormones and other stimuli can directly trigger cells to reproduce without safe limits, especially when the preceding regulatory mechanisms have failed.</p>
<p>8. Aggressive invasion of healthy tissue. This is accomplished by excessive production of enzymes and adhesion molecules that “dissolve” tissue and allow the tumor to literally take root. The word “cancer” itself is derived from the crab-like appearance of fully-developed malignancies, which extend tendrils in all directions into healthy tissue.93</p>
<p>9. Rapid angiogenesis. Tumors require growth of new blood vessels for nourishment. They are endowed with the capacity to spontaneously generate new blood vessels just like healthy tissue. Angiogenesis in cancer tissue is a primary means by which tumors grow.</p>
<p>10. Metastasis. This is the migration of cancerous cells to regions of the body beyond the locus of the primary tumor. Metastases are the distinguishing features of most malignant cancers, and the typically herald the onset of end-stage disease because they disrupt otherwise healthy tissues.<br />
References</p>
<p>1. Available at: http://seer.cancer.gov/statfacts/html/all.html. Accessed November 22, 2010.</p>
<p>2. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB.Curcumin and cancer: an “old-age” disease with an “age-old” solution. Cancer Lett. 2008 Aug 18;267(1):133-64.</p>
<p>3. Subramaniam D, Ramalingam S, Houchen CW, Anant S. Cancer stem cells: a novel paradigm for cancer prevention and treatment. Mini Rev Med Chem. 2010 May;10(5):359-71.</p>
<p>4. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev. 2009 Jun;14(2):141-53.</p>
<p>5. Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer. 2010 Oct;62(7):919-30.</p>
<p>6. Murphy EA, Davis JM, McClellan JL, Gordon BT, Carmichael MD. Curcumin’s effect on intestinal inflammation and tumorigenesis in the Apc(Min/+) Mouse. J Interferon Cytokine Res. 2010 Oct 15.</p>
<p>7. Biswas J, Sinha D, Mukherjee S, Roy S, Siddiqi M, Roy M. Curcumin protects DNA damage in a chronically arsenic-exposed population of West Bengal. Hum Exp Toxicol. 2010 Jun;29(6):513-24.</p>
<p>8. Bachmeier BE, Killian P, Pfeffer U, Nerlich AG. Novel aspects for the application of Curcumin in chemoprevention of various cancers. Front Biosci (Schol Ed). 2010 Jan 1;2:697-717.</p>
<p>9. Sikora E, Bielak-Zmijewska A, Mosieniak G, Piwocka K. The promise of slow down ageing may come from curcumin. Curr Pharm Des. 2010;16(7):884-92.</p>
<p>10. Sajithlal GB, Chithra P, Chandrakasan G. Effect of curcumin on the advanced glycation and cross-linking of collagen in diabetic rats. Biochem Pharmacol. 1998 Dec 15;56(12):1607-14.</p>
<p>11. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J. 2009 Sep;11(3):495-510.</p>
<p>12. Zhang J, Du Y, Wu C, et al. Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186* signaling pathway. Oncol Rep. 2010 Nov;24(5):1217-23.</p>
<p>13. Zhang J, Zhang T, Ti X, et al. Curcumin promotes apoptosis in A549/DDP multidrug-resistant human lung adenocarcinoma cells through an miRNA signaling pathway. Biochem Biophys Res Commun. 2010 Aug 13;399(1):1-6.</p>
<p>14. Clark CA, McEachern MD, Shah SH, et al. Curcumin inhibits carcinogen and nicotine-induced mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma. Cancer Prev Res (Phila). 2010 Sep 17.</p>
<p>15. Cheng CY, Lin YH, Su CC. Curcumin inhibits the proliferation of human hepatocellular carcinoma J5 cells by inducing endoplasmic reticulum stress and mitochondrial dysfunction. Int J Mol Med. 2010 Nov;26(5):673-8.</p>
<p>16. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem. 2010;17(3):190-7.</p>
<p>17. Wang L, Shen Y, Song R, Sun Y, Xu J, Xu Q. An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells. Mol Pharmacol. 2009 Dec;76(6):1238-45.</p>
<p>18. Al-Hujaily EM, Mohamed AG, Al-Sharif I, et al. PAC, a novel curcumin analogue, has anti-breast cancer properties with higher efficiency on ER-negative cells. Breast Cancer Res Treat. 2010 Aug 1.</p>
<p>19. Rowe DL, Ozbay T, O’Regan RM, Nahta R. Modulation of the BRCA1 protein and induction of apoptosis in triple negative breast cancer cell lines by the polyphenolic compound curcumin. Breast Cancer. 2009 Sep 2;3:61-75.</p>
<p>20. Banerjee M, Singh P, Panda D. Curcumin suppresses the dynamic instability of microtubules, activates the mitotic checkpoint and induces apoptosis in MCF-7 cells. FEBS J. 2010 Aug;277(16):3437-48.</p>
<p>21. Bayet-Robert M, Kwiatkowski F, Leheurteur M, et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther. 2010 Jan;9(1):8-14.</p>
<p>22. Yoon MJ, Kim EH, Lim JH, Kwon TK, Choi KS. Superoxide anion and proteasomal dysfunction contribute to curcumin-induced paraptosis of malignant breast cancer cells. Free Radic Biol Med. 2010 Mar 1;48(5):713-26.</p>
<p>23. Sun A, Lu YJ, Hu H, Shoji M, Liotta DC, Snyder JP. Curcumin analog cytotoxicity against breast cancer cells: exploitation of a redox-dependent mechanism. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6627-31.</p>
<p>24. Quiroga A, Quiroga PL, Martinez E, Soria EA, Valentich MA. Anti-breast cancer activity of curcumin on the human oxidation-resistant cells ZR-75-1 with gamma-glutamyltranspeptidase inhibition. J Exp Ther Oncol. 2010;8(3):261-6.</p>
<p>25. Hua WF, Fu YS, Liao YJ, et al. Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells. Eur J Pharmacol. 2010 Jul 10;637(1-3):16-21.</p>
<p>26. Boonrao M, Yodkeeree S, Ampasavate C, Anuchapreeda S, Limtrakul P. The inhibitory effect of turmeric curcuminoids on matrix metalloproteinase-3 secretion in human invasive breast carcinoma cells. Arch Pharm Res. 2010 Jul;33(7):989-98.</p>
<p>27. Ibrahim A, El-Meligy A, Fetaih H, Dessouki A, Stoica G, Barhoumi R. Effect of curcumin and Meriva on the lung metastasis of murine mammary gland adenocarcinoma. In Vivo. 2010 Jul-Aug;24(4):401-8.</p>
<p>28. Kakarala M, Brenner DE, Korkaya H, et al. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat. 2010 Aug;122(3):777-85.</p>
<p>29. Madden K, Flowers L, Salani R, et al. Proteomics-based approach to elucidate the mechanism of antitumor effect of curcumin in cervical cancer. Prostaglandins Leukot Essent Fatty Acids. 2009 Jan;80(1):9-18.</p>
<p>30. Prusty BK, Das BC. Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. Int J Cancer. 2005 Mar 1;113(6):951-60.</p>
<p>31. Yu Z, Shah DM. Curcumin down-regulates Ets-1 and Bcl-2 expression in human endometrial carcinoma HEC-1-A cells. Gynecol Oncol. 2007 Sep;106(3):541-8.</p>
<p>32. Liang YJ, Hao Q, Wu YZ, Wang QL, Wang JD, Hu YL. Aromatase inhibitor letrozole in synergy with curcumin in the inhibition of xenografted endometrial carcinoma growth. Int J Gynecol Cancer. 2009 Oct;19(7):1248-52.</p>
<p>33. Malik M, Norian J, McCarthy-Keith D, Britten J, Catherino WH. Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. Semin Reprod Med. 2010 May;28(3):169-79.</p>
<p>34. Tsuiji K, Takeda T, Li B, et al. Inhibitory effect of curcumin on uterine leiomyoma cell proliferation. Gynecol Endocrinol. 2010 Jul 30.</p>
<p>35. Available at www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics. Accessed November 22, 2010.</p>
<p>36. Teiten MH, Gaascht F, Eifes S, Dicato M, Diederich M. Chemopreventive potential of curcumin in prostate cancer. Genes Nutr. 2010 Mar;5(1):61-74.</p>
<p>37. Piantino CB, Salvadori FA, Ayres PP, et al. An evaluation of the anti-neoplastic activity of curcumin in prostate cancer cell lines. Int Braz J Urol. 2009 May-Jun;35(3):354-60; discussion 61.</p>
<p>38. Khan N, Adhami VM, Mukhtar H. Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer. 2010 Mar;17(1):R39-52.</p>
<p>39. Thangapazham RL, Shaheduzzaman S, Kim KH, et al. Androgen responsive and refractory prostate cancer cells exhibit distinct curcumin regulated transcriptome. Cancer Biol Ther. 2008 Sep;7(9):1427-35.</p>
<p>40. Tsui KH, Feng TH, Lin CM, Chang PL, Juang HH. Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells. J Androl. 2008 Nov-Dec;29(6):661-8.</p>
<p>41. Shi Q, Shih CC, Lee KH. Novel anti-prostate cancer curcumin analogues that enhance androgen receptor degradation activity. Anticancer Agents Med Chem. 2009 Oct;9(8):904-12.</p>
<p>42. Choi HY, Lim JE, Hong JH. Curcumin interrupts the interaction between the androgen receptor and Wnt/beta-catenin signaling pathway in LNCaP prostate cancer cells. Prostate Cancer Prostatic Dis. 2010 Dec;13(4):343-9.</p>
<p>43. Wan SB, Yang H, Zhou Z, et al. Evaluation of curcumin acetates and amino acid conjugates as proteasome inhibitors. Int J Mol Med. 2010 Oct;26(4):447-55.</p>
<p>44. Herman JG, Stadelman HL, Roselli CE. Curcumin blocks CCL2-induced adhesion, motility and invasion, in part, through down-regulation of CCL2 expression and proteolytic activity. Int J Oncol. 2009 May;34(5):1319-27.</p>
<p>45. Nautiyal J, Banerjee S, Kanwar SS, et al. Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. Int J Cancer. 2010 Apr 19.</p>
<p>46. Patel VB, Misra S, Patel BB, Majumdar AP. Colorectal cancer: chemopreventive role of curcumin and resveratrol. Nutr Cancer. 2010 Oct;62(7):958-67.</p>
<p>47. Patel BB, Majumdar AP. Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview. Nutr Cancer. 2009 Nov;61(6):842-6.</p>
<p>48. Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, Majumdar AP. Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX. Transl Oncol. 2009 Dec;2(4):321-8.</p>
<p>49. Patel BB, Gupta D, Elliott AA, Sengupta V, Yu Y, Majumdar AP. Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res. 2010 Feb;30(2):319-25.</p>
<p>50. Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP, Dou QP. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res. 2008 Sep 15;68(18):7283-92.</p>
<p>51. Watson JL, Hill R, Yaffe PB, et al. Curcumin causes superoxide anion production and p53-independent apoptosis in human colon cancer cells. Cancer Lett. 2010 Nov 1;297(1):1-8.</p>
<p>52. Han Y, Haraguchi T, Iwanaga S, et al. Consumption of some polyphenols reduces fecal deoxycholic acid and lithocholic acid, the secondary bile acids of risk factors of colon cancer. J Agric Food Chem. 2009 Sep 23;57(18):8587-90.</p>
<p>53. Wang BM, Zhai CY, Fang WL, Chen X, Jiang K, Wang YM. The inhibitory effect of curcumin on the proliferation of HT-29 colonic cancer cell induced by deoxycholic acid. Zhonghua Nei Ke Za Zhi. 2009 Sep;48(9):760-3.</p>
<p>54. Majumdar AP, Banerjee S, Nautiyal J, et al. Curcumin synergizes with resveratrol to inhibit colon cancer. Nutr Cancer. 2009;61(4):544-53.</p>
<p>55. Xu G, Ren G, Xu X, et al. Combination of curcumin and green tea catechins prevents dimethylhydrazine-induced colon carcinogenesis. Food Chem Toxicol. 2010 Jan;48(1):390-5.</p>
<p>56. Sandur SK, Deorukhkar A, Pandey MK, et al. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):534-42.</p>
<p>57. Bartik L, Whitfield GK, Kaczmarska M, et al. Curcumin: a novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention. J Nutr Biochem. 2010 Feb 11.</p>
<p>58. Koo JY, Kim HJ, Jung KO, Park KY. Curcumin inhibits the growth of AGS human gastric carcinoma cells in vitro and shows synergism with 5-fluorouracil. J Med Food. 2004 Summer;7(2):117-21.</p>
<p>59. Tang XQ, Bi H, Feng JQ, Cao JG. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacol Sin. 2005 Aug;26(8):1009-16.</p>
<p>60. Cai XZ, Wang J, Li XD, et al. Curcumin suppresses proliferation and invasion in human gastric cancer cells by downregulation of PAK1 activity and cyclin D1 expression. Cancer Biol Ther. 2009 Jul;8(14):1360-8.</p>
<p>61. De R, Kundu P, Swarnakar S, et al. Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob Agents Chemother. 2009 Apr;53(4):1592-7.</p>
<p>62. Zaidi SF, Yamamoto T, Refaat A, et al. Modulation of activation-induced cytidine deaminase by curcumin in Helicobacter pylori-infected gastric epithelial cells. Helicobacter. 2009 Dec;14(6):588-95.</p>
<p>63. Uddin S, Khan AS, Al-Kuraya KS. Developing curcumin into a viable therapeutic for lymphoma. Expert Opin Investig Drugs. 2009 Jan;18(1):57-67.</p>
<p>64. Vyas HK, Pal R, Vishwakarma R, Lohiya NK, Talwar GP. Selective killing of leukemia and lymphoma cells ectopically expressing hCGbeta by a conjugate of curcumin with an antibody against hCGbeta subunit. Oncology. 2009;76(2):101-11.</p>
<p>65. Xiao H, Zhang KJ, Zuo XL. Reversal of multidrug resistance of the drug resistant human multiple myeloma cell line MOLP-2/R by curcumin and its relation with FA/BRCA pathway. Zhonghua Xue Ye Xue Za Zhi. 2009 Jan;30(1):33-7.</p>
<p>66. Cotto M, Cabanillas F, Tirado M, Garcia MV, Pacheco E. Epigenetic therapy of lymphoma using histone deacetylase inhibitors. Clin Transl Oncol. 2010 Jun;12(6):401-9.</p>
<p>67. Kelkel M, Jacob C, Dicato M, Diederich M. Potential of the dietary antioxidants resveratrol and curcumin in prevention and treatment of hematologic malignancies. Molecules. 2010;15(10):7035-74.</p>
<p>68. Kikuchi H, Kuribayashi F, Kiwaki N, Nakayama T. Curcumin dramatically enhances retinoic acid-induced superoxide generating activity via accumulation of p47-phox and p67-phox proteins in U937 cells. Biochem Biophys Res Commun. 2010 Apr 23;395(1):61-5.</p>
<p>69. Sanchez Y, Simon GP, Calvino E, de Blas E, Aller P. Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines. J Pharmacol Exp Ther. 2010 Oct;335(1):114-23.</p>
<p>70. Zhang C, Li B, Zhang X, Hazarika P, Aggarwal BB, Duvic M. Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients’ PBMCs: potential role for STAT-3 and NF-kappaB signaling. J Invest Dermatol. 2010 Aug;130(8):2110-9.</p>
<p>71. Chadalapaka G, Jutooru I, Chintharlapalli S, et al. Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res. 2008 Jul 1;68(13):5345-54.</p>
<p>72. Leite KR, Chade DC, Sanudo A, Sakiyama BY, Batocchio G, Srougi M. Effects of curcumin in an orthotopic murine bladder tumor model. Int Braz J Urol. 2009 Sep-Oct;35(5):599-606; discussion 06-7.</p>
<p>73. Chadalapaka G, Jutooru I, Burghardt R, Safe S. Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol Cancer Res. 2010 May;8(5):739-50.</p>
<p>74. Tharakan ST, Inamoto T, Sung B, Aggarwal BB, Kamat AM. Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers. Biochem Pharmacol. 2010 Jan 15;79(2):218-28.</p>
<p>75. Purkayastha S, Berliner A, Fernando SS, et al. Curcumin blocks brain tumor formation. Brain Res. 2009 Feb 10.</p>
<p>76. Schaaf C, Shan B, Buchfelder M, et al. Curcumin acts as anti-tumorigenic and hormone-suppressive agent in murine and human pituitary tumour cells in vitro and in vivo. Endocr Relat Cancer. 2009 Dec;16(4):1339-50.</p>
<p>77. Bangaru ML, Chen S, Woodliff J, Kansra S. Curcumin (diferuloylmethane) induces apoptosis and blocks migration of human medulloblastoma cells. Anticancer Res. 2010 Feb;30(2):499-504.</p>
<p>78. Elamin MH, Shinwari Z, Hendrayani SF, et al. Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells. Mol Carcinog. 2010 Mar;49(3):302-14.</p>
<p>79. Schaaf C, Shan B, Onofri C, et al. Curcumin inhibits the growth, induces apoptosis and modulates the function of pituitary folliculostellate cells. Neuroendocrinology. 2010;91(2):200-10.</p>
<p>80. Su CC, Yang JS, Lu CC, et al. Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model. Phytother Res. 2010 Feb;24(2):189-92.</p>
<p>81. Wu SH, Hang LW, Yang JS, et al. Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade- and mitochondria-dependent pathways. Anticancer Res. 2010 Jun;30(6):2125-33.</p>
<p>82. Lin YC, Chen HW, Kuo YC, Chang YF, Lee YJ, Hwang JJ. Therapeutic efficacy evaluation of curcumin on human oral squamous cell carcinoma xenograft using multimodalities of molecular imaging. Am J Chin Med. 2010;38(2):343-58.</p>
<p>83. Rai B, Kaur J, Jacobs R, Singh J. Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress. J Oral Sci. 2010;52(2):251-6.</p>
<p>84. Shin HK, Kim J, Lee EJ, Kim SH. Inhibitory effect of curcumin on motility of human oral squamous carcinoma YD-10B cells via suppression of ERK and NF-kappaB activations. Phytother Res. 2010 Apr;24(4):577-82.</p>
<p>85. Wong TS, Chan WS, Li CH, et al. Curcumin alters the migratory phenotype of nasopharyngeal carcinoma cells through up-regulation of E-cadherin. Anticancer Res. 2010 Jul;30(7):2851-6.</p>
<p>86. Glienke W, Maute L, Wicht J, Bergmann L. Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of survivin/BIRC5 gene expression. Cancer Invest. 2010 Feb;28(2):166-71.</p>
<p>87. Jutooru I, Chadalapaka G, Lei P, Safe S. Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J Biol Chem. 2010 Aug 13;285(33):25332-44.</p>
<p>88. Kanai M, Yoshimura K, Asada M, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol. 2010 Sep 22.</p>
<p>89. Lin L, Hutzen B, Zuo M, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res. 2010 Mar 15;70(6):2445-54.</p>
<p>90. Ramachandran C, Resek AP, Escal on E, Aviram A, Melnick SJ. Potentiation of gemcitabine by Turmeric Force in pancreatic cancer cell lines. Oncol Rep. 2010 Jun;23(6):1529-35.</p>
<p>91. Bengmark S. Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. JPEN J Parenter Enteral Nutr. 2006 Jan-Feb;30(1):45-51.</p>
<p>92. Bengmark S, Mesa MD, Gil A. Plant-derived health: the effects of turmeric and curcuminoids. Nutr Hosp. 2009 May-Jun;24(3):273-81.</p>
<p>93. Argyle DJ, Blacking T. From viruses to cancer stem cells: dissecting the pathways to malignancy. Vet J. 2008 Sep;177(3):311-23.<br />
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.</p>
]]></content:encoded>
			<wfw:commentRss>http://defeatosteosarcoma.org/2011/03/how-curcumin-protects-against-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Trying to connect with pot&#8217;s cancer-fighting properties</title>
		<link>http://defeatosteosarcoma.org/2011/03/trying-to-connect-with-pots-cancer-fighting-properties/</link>
		<comments>http://defeatosteosarcoma.org/2011/03/trying-to-connect-with-pots-cancer-fighting-properties/#comments</comments>
		<pubDate>Mon, 21 Mar 2011 05:53:21 +0000</pubDate>
		<dc:creator>James Street</dc:creator>
				<category><![CDATA[Cannabis]]></category>
		<category><![CDATA[Natural Therapies]]></category>

		<guid isPermaLink="false">http://defeatosteosarcoma.org/?p=2023</guid>
		<description><![CDATA[By Dana M. Nichols March 20, 2011 Record Staff Writer SAN ANDREAS &#8211; Two of the major compounds in marijuana &#8211; THC and CBD &#8211; have cancer-fighting properties, according to scientists researching them. While THC and the biological mechanisms it uses are well documented, there are still mysteries surrounding the lesser-known chemical CBD. Clinical trials [...]]]></description>
			<content:encoded><![CDATA[<p>By Dana M. Nichols<br />
March 20, 2011<br />
Record Staff Writer</p>
<p>SAN ANDREAS &#8211; Two of the major compounds in marijuana &#8211; THC and CBD &#8211; have cancer-fighting properties, according to scientists researching them.</p>
<p>While THC and the biological mechanisms it uses are well documented, there are still mysteries surrounding the lesser-known chemical CBD.</p>
<p>Clinical trials prove that it eases pain and inflammation. Sean McAllister, a scientist at California Pacific Medical Center Research Institute in San Francisco, and his research associates have used the compound to shrink tumors.</p>
<p>But it does not fit well in the already discovered human receptors that fit THC, and scientists have not yet traced the mechanisms that allow it to modulate some of the same systems, McAllister said.</p>
<p>&#8220;There is not a lot of data on it,&#8221; McAllister said.</p>
<p>Right now, McAllister is looking at how CBD attacks a gene called Id-1 that is key to the functioning of cancerous cells.</p>
<p>&#8220;If cancer cells adopt this protein, it allows them to metastasize,&#8221; McAllister said. &#8220;The hypothesis would be that if you can knock this gene down or inhibit it, then the cancer won&#8217;t metastasize.&#8221;</p>
<p>One big advantage to both chemicals is that they are virtually non-toxic, unlike many cancer drugs.</p>
<p>&#8220;There is no way to actually kill yourself with the natural compounds,&#8221; McAllister said. Overdoses of the kind that kill opiate users are impossible with cannabis because they interact with different receptors.</p>
<p>&#8220;There are no cannabinoid receptors on the brain stem which controls breathing,&#8221; McAllister said. &#8220;It is quite a safe compound actually.&#8221;</p>
<p>Contact reporter Dana M. Nichols at (209) 607-1361 or dnichols@recordnet.com. Visit his blog at recordnet.com/calaverasblog.</p>
]]></content:encoded>
			<wfw:commentRss>http://defeatosteosarcoma.org/2011/03/trying-to-connect-with-pots-cancer-fighting-properties/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

